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General Introduction
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Anatomy and function
The pancreas is a small secretory gland, about 15 centimeters in length, in the 
retroperitoneal cavity of the abdomen, weighing 60-150 grams. It is commonly 
divided in a head, body and tail region. The pancreas has two major functions: 
exocrine enzyme secretion and endocrine hormone secretion. Exocrine 
pancreatic tissue consists of lobules composed of small acinar cells that drain 
in the main pancreatic duct. This main duct usually empties in the common 
bile duct, just proximal to the ampulla of Vater and the duodenum. The most 
important pancreatic exocrine enzymes are trypsinogen, amylase and lipase, 
all necessary for an adequate food digestion. Pancreatic endocrine hormones 
are insulin, glucagon and somatostatin, and all of these are released into the 
circulation in order to facilitate in the glucose and energy metabolism. 
Disease of the pancreas
The most common disorders of the pancreas are inflammatory diseases, 
such as acute and chronic pancreatitis, and pancreatic malignancies. Chronic 
pancreatitis is a progressive disorder, leading to an irreversible destruction 
of the pancreas. Main symptoms are pain and/or endocrine and exocrine 
pancreas insufficiency. This thesis, however, focus on acute pancreatitis. 
Acute pancreatitis
Acute pancreatitis is the acute inflammation of the pancreas which may or may 
not be accompanied with a systemic inflammatory response syndrome (SIRS). 
The exact pathophysiology of acute pancreatitis is still unknown, however, 
it is generally accepted that in acute pancreatitis premature activation of 
trypsin occurs in the pancreas, leading to activation of digestive enzymes and 
autodigestion of the pancreas. Sometimes the surrounding tissue is involved 
as well.1-4 In Western countries, the main causes of acute pancreatitis are 
gallstones (~55%) and alcohol (~20%).5,6 In biliary pancreatitis, gallstones or 
gall sludge (temporarily) occlude the common bile duct proximal of the main 
pancreatic duct, resulting in stasis of pancreatic secretions and ultimately acute 
pancreatitis. Acute pancreatitis can also have several other, more rare, causes, 
like medication and hereditary factors. However, the exact pathophysiological 
mechanism of acute pancreatitis is yet unknown. 
 The majority (~80%) of patients with an attack of acute pancreatitis 
experience the mild form of the disease.7 Clinical signs of acute pancreatitis 
are severe (upper) abdominal pain, usually accompanied with nausea 
and vomiting.8 Biochemically, serum amylase and lipase are increased. 
Approximately a fifth of patients develop severe acute pancreatitis, which is 
associated with pancreatic and peripancreatic necrosis, persistent (multiple) 
organ failure and increased morbidity and mortality.8-10 In general, the clinical 
course of severe acute pancreatitis is biphasic. In the early phase (i.e., first 
two weeks after onset of symptoms), the patient develops in varying amounts 
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pancreatic and/or peripancreatic necrosis (necrotizing pancreatitis) and SIRS, 
which may progress towards (multiple) organ failure and ultimately death. 
This early phase is immune-mediated, although bacterial infections may play a 
role.11,12 In the second phase of acute pancreatitis (i.e., more than two weeks 
after onset of symptoms) the systemic inflammation declines and the influence 
of infectious complications become more prominent. In approximately a third 
of patients clinical signs of infection of the (peri-)pancreatic collections become 
manifest, usually 3-4 weeks after onset of symptoms. Patients with infected 
necrotizing pancreatitis usually need some sort of intervention to remove the 
infected necrosis, as without intervention mortality is almost 100%.9 
Bacterial translocation
Bacterial translocation from the small bowel is considered to be the 
main route of infection of (peri-)pancreatic necrosis.13-15 Three major 
pathophysiological steps are thought to precede bacterial translocation: 
1) bacterial overgrowth of the small bowel, 2) dysfunction of the local 
and systemic immune system, resulting in mucosal barrier dysfunction, 
and 3) increased intestinal permeability with ultimately bacterial 
translocation. Since infectious complications (e.g., infected necrosis) are 
associated with an increased mortality and morbidity, any treatment 
regimen capable of lowering the infection rate in acute pancreatitis could 
potentially reduce both morbidity and mortality. Prophylactic administration 
of antibiotics and probiotics both have been tried to lower the rate of 
infection, assuming that administration very early in the course of the disease 
would effectively remove the early circulating bacteria from the bloodstream. 
Several meta-analyses have shown that prophylactic administration of 
antibiotics did not result in lower morbidity and mortality.16.17 In 2002, 
Olah et al suggested that probiotics could interfere with the intestinal 
flora, thus preventing bacterial translocation and ultimately lower the 
number of infections in patients with acute necrotizing pancreatitis.18 
Since then, several clinical and experimental studies have been performed on 
the effect of probiotic prophylaxis in necrotizing pancreatitis.19-24 
PROPATRIA 
The Dutch Pancreatitis Study Group launched the PROPATRIA trial in 2004.25 
This multicentre, double-blinded, placebo-controlled trial randomized 
patients with predicted severe pancreatitis between placebo and 
probiotic prophylaxis for 28 days, with the first gift administered within 
the first 72 hours after hospital admission. All patients received enteral 
nutrition through a nasojejunal feeding tube. Primary endpoint of the 
study was the total number of infectious complications; secondary 
endpoints were mortality, hospital stay and adverse events. In 2008, totally 
unexpected, the results of the PROPATRIA trial showed a higher mortality in 
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patients with probiotic prophylaxis as compared to the placebo group (16% 
vs. 6%, p=0.01) although the overall mortality was not higher than expected 
(11%). Another unexpected finding was non-occlusive mesenteric ischemia 
(NOMI), observed in 9 out of 152 patients (6%) with probiotic prophylaxis vs. 
0/144 patients (0%) with placebo treatment (p=0.004).19 Since then, no new 
studies on probiotic prophylaxis in patients with acute pancreatitis have been 
performed and many questions have been left unanswered, once all data had 
been analyzed with scrutiny.
PANTER
In the last decade, several (minimally invasive) intervention strategies are 
implemented in daily care as substitution or addition to conventional open 
surgical necrosectomy.26-30 Unfortunately, even after intervention, mortality 
in patients with infected necrotizing pancreatitis remains between 10-25% 
and morbidity is even higher (50-100%).31-35 The second multicentre trial 
conducted by the Dutch Pancreatitis Study Group was the PANTER trial.29 
Patients with suspected infection of necrosis were randomized between 
open surgical necrosectomy and the minimally invasive step-up approach, 
consisting of primarily percutaneous catheter drainage (PCD) of (peri-)
pancreatic fluid collections, if unsuccessful followed by a video-assisted 
retroperitoneal debridement (VARD). Furthermore, intervention was 
postponed for preferably 4 weeks, allowing encapsulation of the necrotic cavity 
to facilitate necrosectomy, assumed to lead to a reduction of per-operative 
complications such as bleeding and intestinal perforation. The PANTER trial 
showed that the minimally invasive step-up approach is superior to the open 
surgical necrosectomy in terms of lowering the combined endpoint of major 
complications or death. Furthermore, it was shown that almost a third of 
patients recovered with only PCD, making surgical necrosectomy unnecessary 
and that costs were considerably lower for the step-up approach.29 
Thesis outline
Both these randomized controlled trials left crucial questions unanswered. 
This was felt more strongly for the PROPATRIA trial than for the PANTER trial. 
A satisfactory explanation for the excess death of 15 patients in the group 
that received probiotic prophylaxis had not been provided and the following 
questions were remaining:
1.  Is unfavourable interaction between probiotics and enteral nutrition in 
acute pancreatitis the driving force behind the increased mortality? This 
question was subdivided into three questions to be addressed in further 
studies that were designed after the PROPATRIA trial was analyzed in depth.
 a.  Under which intraluminal conditions does a mixture of six different 
probiotic strains show the highest metabolic activity in terms of lactate 
and short-chain fatty acid production?
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 b.  Does the administration of probiotics and enteral nutrition influence 
infectious complications and outcome in a rat model for severe acute 
pancreatitis? 
 c.  What is the clinical outcome of patients without early organ failure 
treated with probiotics and enteral nutrition?  
2.  Could the increased mortality in the probiotic group be explained by an 
incorrect statistical interpretation of the data? The PROPATRIA study 
was powered for showing a meaningful difference in terms of infectious 
complications and the study was underpowered for mortality, which was 
not a primary endpoint. 
These questions are addressed in the first part of this thesis. In the second 
part, the follow-up topics arising from the PANTER trial were studied:
1.  How to accurately diagnose infection and how to design further 
interventional strategies in acute pancreatitis?
2.  What is the role of routine fine-needle aspiration (FNA) in the diagnostic 
work-up in patients with suspected infection in necrotizing pancreatitis?
3.  What is the role of percutaneous drainage in patients with suspected or 
documented infected pancreatic necrosis? 
4.  What is the role of transpapillary stenting as opposed to conservative 
management in patients with fistula after necrotizing pancreatitis?
5. What is the optimal timing of cholecystectomy after mild acute pancreatitis?
Interaction between probiotics and enteral nutrition in acute 
pancreatitis
Since the unexpected results of the PROPATRIA trial in 2007, no clinical 
research on probiotic treatment in patients with acute pancreatitis has been 
published. While probiotics were long thought to be harmless, the PROPATRIA 
trial has strongly suggested that probiotics could be dangerous under certain 
conditions in severely ill patients.19 In PROPATRIA, eight out of nine patients 
with non-occlusive mesenteric ischemia suffered from early (multiple) organ 
failure (i.e. within the first three days of hospital admission). These patients 
were enterally fed with fibre-rich enteral nutrition through a naso-jejunal 
feeding tube. Up to now, a causal relationship between administration of 
probiotics and non-occlusive bowel ischemia has not been demonstrated. 
Although it is suggested that the interaction of probiotics and enteral nutrition 
and the presence of (multiple) organ failure have played a major role in this 
mechanism, convincing evidence is lacking. 
 Chapter 2 describes the results of an in vitro computer-controlled 
gastrointestinal model in which the interaction between probiotics and enteral 
nutrition is investigated under several different physiological conditions. 
Although we do know that the metabolic activity of certain probiotic strains, 
especially lactic acid bacteria, is reflected by the production of lactic acid, 
14
the exact influence of the presence of bile salts, pancreatic enzymes and 
composition of enteral nutrition in the bowel lumen on probiotic activity 
remains unclear. This study provides clues and new insights in the behavior of 
the probiotic strains in the bowel lumen.
 Prior to the PROPATRIA trial, experimental studies have been performed 
studying the effect of probiotic prophylaxis in acute pancreatitis. Van Minnen 
et al described the use of a specific probiotic mixture in an experimental 
rat model for severe acute pancreatitis.36 This experimental study showed 
that mortality was lower in the animals pretreated with probiotics and that 
bacterial translocation to the pancreas occurred more frequently in animals 
treated with placebo. A major difference with the PROPATRIA trial was that 
all animals had free access to water and food, while most patients received 
enteral nutrition directly into the jejunum. As it is suggested that the 
administration of enteral nutrition and the interaction with the administered 
probiotics played a significant role in the occurrence of NOMI in PROPATRIA, 
Chapter 3 describes an experimental rat model of severe acute pancreatitis 
in which clinical outcome and bacterial translocation were analyzed in rats 
treated with enteral nutrition and probiotics.
 Several studies investigating the role of probiotics in critically ill patients were 
preliminary terminated because of the dramatically results of the PROPATRIA 
trial.20,21 Since 2008, only experimental studies to probiotic treatment in acute 
pancreatitis have been performed.22-24 Chapter 4 describes the first study since 
the PROPATRIA trial investigating the effect of probiotic treatment and enteral 
nutrition in 99 patients with predicted severe pancreatitis. In these patients, 
clinical outcome was assessed in terms of infectious complications, bowel 
ischemia and mortality.
Diagnosis of infection and interventional strategies in acute 
pancreatitis
For long, suspicion or proof of infected necrosis in patients with necrotizing 
pancreatitis was a key indication for surgical (emergency) intervention.33,37,38 
In the last decade, minimally invasive strategies have gained popularity in the 
interventional treatment in these critically ill patients. The newly introduced 
techniques decreased morbidity and mortality significantly, however, the rate 
of infection in the different series described vary considerably.31-35 Since sterile 
necrosis is associated with a low mortality and generally does not require 
surgical or radiological intervention, establishment of the diagnosis of infected 
necrosis seems crucial. In the PANTER trial, patients with (suspected) infected 
necrosis were randomized between a minimally invasive step-up approach 
and the conventional open necrosectomy.29 In this trial, the infection rate 
was high without routine use of FNA for confirmation of infection and the 
clinical condition was dominant in deciding on the timing of intervention. 
The discussion on when and how to use FNA in case of suspected infection 
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is still awaiting a satisfactory answer. Chapter 5 describes the value of FNA in 
diagnosing infected necrosis in 208 patients who underwent an intervention 
due to suspected infected necrosis, as compared to the presence of gas 
bubbles in necrotic fluid collections and clinical signs only. 
 After the difficulty of correctly diagnosing infected necrosis and postponing 
intervention as long as possible, the next obstacle is to choose the optimal 
intervention strategy. Although primary open surgical necrosectomy was 
standard practice of care for decades, the PANTER trial showed that a third of 
patients could be treated with percutaneous catheter drainage only, without 
the need for surgical necrosectomy.29 Patients who did not improve after PCD 
underwent a VARD procedure. The PANTER trial was the first randomized trial 
showing that PCD could act as definitive treatment for infected necrosis and 
obviates surgical necrosectomy in over 30% of patients. Having found that, we 
performed a systematic review on the use of PCD in patients with (suspected) 
infected necrotizing pancreatitis, described in Chapter 6, including the results 
of the PANTER trial.
 A well-known complication of pancreatic surgery in patients with 
necrotizing pancreatitis is a long lasting pancreatico-cutaneous fistula, with a 
reported incidence of 17-76%.39-42 Most of these fistulas persist after removal 
of a percutaneous drain left after necrosectomy or PCD. In the PANTER trial, 
this complication occurred in 29/88 of the randomized patients (33%), without 
difference in incidence between patients with open surgical necrosectomy and 
the minimally invasive step-up approach.29 Pancreatic fistulas are associated 
with considerably morbidity, consisting of metabolic and nutritional 
disturbances, they prolong hospitalization and frequently mandate surgical 
re-interventions.40 Conservative treatment is preferred but spontaneous 
resolution could take as long as weeks to months. Endoscopic transpapillary 
stenting (ETS) is proposed to be a proper alternative to conservative treatment 
in patients with pancreatico-cutaneous fistulas.43-45 Chapter 7 described 35 
patients identified from the PROPATRIA and PANTER studies with a persisting 
fistula who were managed conservatively or with ETS and showed that ETS 
could be a safe and feasible alternative to conservative treatment.
 In 2011, our group reported on the timing of cholecystectomy in patients 
with mild biliary pancreatitis.46 Only 142/267 patients (53%) underwent 
cholecystectomy within the 3 weeks after index admission, as recommended 
in the Dutch guidelines. Moreover, of all 249 patients who were discharged 
after index admission for delayed cholecystectomy, 14% of patients (n=34) 
suffered from recurrent biliary events (10%, n=24, biliary pancreatitis) in the 
interval prior to cholecystectomy. Current international guidelines for acute 
pancreatitis recommend early cholecystectomy after mild biliary pancreatitis, 
however, consensus on the definition of “early” is lacking.5,8,9,47 Chapter 8 shows 
the results of a systematic review on the optimal timing of cholecystectomy in 
patients with mild biliary pancreatitis.
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ABSTRACT
Objectives: Enteral nutrition and probiotic prophylaxis in patients with 
predicted severe acute pancreatitis may lead to an increased mortality, 
possibly related to non-occlusive bowel ischemia. We investigated the 
interaction between enteral nutrition and probiotics in the gastro-intestinal 
tract in a dynamic, computer-controlled model of the small intestine (TIM-1).
Methods: The TIM-1 system mimics the gastro-intestinal tract. Several effects 
were tested in this system: a) the addition of pancreatic enzymes and/or, b) the 
addition of probiotics, and c) the administration of different types of enteral 
nutrition: ‘fibre-rich’ and ‘protein-rich’. Total lactic acid and short-chain fatty 
acids (SCFA) production were to determine the effect of digestive enzymes 
and enteral nutrition on local probiotic activity. 
Results: Metabolic activity of the probiotics, expressed as lactic acid and 
SCFA production, increased when pancreatic enzymes were added to the 
TIM-1 system while addition of bile salts decreased metabolic activity. Fibre-
rich enteral nutrition resulted in a higher SCFA production than protein-rich 
enteral nutrition. 
Conclusion: Pancreatic enzymes increased and bile salts decreased 
metabolic activity of probiotics. Fibre-rich enteral nutrition resulted in more 
heterofermentative bacterial activity and SCFA production. No direct clues 
have been found in the search for the increased mortality in patients with 
pancreatitis treated with probiotics.  
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INTRODUCTION
Bacterial translocation from the small bowel is generally considered to be the 
main cause of bacteriaemia and ensuing infection of pancreatic necrosis.1-3 
Early start of enteral feeding, prophylactic use of antibiotics, and prophylactic 
use of probiotics have been hypothesized to reduce the infection rate in 
acute pancreatitis (AP). Only for enteral nutrition a reduction of infections 
and mortality in AP has been indeed reported.4,5 Although antibiotics are 
widely used, several meta-analyses show that prophylactic use does not 
reduce infectious complications and mortality.6,7 Three randomized trials have 
evaluated the prophylactic use of probiotics in patients with predicted severe 
pancreatitis.8-10 The first trial by Olah et al showed a reduction of systemic 
infection and the second trial showed no effect.8 Both trials by Olah et al, 
although promising, had some distinct shortcomings (e.g. small sample size 
and poor methodological quality).8,9 The Dutch PROPATRIA study included 
almost 300 patients with predicted severe pancreatitis who were randomized 
for prophylactic use of probiotics or placebo.10 The study hypothesis was 
that prophylactic use of probiotics would reduce the rate of infectious 
complications, but no effect on this endpoint was shown. Unexpectedly, 
probiotic prophylaxis was associated with increased mortality and a high rate 
of non-occlusive bowel ischemia.10 A causal relation between administration of 
probiotics and non-occlusive bowel ischemia has not been established yet. It 
has been hypothesized that, in these very sick patients, a negative interaction 
between enteral administration of probiotics and enteral feeding through a 
nasojejunal feeding tube has led to an increased oxygen demand, resulting in 
non-occlusive bowel ischemia. An alternative, but not mutual exclusive theory, 
is that probiotics had generated potentially cytotoxic fermentation products 
from the enteral nutrition. However, up to now, neither of these hypotheses 
has been tested in an experimental setting.
 In 1995, Minekus et al developed a dynamic, computer-controlled model 
to allow simulation of in vivo conditions of the stomach and small bowel, 
nick-named TIM-1.11 This in vitro model mimics the gradual transit of ingested 
compounds through the upper digestive tract and has been validated and used 
for many studies, including survival and metabolic activity of probiotics in the 
gastro-intestinal tract.12,13
 The objective of this study was to investigate the effect of the probiotic 
mixture and enteral nutrition used in the PROPATRIA study in TIM-1 to identify 
fermentation products which are suggested to have a cytotoxic effect on 
intestinal mucosa in patients with systemic inflammatory syndrome (SIRS) in 
general and acute pancreatitis specifically. It was hypothesized that in case 
of severe pancreatitis, the production of pancreatic exocrine enzymes and 
endocrine function are severely suppressed and as a consequence, pancreatic 
enzyme excretion to the duodenum would be significantly decreased. 
In addition, obstructive jaundice is a common co-phenomenon in acute 
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pancreatitis leading to a decrease in bile salt secretion to the duodenal lumen. 
Thus, the experiments were designed to mimic these pathophysiological 
processes in the proximal part of the small bowel.
 We were particularly interested in: 1) which intraluminal conditions 
increased the metabolic activity of the probiotics most and 2) whether the 
composition of enteral nutrition could influence the metabolic activity of the 
probiotics.
MATERIALS AND METHODS
Dynamic gastrointestinal system
TNO’s dynamic, computer-controlled in vitro gastro-intestinal model of the 
stomach and small intestine (TIM-1) was used in the current study and is 
schematically shown in Figure 1. The technical details of system, including 
validation, were previously described by Minekus et al.11 In short, the system 
comprises four different compartments, the stomach, duodenum, jejunum 
and ileum which are sequentially connected via computer-controlled valves, 
controlling the transit time through the compartments. A temperature of 37°C 
is maintained throughout the system. In the stomach compartment, water, 
gastric acid and stomach enzymes are added, whereas bile salts, pancreatic 
enzymes and electrolytes are added in the duodenum. Addition of bicarbonate 
takes place in the small intestinal compartments, to control and maintain 
the pH. Peristaltic gastrointestinal movements are simulated by alternate 
contractions of the flexible walls of the different compartments. Dialysis of 
bowel content is performed in the jejunum and ileum compartments by two 
hollow fiber devices with a closed dialysis system (Figure 1). For further details 
see Martinez et al.13 
Probiotics
A probiotic mixture, identical to the product used in the clinical trial, of six viable 
and freeze-dried probiotic strains was used (Ecologic® 641; Winclove Probiotics 
b.v., Amsterdam, the Netherlands) containing three Lactobacillus strains 
(L. aidophilus W70, L. casei W56 and L. salivarus W24), two Bifidobacterium 
strains (B. bifidum W23 and B. lactis W52 (previously classified as B. infantis 
W52)) and Lactococcus lactis W58, together with carrier substance (corn-
starch). The placebo consisted of carrier substance only. The probiotic or 
placebo product was reconstituted in sterile water for 15 minutes at 37°C 
before addition to TIM-1. The probiotic mixture was administered in a single 
shot of 5.0 ml (containing a total of 5 x 109 CFU bacteria) to the duodenum 
compartment one hour after start of the experiment, to mimic administration 
in the PROPATRIA patients.10
CHAPTER 2: METABOLIC CONSEQUENCES OF THE INTERACTION BETWEEN ENTERAL NUTRITION AND 
MULTISPECIES PROBIOTICS (ECOLOGIC® 641) IN AN IN VITRO MODEL OF THE SMALL INTESTINE
27
Figure 1. Schematic view of the TIM-1 system. A: gastric compartment; B: pyloric sphincter; 
C: duodenum compartment; D: peristaltic valve; E: jejunum compartment; F: peristaltic 
valve; G: ileum compartment; H: ileo-cecal valve; I: stomach secretion of water, enzymes and 
acid; J: duodenum secretion bottles with bile, pancreatin and bicarbonate; K: secretion of 
bicarbonate to control the intestinal pH; L: pre-filter system; M: semi-permeable membrane 
system (hollow fibers); N: closed dialyzing and water absorption system; O: dialysate; P: pH 
electrodes; Q: level sensor; R: temperature sensor; S: pressure sensor.11,13
Table 1. Experimental conditions used. PP: Nutrison Protein Plus, MF: Nutrison Multi Fibre, BS: 
bile salts, PE: pancreatic enzymes  
Experiment Condition
1 PP + placebo
2 PP + placebo + BS
3 PP + placebo + PE + BS
4 PP + probiotics
5 PP + probiotics + BS
6 PP + probiotics + PE
7 PP + probiotics + PE + BS
8 MF + probiotics
9 MF + probiotics + PE + BS
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Enteral nutrition
To resemble the clinical situation of patients with acute pancreatitis, enteral 
nutrition (Nutrison Multi Fibre or Nutrison Protein Plus, Nutricia, Zoetermeer, 
the Netherlands) was administered directly into the duodenal compartment, 
bypassing the gastric compartment. By using a syringe pump, enteral nutrition 
was continuously administered to the duodenal compartment with an infusion 
rate of 33 ml per hour (as in proportion to the in vivo situation in patients). 
Preliminary batch experiments (not shown) did not reveal a difference in 
lactic acid production by the probiotic mixture between both types of enteral 
nutrition. Although Nutrison Multi Fibre was used in the PROPATRIA study, 
nowadays in the clinical setting protein enriched-enteral nutrition is preferred 
above fibre-enriched enteral nutrition. Therefore, and since there was no 
difference between the two nutrition types in batch experiments, most of the 
experiments were performed with Nutrison Protein Plus.
Experimental design
Each experiment with TIM-1 lasted six hours, in an attempt to copy the slower 
transit time through the small intestinal tract of a pancreatitis patient. Table 
1 shows the different conditions for each experiment. During the TIM-1 
experiments, the pH in each small intestinal compartment was continuously 
monitored and kept at constant values (duodenum 6.3, jejunum 6.8, and 
ileum 7.2) by addition of bicarbonate, an integral part of exocrine pancreatic 
secretion. The amount of bicarbonate administered during an experiment 
consists of the amount required for maintaining the pH in the compartments 
plus the amount for neutralizing the extra pH decrease, mainly caused by the 
acid produced by probiotic fermentation. Each experiment was performed 
in duplicate. Lactic acid and SCFA production were measured to monitor 
metabolic activity of the probiotics. To that end, every hour, the dialysate (of 
both the jejunum and ileum compartment) and the ileal efflux were collected. 
Samples were taken and stored at -80°C until analysis. 
Measurement of (L- and D-) lactic acid and short-chain fatty 
acids 
Dialysis and effluent samples were centrifuged (12000 rpm, 5 min) and both L- 
and D-lactic acid were determined enzymatically in the supernatant (based on 
Boehringer, UV-method, Cat. No. 1112821) by a Cobas Mira plus autoanalyzer 
(Roche, Almere, The Netherlands). The dialysis samples were analyzed by 
gaschromatography to determine the SCFA concentrations in a Chrompack 
CP9001 gas chromatograph using an automatic sampler (Chrompack liquid 
sampler CP9050; Varian Chrompack). This methodology allows detection of 
acetic acid, propionic acid, butyric acid and valeric acid.14
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Statistical analysis
Per experiment, the total amount of bicarbonate added to the TIM-1 system 
during the experiment was measured and the total amount of lactic acid and 
SCFA in each compartment was calculated. The Mann-Whitney Test was used 
to test statistical differences between groups. All statistics were performed 
with IBM® SPSS Statistics version 20.0.0 (IBM, Chicago, Illinois, USA).
RESULTS
Bicarbonate consumption
In experiments in which pancreatic enzymes were added, significantly more 
bicarbonate was needed to maintain the target pHs in each compartment 
compared to experiments in which pancreatic enzymes were absent (Figure 2) 
(P<0.001). Type of enteral nutrition and the presence or absence of probiotics 
and bile salts did not influence the total amount of bicarbonate needed.
Figure 2. Addition of bicarbonate to the small intestinal compartments of the TIM-1 system, 
used to maintain the pH in these compartments (n=2). MF: Nutrison Multi Fibre, PP: Nutrison 
Protein Plus, PE: pancreatic enzymes, BS: bile salts  
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Total lactic acid production
Figure 3A shows the cumulative lactic acid production under different 
conditions with probiotics and Nutrison Protein Plus. Lactic acid production 
was detected from 60 minutes after start of the experiments onwards, which 
is directly after addition of the probiotics into the duodenal lumen. In the 
presence of pancreatic enzymes, lactic acid production was further increased, 
indicative for enhanced metabolic activity of the probiotics. Bile salts, 
however, decreased total lactic acid production. This inhibitory effect was 
partially compensated by the presence of pancreatic enzymes. The two types 
of enteral nutrition were compared under two different conditions (i.e., in the 
presence of bile salts and pancreatic enzymes, and in the absence of both), as 
shown in Figure 3B. Lactic acid production was increased when Nutrison Multi 
Fibre was used compared to Nutrison Protein Plus. This increased production 
in favour of Nutrison Multi Fibre was also observed when pancreatic enzymes 
and bile salts were added to the system. In none of the experiments with 
placebo (i.e. without the addition of live bacteria), lactic acid production was 
detected (data not shown).
 It is important to note that the differences in lactic acid production between 
the different conditions became apparent after a test period of four hours or 
more. In the first four hours after start of the experiment, no clear differences 
between the various experimental conditions were detectable. In the last 
two hours of an experiment, under conditions with pancreatic enzymes (PE), 
metabolic activity of the probiotics increased (Fig. 3A and 3B).
SCFA production
Production of SCFA, mainly acetic acid (data on proportions of SCFA not shown), 
was measured in four selected experiments in which both types of enteral 
nutrition were compared under two different conditions. The cumulative 
amount of SCFA is shown in Figure 4. In general, the cumulative production 
of SCFA (Fig. 4) was higher than that of lactate (Fig. 3B). As for lactic acid, 
production of SCFA started almost directly after introduction of the probiotic 
mixture in TIM-1. However, again, clear differences between the experiments 
were generally seen four hours after start of the experiment (i.e., three hours 
after administration of the probiotic mixture into the duodenum). In the 
presence of Nutrison Multi Fibre, SCFA production was increased compared to 
Nutrison Protein Plus, as was observed for lactate.
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Figure 3A. Effect of pancreatic enzymes and bile salts on production of lactic acid by probiotics 
in protein-enriched enteral nutrition. The lowest detection level for lactic acid was 0.05 
mmol/L. Pancreatic enzymes enhanced  lactic acid production by the probiotic bacteria. Once 
combined with bile salts, the effect of pancreatic enzymes was neutralized. PP: Nutrison 
Protein Plus, PE: pancreatic enzymes, BS: bile salts
Figure 3B. Effect of pancreatic enzymes and bile salts on production of lactic acid by 
probiotics in different types of enteral nutrition. There was no statistical significant difference 
in metabolic activity of the probiotic bacteria in the presence of a fibre-rich as compared 
to protein-rich type of enteral nutrition of enteral feeding. Once bile salts and pancreatic 
enzymes were added to the substrate, more lactic acid was produced in the presence of fibre-
enriched enteral nutrition. MF: Nutrison Multi Fibre, PP: Nutrison Protein Plus, PE: pancreatic 
enzymes, BS: bile salts  
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DISCUSSION
This study was designed to study the metabolic activity of probiotic strains 
in a controlled environment to investigate whether the combination of acute 
pancreatitis and administration of probiotics with enteral feeding would 
enhance lactic acid and SCFA production. To this end, several circumstances 
such as absence of pancreatic enzymes, and changes in bile salt excretion were 
mimicked. The probiotic mixture was identical to that used in the PROPATRIA 
study (Ecologic® 641).10 
 The findings of this study can be summarized as follows: 1) in the presence 
of pancreatic enzymes the metabolic activity of probiotics is higher. Once 
combined with bile salts, the effect of pancreatic enzymes was abolished. So 
based on these two findings, it seems that pancreatic enzymes play a dominant 
role in the probiotic-lowering of the pH in this model; 2) in the presence of 
Nutrition Protein Plus and probiotics, again the addition of pancreatic enzymes 
has the dominant effect on the pH, demonstrated by the highest production of 
lactic acid under these circumstances. Addition of bile salts seems to mitigate 
this lactic acid production; 3) when Nutrison Protein Plus is replaced by 
Nutrison Multifibre, pancreatic enzyme addition, again, leads to increase of 
lactic acid production; 4) SCFA production was highest after administration of 
pancreatic enzymes, irrespective of the type of enteral feeding added to the 
TIM-1 system. So, on balance it seems that, in a study to compare the in vitro 
effect of composition of enteral feeding, bile salts, pancreatic enzymes and 
probiotics, only the addition of pancreatic enzymes has an overriding effect 
on the lowering of the pH in the lumen of the duodenum and jejunum by 
Figure 4. Production of SCFA with different types of enteral nutrition. The presence of a fibre-
rich type of enteral nutrition resulted in a higher higher production of SCFA by the probiotics 
as compared to a protein-rich type of enteral nutrition. SCFA: Short-chain fatty acids, PP: 
Nutrison Protein Plus, PE: pancreatic enzymes, BS: bile salts
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the probiotics. Apparently, the pancreatic enzymes digest components of the 
enteral nutrition such that the probiotics can metabolize them into lactic acid 
and SCFA.
 In the current study, a validated in vitro model for gastrointestinal passage 
was used. The advantage of the TIM-1 system is the ability to investigate the 
metabolic activity of the probiotics under specific conditions, such as presence 
or absence of bile and pancreatic juice. Samples from different compartments 
could be taken any time during the experiment and transit times of the 
system could be adapted, allowing mimicking patients with acute pancreatitis. 
Since the system does not contain host cells, the metabolites produced by 
the bacteria are not used by the host cells and therefore the production of 
metabolites can be monitored. Consequently, the results of this study are very 
useful for further in vitro and in vivo studies. Extrapolation of the results to the 
clinical situation, however, is difficult because of the absence of bowel mucosa 
and resident intestinal microbiota. Furthermore, the temporal changes in bile 
salt secretion and/or pancreatic enzyme production during acute pancreatitis 
have not been studied in detail and published data are controversial. 
 How can our findings – dominant effect of pancreatic enzymes leading 
to lowering of intraluminal pH by the probiotics – be put into the clinical 
perspective of a higher death rate and a possible induction of small and large 
bowel ischemia in patients with severe pancreatitis receiving the combination 
of enteral feeding and enteral probiotics? Or can our findings be balanced 
with our hypothesis that lactic acid and SCFA may have a toxic effect on 
bowel mucosa leading to mucosal necrosis and ensuing complications like 
bacteriemia with infection of pancreatic necrosis, bowel perforation and 
increase of mortality as a result of these complications? Data in the literature 
on enzyme secretion in acute pancreatitis are scarce. In 2005, O’Keefe et al 
showed that patients with acute pancreatitis have lower rates of secretion 
of digestive enzymes in the duodenum compared to healthy volunteers.15 
However, it was also shown that patients with severe necrotizing pancreatitis 
synthesized newly pancreatic enzymes more rapidly than patients with mild 
pancreatitis or even healthy volunteers.15 Unfortunately, only 12 patients 
were included in this study and at least three patients suffered from recurrent 
attacks of acute pancreatitis. One may question whether these patients with 
recurrent attacks did not already suffer from exocrine dysfunction due to a 
subclinical chronic pancreatitis. So, no clue is given on the exact changes in 
secretion during acute pancreatitis and its potential effect on complications. 
In contrast to these clinical data, Czako et al found that the basal pancreatic 
fluid secretion in the duodenum was greatly increased in a mouse model of 
experimental pancreatitis. However, the concentration of pancreatic enzymes 
in the pancreatic fluid was dependent of the severity of the pancreatitis, with a 
lower enzyme concentration in rodents that show a more severe pancreatitis.16  
In our in vitro study, two ‘extreme’ conditions regarding pancreatic enzyme 
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secretion were tested, i.e. with and without pancreatic enzymes in the 
duodenum. Although in the literature no exact data are available on the 
exact level of increase or decrease in duodenal concentrations of pancreatic 
enzymes, it is generally accepted that there still is some residual pancreatic 
enzyme secretion in the duodenum during an attack of acute pancreatitis.15,16 
Therefore, we think that in our study the conditions with the presence of 
pancreatic enzymes reflect the pathophysiological situation, like in acute 
pancreatitis, best.
  There is also limited information on the effect of lactic acid production in 
case of severe pancreatitis. In the last two decades, the heterofermentative 
capacity of lactic acid producing bacteria has extensively been investigated in 
the food industry.17-19 In addition to lactic acid, lactobacilli produce acetate. In 
the current study, acetic acid was the most predominant SCFA present in the 
ileal efflux of the TIM-1system (60-80%). The probiotic strain which is thought 
to be mainly responsible for production of the acetate in our experiments is 
L. casei, although bifidobacteria also produce acetate. All other Lactobacillus 
and Lactococcus species in Ecologic 641 are homofermentative. It is to be 
expected that the SCFA production by bifidobacteria in Ecologic 641, would 
mainly take place in the colon and not in the small bowel.20,21
 Up to now, it is completely unknown what underlying mechanism can 
possibly be held responsible for a probiotic-induced bowel ischemia in the 
patients with pancreatitis. The current study shows that a considerable amount 
of lactic acid and SCFA are produced when enteral feeding and a probiotic 
mixture are administered in the artificial bowel lumen.  Addition of pancreatic 
enzymes seems to further accelerate the metabolic activity of the probiotics, 
reflected in a further increase of lactic acid and SCFA production. However, 
whether these production levels of lactic acid and SCFA are comparable with 
the clinical situation is not known, since concentrations in vivo cannot be 
measured. Moreover, whether or not these lactic acid and SCFA concentrations 
can be harmful in man in case of pancreatitis cannot be tested in the type of 
experiment that we have conducted. 
 In the TIM-1 experimental set-up, it is not possible to test the cytotoxic 
effect of lactic acid and SCFA on enterocytes, because of the absence of gut 
epithelial cells in the TIM-1 system. Although it was assumed that the probiotic 
strains in Ecologic® 641 would produce lactic acid and SCFA, it is unknown at 
what concentration these become toxic to the gut mucosa of AP patients. 
 This in vitro study has obvious limitations. Only one single dose of 
probiotics was administered, whereas in the PROPATRIA study probiotics 
were administered for 28 consecutive days.10 Whether such prolonged 
administration of probiotics and thus prolonged exposure of enterocytes to 
lactic acid or other microbial metabolites have led to the dramatic results of 
the PROPATRIA study remains unclear. The facts that TIM-1 does not carry 
endogenous intestinal microbiota, has no intestinal mucosa and only allows 
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for acute experiments, are distinct drawbacks and limitations. However, 
this model was chosen, since TIM-1 has been shown to be very useful for 
metabolic studies in general and, as a consequence, to study the effect of 
probiotics under several experimental conditions, impossible to be conducted 
in vivo. Furthermore, since bowel mucosa is absent, a full mass balance of the 
produced microbial metabolites could be made without interference of other 
local metabolic processes induced or facilitated by resident microbiota in the 
ileum of patients with acute pancreatitis. The main strength of the current 
study, is that in the TIM-1 model probiotic activity can directly be tested under 
several preset conditions in each compartment of the digestive tract, thus 
allowing mechanistic studies on pathophysiological phenomena in the gut. To 
answer the question on the relation between concentration of lactic acid/SCFA 
and cytotoxicity and whether this could contribute to non-occlusive mucosal 
ischemia, in vitro experiments with cell cultures (e.g., Caco-2 cells) would have 
to be performed.
 In summary, the current study shows that pancreatic enzymes increase the 
probiotic activity. The administration of fibre-rich enteral nutrition resulted 
in an increase of lactate and SCFA production more than protein-rich enteral 
nutrition. Future experiments are directed towards effects of microbial 
metabolites on in vitro cell cultures to unravel the underlying mechanism of 
probiotic-induced bowel ischemia.
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ABSTRACT
Background / Objectives: Recently, a randomized controlled trial showed 
that probiotic prophylaxis was associated with an increased mortality in 
enterally fed patients with predicted severe pancreatitis. In a rat model for 
acute pancreatitis, we investigated whether an association between probiotic 
prophylaxis and enteral nutrition contributed to the higher mortality rate.
Methods: Male Sprague-Dawley rats were allocated to four groups: 1) acute 
pancreatitis (n=9), 2) acute pancreatitis and probiotic prophylaxis (n=10), 3) 
acute pancreatitis and enteral nutrition (n=10), and 4) acute pancreatitis, 
probiotic prophylaxis and enteral nutrition (n=11). Acute pancreatitis was 
induced by intraductal glycodeoxycholate and intravenous cerulein infusion. 
Enteral nutrition, saline, probiotics and placebo were administered through a 
permanent jejunal feeding. Probiotics or placebo were administered starting 
4 days before induction of pancreatitis and enteral nutrition 1 day before start 
until the end of the experiment, 6 days after induction of pancreatitis. Tissue 
samples and body fluids were collected for microbiological and histological 
examination. 
Results: In all animals, serum amylase was increased six hours after induction 
of pancreatitis. After fulfilling the experiment, no differences between groups 
were found in histological severity of pancreatitis, degree of discomfort, 
weight loss, histological examination of small bowel and bacterial translocation 
(all p>0.05). Overall mortality was 10% without differences between groups 
(p=0.54). 
Conclusion: No negative association was found between prophylactic 
probiotics and enteral nutrition in acute pancreatitis. No new clues for a 
potential mechanism responsible for the higher mortality and bowel ischemia 
in the PROPATRIA study were found.
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INTRODUCTION
Acute pancreatitis runs a mild course in the majority of patients. However, 20% 
of patients develop a severe pancreatitis with the presence of peripancreatic 
or pancreatic necrosis and (multiple) organ failure.1 If the necrosis becomes 
infected, this is associated with a mortality of 15-25% and a morbidity rate 
of 50-100%.2-5 Infection of necrotic pancreatic tissue is caused by bacterial 
translocation from the intestines and is thought to be preceded by three 
pathophysiological processes: 1) bacterial overgrowth of the small bowel due 
to decreased bowel motility, 2) dysfunction of the local mucosal and systemic 
immune system, and 3) increased intestinal permeability, resulting in bacterial 
translocation to other sites, such as the pancreas.6-8 Reduction of bacterial 
translocation may reduce the rate of secondary infection of the pancreatic 
necrosis and decrease mortality and morbidity. 
 In 2006, our study group started a multicenter placebo-controlled 
randomized trial (PROPATRIA) on probiotic prophylaxis in patients with 
predicted severe pancreatitis.9 Based on the results of a smaller trial, the aim of 
the study was to reduce the number of infectious complications. However, no 
difference in infection rate between the two groups was observed.10 Strikingly, 
probiotic prophylaxis turned out to be associated with an unexpected high 
mortality rate, possibly related to the presence of bowel ischemia (4% vs. 0% 
in the placebo arm, p=0.004).10 These unexpected and unexplained findings 
prompted others to stop planned and ongoing trials on probiotic prophylaxis 
in severely ill patients.11,12 
In previous experiments we observed that prophylactic use of probiotics 
improved survival in rats.13,14 The underlying mechanism for the negative effect 
of the combination of enteral probiotics with enteral nutrition in patients with 
predicted severe pancreatitis is unknown and stands in strong contrast to the 
previous findings of the protective effect of prophylactic probiotics in rats with 
acute pancreatitis. In order to address this mechanism, we investigated the 
relation between probiotic administration and enteral nutrition in a rat model 
of acute pancreatitis.
MATERIALS AND METHODS
Animals
Male specific pathogen-free Sprague-Dawley rats (Harlan, Horst, the 
Netherlands) with a mean bodyweight of 328 grams (range 91 grams) and 
age between 10-12 weeks were kept under constant housing conditions 
(temperature 22°C), relative humidity (60%) and a 12-hour light-dark cycle). 
Prior to the first surgical procedure, rats were allowed to adjust to these 
conditions for at least one week. During this week, all animals had unlimited 
access to water and food. Rats were randomly divided into four groups: 1) acute 
pancreatitis (jejunal cannula, 0.9% sodium chloride and placebo, n=9), 2) acute 
pancreatitis and probiotics (jejunal cannula and 0.9% sodium chloride, n=10), 
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3) acute pancreatitis and enteral nutrition (jejunal cannula and placebo, n=11) 
and 4) acute pancreatitis, probiotics and enteral nutrition (jejunal cannula, 
n=11). Animals were terminated at the end of the experiment, 6 days after 
induction of acute pancreatitis. The experimental design, as shown in Figure 1, 
was approved by the Regional Animal Ethics Committee of the Radboud UMC 
and was conducted under the guidelines of the Dutch Council for Animal Care 
and the National Institutes of Health.
Enteral nutrition
The animals allocated to group 3 and 4 received sterile enteral nutrition 
(Nutrison Multi Fibre, Nutricia, Zoetermeer, the Netherlands). Animals in groups 
one and two received (sterile) saline as substitution to the enteral nutrition. 
The saline and enteral nutrition were infused through the permanent jejunal 
cannula from day -1 to the end of the experiment on day 6 (Figure 1). On day 
-12, a swivel jacket was fitted and the rat was able to adjust to the jacket for 
one week. The swivel jackets were checked daily and, if necessary, adapted to 
the body size of the rat. From day -1 to the end of the experiment, each animal 
was connected to a swivel system for nine hours per day (usually from 9.00 
a.m. to 6.00 p.m.). As shown in Figure 2, the complete swivel system consisted 
of a syringe pump, a swivel device and a swivel mount, all interconnected by 
tubing. The system was used to allow free movement of the animal through 
the cage during connection (all parts of the swivel system and swivel jacket: 
Instech Laboratries Inc, Plymouth, PA, USA). When connected, the syringe 
pump continuously administered the enteral nutrition or the saline with an 
infusion rate of 1.5 ml/hour. During the nine hours of connection to the swivel 
system rats were withheld from other food. However, when disconnected, 
animals had unlimited access to food (RMH 11110, Hope Farms, Woerden, 
The Netherlands). Throughout the whole experiment, whether connected or 
disconnected to the swivel system, all animals had free access to water. 
Probiotics and placebo
The probiotics (Ecologic® 641, Winclove Probiotics, Amsterdam, the Netherlands) 
consisted of six viable and freeze-dried probiotic strains; four lactobacilli 
(Lactobacillus acidophilus (W70), Lactobacillus casei (W56), Lactobacillus 
salivarus (W24), Lactobacillus lactis (W58)), and two bifidobacteria strains 
(Bifidobacterium bifidum (W23) and Bifidobacterium infantis (W52)). The placebo 
consisted of carrier substance only (corn-starch). Directly before administration 
of the probiotics and the placebo, both products were reconstituted in sterile 
water for 15 minutes at 37°C. A single probiotics dose in a volume of 1.0 ml 
contained a total of 5 x 109 Colonic Forming Unit (CFU) bacteria. According to 
van Minnen et al, both probiotics and placebo were administered once daily 
through the permanent jejunal cannula, starting five days prior to induction of 
the pancreatitis until the end of the experiment.13
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Figure 1. Experimental design. At the start of the experiment, 12 days prior to induction of 
acute pancreatitis, a swivel jacket was fitted to all animals, which were subsequently allowed 
to adjust to this jacket for seven days. On day -5, a jejunal cannula was fitted. From day -4 
onwards, daily probiotics or placebo were administered through the permanent cannula. One 
day before induction of the pancreatitis, animals received daily enteral nutrition or saline 
which continued until the end of the experiment. On day 0, acute pancreatitis was induced 
and seven days later, on day 6, all surviving animals were anesthetized to allow sterile removal 
of organs and blood samples, followed by termination.
Figure 2. Swivel system. A: The complete swivel system consisted of a syringe pump, a swivel 
mount with a swivel device, all interconnected with tubing. B and C: fitting the swivel jacket 
to the proportion of the rat. D: Connection of the swivel arm to the swivel jacket. Illustrations 
provided by Instech Laboratories Inc, Plymouth, PA, USA.
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Surgical procedures
All surgical procedures were performed by the responsible researcher (MCvB), 
usually with assistance of members of the technical staff (MvR, FvdP or IvdB). 
Every procedure was conducted under general anaesthesia, using continuous 
intravenous administration of 30 mg/kg/h Alfaxan® (alfaxalone 10 mg/ml, 
Vetoquinol UK limited, Buckinham, United Kingdom) via a tail vein. However, 
rarely, in case of very poor vascular access, gas anaesthesia through a snout 
mask was used as an alternative (2% isoflurane gas, flow: 0.5 l/min O2, 1.5 l/
min air). At least at 30 minutes prior to every surgical procedure, as well as up 
to three days post-operatively, once daily intra-muscular injections of 5 mg/
kg Rimadyl (Carprofen 50 mg/ml, Pfizer Animal Health, West Ryde, New South 
Wales, Australia), a long-acting non-steroidal anti-inflammatory drug (NSAID), 
was administered for pain relief. All surgical procedures were performed on a 
heated operating table with sterile instruments under aseptic conditions. Body 
temperature of all animals was kept between 37 and 38.5 degrees Celcius.
Jejunal cannulation
Seven days after fitting the swivel jacket, rats were anaesthetized to fit the 
permanent silicone jejunal cannula (outer diameter 1.4 mm, inner diameter 0.6 
mm, Instech Laboratories Inc, Plymouth, PA, USA). Under general anaesthesia, 
a 1.5 cm midline laparotomy was made to insert the end of the jejuna cannula 
into the stomach through a puncture in the greater curvature. Subsequently, 
the cannula was tunneled through the stomach and the sphincter and moved 
up manually through the duodenum into the jejunum. The cannula was 
securely fixed with a purse-string suture in the stomach wall. A puncture hole 
was made in the muscular layer, through which the other end of the cannula 
entered the subcutaneous space. Subsequently, the cannula was tunneled 
subcutaneously from the abdominal wall to the back, penetrating the skin 
between the scapulae, just underneath the connection part of the swivel 
jacket. The cannula was connected to the swivel jacket and the abdomen was 
closed in two layers. All animals were allowed to recover for one day before 
administration of the probiotics or placebo and for five days before induction 
of the pancreatitis.
Induction of acute pancreatitis
On day 0, five days after fitting the permanent jejunal cannula, acute 
pancreatitis was induced by the internationally well accepted model for acute 
pancreatitis, described by Schmidt et al.18 Under general anaesthesia, with 
a midline relaparotomy, the papilla of Vater was cannulated transduodenally 
(24G Abbocath®-T i.v. infusion cannula, Abbott, Sligo, Republic of Ireland). 
Subsequently, the common bile duct was clamped and 0.5 ml (infusion rate: 
3 ml/hour) sterilized glycodeoxycholic acid in glycylglycine-NaOH-buffered 
solution (10 mmol/l, pH 8.0, 37°C, chemicals obtained from Sigma-Aldrich 
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Chemie BV, Zwijndrecht, the Netherlands) was infused into the common bile 
duct and pancreas. Directly after infusion, the clamp was removed and the 
puncture hole in the duodenum was sutured. After closure the abdomen in two 
layers, rats were kept under general anesthesia to allow intravenous cerulein 
infusion with 5 μg/kg/hr for six hours (Cerulein, Sigma-Aldrich Chemie BV, 
Zwijndrecht, the Netherlands). During these six hours, body temperature was 
maintained with a heating pad and rats were connected to a pulse-oxy device 
to check vital parameters every 15 minutes. Due to ventilation problems 
which were encountered in earlier experiments (not published), all animals 
were intubated to maintain a free airway and glycopyrrolate (0.04mg/kg body 
weight every 2 hours during general anesthesia) (Sigma-Aldrich Chemie BV, 
Zwijndrecht, the Netherlands) was administered to reduce salivary, pharyngeal 
and tracheobroncheal secretions. Fluid substitution was provided by hourly 
subcutaneously injections of 2 ml 0.9% sodium chloride. After six hours of 
cerulein infusion, all animals were disconnected and were allowed to recover 
in their home cage.
Pain relief
As mentioned before, prior to every surgical procedure and up to three days 
postoperatively, a long-acting NSAID was administered (Rimadyl). Since in 
humans acute pancreatitis is a very painful disease, all animals received daily 
subcutaneous injections of this long-acting NSAID, starting at induction of the 
pancreatitis to the end of the experiment. 
Animal welfare
Animal welfare was assessed by daily repeated observations and bodyweight 
measurements. For scoring the clinical response a multiple aspect, 0-2 points 
scoring system was used: Grooming behaviour: normal = 0 points, moderate 
decrease = 1 point, severe decrease = 2 points. Mobility: normal = 0 points, 
small-moderate decrease = 1 point, severe decrease = 2 points. Response to 
external stimuli: normal = 0 points, small-moderate hypo/hyperresponsive 
= 1 point, severe hypo/hyperresponsive = 2 points. Pain posture: none = 0 
points, moderate pain posture = 1 points, severe pain posture = 2 points. A low 
cumulative score reflects mild discomfort, whereas a high cumulative score 
reflects severe discomfort. Aspects of this scoring system are well recognized 
behavioural parameters expressing health or morbidity, including abdominal 
and visceral pain.15 A cumulative score of 7 or more was defined as extreme 
suffering (and considered to be the humane endpoint). In case of extreme 
suffering, rats were euthanized without delay by suffocation with CO2, followed 
by cervical dislocation. Obduction was performed in all euthanized animals.
Collection of tissue and fluid samples
Blood samples (0.2 ml) were taken from the tail vein immediately before (t 
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= 0 hrs), and after 6 hours (t = 6 hrs), 24 hours (t = 24 hrs) and at the end 
of the experiment, 6 days after induction of acute pancreatitis. In case of 
survival without extreme suffering, animals were terminated at the end of 
the experiment, six days after induction of the acute pancreatitis. These 
animals were anesthetized to allow sterile removal of the pancreas. In order to 
control for potential organ damage, all organs were subjected to macroscopic 
inspection. After tissue collection, rats were euthanized by terminal blood 
loss, followed by cervical dislocation.
Histological examination
Samples from the jejunum, ileum and pancreas were collected and stored 
in formalin and subsequently embedded in paraffin for histopathological 
analysis. A standard haematoxylin and eosin (H&E) staining was performed. 
Histopathological severity of acute pancreatitis was assessed based on the 
acute pancreatitis scoring system as previously described (Table 1).16 Intestinal 
histology was assessed by the following parameters: crypt-villus proportion, 
ischemia throughout the different layers of the bowel wall, presence of 
inflammatory cells, localisation of the inflammatory cells, hemorrhagic 
changes, epithelial destruction, oedema, arteriitis, and the presence of 
peritonitis (Table 2). Scores of the jejunum and ileum were added to obtain 
a final score. Severe tissue damage is reflected by a high cumulative score, 
whereas minor damage is reflected by a low cumulative score.
DNA isolation and real-time PCR assay for total bacterial 
quantification
Pancreas biopsies were stored at -80°C prior to DNA extraction. Total DNA 
was extracted from pancreas biopsies using the repeated bead beating 
method in combination with the QiaAmp DNA Mini Stool Kit (Qiagen, Hilden, 
Germany). DNA was quantified using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop® Technologies, Wilmington, DE) and adjusted to 10-20 ng/μl as 
template for subsequent 16S rRNA gene PCR analysis. Quantitative PCR (qPCR) 
was performed in 384-well PCR plates (Bio-Rad Laboratories, Hercules, CA) 
sealed with Microseal B film (Bio-Rad) using a CFX384 Touch™ Real-Time PCR 
Detection System with CFX manager™ software version 2.0 (Bio-Rad). Each 
reaction was carried out in a total volume of 25 μl using iQ™ SYBR Green 
Supermix (Bio-Rad) according to the manufacturer’s instructions with 200 nM 
of each primer and 5 μl template DNA. The universal primer set Bact1369 
(5’-CGG TGA ATA CGT TCY CGG-3’) and Prok1492 (5’-GGW TAC CTT GTT ACG 
ACT T-3’) was used for quantification of total bacterial 16S rRNA gene copies. 
The amplification program consisted of an initial denaturation step at 95°C for 
10 min, followed by 40 cycles of 15 s at 95°C, 30 s at 56°C, and 30 s at 72°C, 
followed by a melt-curve analysis. All reactions were performed in triplicate. 
Standard curves were generated from a dilution series of 16S rRNA gene 
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Item description Score
Peripancreatic
No pathology
Fat inflammation / mild peritonitis
Fat necrosis / peritonitis
0
1
2
Edema
None
Interlobular expansion
Interacinar expansion
0
1
2
Ducti / Ductuli
No pathology
Inflammation
0
1
Inflammatory infiltrate
None
1 - 10 intralobular or perivascular leukocytes / HPF
11 - 20 intralobular or perivascular leukocytes / HPF
21 - 30 intralobular or perivascular leukocytes / HPF
> 30 intralobular or perivascular leukocytes / HPF
0
1
2
3
4
Acinar cell pathology
None
Focal cytoplasmatic changes
Extensive cytoplasmatic changes
Degeneration with nuclear changes
Focal necrosis
Extensive necrosis
0
1
2
3
4
5
Acinar dilatation
None
Focal
Extensive
0
1
2
Hemorrhagic changes
None
Focal interlobular erythrocytes
Extensive interlobular erythrocytes
Focal parenchymal erythrocytes
Extensive parenchymal erythrocytes
0
1
2
3
4
TOTAL SCORE Max 20
Table 1. Histopathologic scoring criteria pancreas. HPF: High power field (400x). Modified from 
Schmidt et al.18
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fragments amplified from the target sequence (108 to 100 copies/μl). Number 
of rRNA gene copies per gram pancreatic tissue were calculated and compared 
between groups.
Serum amylase assay
Serum amylase concentrations were determined in blood samples collected 
on t = 0 hrs, t = 6 hrs, t = 24 hrs and at the end of the experiment, 6 days after 
induction of acute pancreatitis. After sample collection, blood was centrifuged 
on 13.000 rpm for 10 minutes and the serum was stored at -80°C until analysis. 
For amylase quantification an amylase kit (DAMY-100 QuantiChromTM 
α-Amylase Assay Kit, Gentaur, Kampenhout, Belgium) was used according to 
the manufacture’s guidelines. All samples were tested at 1:2, 1:4, 1:15 and 1:40 
dilutions and the amylase concentration was calculated from the dilution(s) 
with a reading in the linear part of the calibration curve.
Statistical analysis
Mortality was analyzed with the Chi-square test. Health scores and body 
weights were analyzed with repeated measurement ANOVA, followed by 
Bonferroni posthoc analyses. Histological scores and bacterial translocation 
were compared between groups using ANOVA. Only animals which completed 
the experiment or animals euthanized because of reaching the humane 
endpoint were used to calculate the histological scores. All other scores were 
calculated with animals which completed the experiment. P-values <0.05 were 
considered statistically significant. All analyses were performed using SPSS® 
for Windows® version 20 (IBM, Chicago, Illinois, USA).
RESULTS
Morbidity and mortality
Placement of the jejunal canula on day -5 resulted in mild post-operative 
discomfort, as indicated in Figure 3. On day 0, the time of induction of 
acute pancreatitis, mean average degree of discomfort was 0.68 (range 0-1), 
indicating that all animals recovered well from surgery. After induction of 
pancreatitis, all animals showed an increase in discomfort which lasted until 
the end of the experiment. Although the degree of discomfort fluctuated, no 
clear-cut pattern was observed. No difference in degree of discomfort was 
found between groups throughout the experiment, suggesting that probiotics 
did not reduce clinical severity of acute pancreatitis and that enteral feeding 
has no additional effect.
 Next to the behaviour scoring system as parameter for clinical severity of 
experimental pancreatitis, overall change in bodyweight also was taken as 
marker for severity of acute pancreatitis. Figure 4 shows the changes in mean 
bodyweight per group throughout the experiment. Prior to induction of acute 
pancreatitis, all animals regained their initial bodyweight after insertion of the 
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Item description Score
Crypt-villi proportion
Normal 
Crypt hyperplasia
Partial villous atrophy
Total villous atrophy
0
1
2
3
Ischemia
None
Thrombi
Necrosis
0
1
2
Inflammation
None
Focal neutrophylic infiltration
Extensive neutrophylic infiltration
0
1
2
Localisation of inflammation
None
Mucosal
Submucosal
Muscular
0
1
2
3
Hemorrhagic changes
None
Mild
Severe
0
1
2
Epithelial destruction
None
Focal
Extensive
0
1
2
Edema submucosa
None
Focal
Extensive
0
1
2
Edema lamina propria
None
Focal
Extensive
0
1
2
Arteriitis
None
Mild
Severe
0
1
2
TOTAL SCORE Max 20
Table 2. Histopathologic scoring criteria of the small bowel. 
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jejunal canula. From induction of pancreatitis until the end of the experiment, 
all animals lost 9% body weight, on average (mean loss of body weight of 29 
grams). Animals treated with probiotics and enteral feeding started to gain 
weight from day 4 onwards, however, the differences in total bodyweight at 
the end of the experiment were not significant. 
 Overall mortality during the experiment (within the 6 days after induction 
of acute pancreatitis) was 4/41 animals (10%); in group 1, one animal died; in 
group 3, two animals died and in group 4, one animal died. All animals in group 
2 (administration of probiotics) survived. Mortality did not differ between the 
groups (p=0.57).
Induction and severity of acute pancreatitis
All animals showed a significant (on average >10-fold) increase in serum 
amylase concentrations 6 hours after induction of pancreatitis, indicating a 
successful induction of acute pancreatitis (mean concentration serum amylase 
483 IU/L at t=0 vs. 5014 IU/L at t=6). Serum amylase concentrations decreased 
during the next 18 hours after induction and returned to almost normal levels 
6 days after induction (Figure 5). No difference in serum amylase levels was 
found between the four experimental groups.
 Histological analysis (H-E staining) was performed on pancreatic tissue at 
the end of the experiment. As shown in Figure 6, histological scores were 
comparable between groups, suggesting that all animals developed acute 
pancreatitis of equal severity (p=0.55).
Intestinal inflammation and ischemia
Histopathological analysis of the jejunum and ileum at 6 days after induction 
of acute pancreatitis showed signs of mild to moderate serositis in nearly 
all animals. All rats developed serositis of different extent and with wide 
inter-individual variation; in some animals inflammatory changes included 
the entire bowel wall, including the mucosa. Histopathological scores are 
shown in Figure 7, without differences between groups (p=0.52). In none of 
the surviving animals signs of bowel ischemia were observed. Post-mortem 
analysis of the animals that died during the experiment or preliminary 
terminated the experiment, showed large bowel obstruction in combination 
with severe peritonitis and necrotic changes and perforation of the terminal 
ileum in one animal (group 3). In all other diseased animals no signs of (non-
occlusive) bowel ischemia were found.
Bacterial translocation
One of the hallmarks of the pathophysiology of acute pancreatitis is bacterial 
translocation from the intestine to necrotic pancreas tissue. Determination 
of the bacterial load in the pancreas was performed by bacterial counts 
in the pancreas by qPCR for 16S rRNA. Although the process of bacterial 
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Figure 3. Morbidity induced by the acute pancreatitis was evaluated by daily measurement 
of the degree of discomfort. In all 4 experimental groups (Group 1, acute pancreatitis, saline 
and placebo (n=9); group 2, acute pancreatitis, saline and probiotics (n=10); group 3, acute 
pancreatitis, enteral nutrition and placebo (n=10); group 4, acute pancreatitis, probiotics 
and enteral nutrition (n=11)) induction of pancreatitis caused discomfort during the 6 days 
afterwards. This discomfort was present from day 1 onwards and persisted during the whole 
observation period. No difference between the 4 experimental groups was seen in degree of 
discomfort (p>0.05).
Figure 4. Change in bodyweight during acute pancreatitis. From day -5 until the end of the 
experiment, all animals were weighed daily. All rats initially lost, but subsequently regained 
bodyweight in the period between placement of the jejunal cannula (t = -5 days) and induction 
of acute pancreatitis (t = 0 days). Bodyweight decreased after induction of acute pancreatitis 
(Group 1, acute pancreatitis, saline and placebo (n=9); group 2, acute pancreatitis, saline and 
probiotics (n=10); group 3, acute pancreatitis, enteral nutrition and placebo (n=10); group 
4, acute pancreatitis, probiotics and enteral nutrition (n=11)). At the end of the experiment, 
mean body weight in group 4 was 20 grams higher than in the other 3 experimental groups, 
however these differences were not significant (p>0.05). 
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Figure 5. Serum amylase concentrations during acute pancreatitis. A peak in serum amylase 
activity is seen 6 hours after induction of acute pancreatitis in all 4 experimental groups 
(Group 1, acute pancreatitis, saline and placebo (n=9); group 2, acute pancreatitis, saline and 
probiotics (n=10); group 3, acute pancreatitis, enteral nutrition and placebo (n=10); group 4, 
acute pancreatitis, probiotics and enteral nutrition (n=11)). After 24 hrs, amylase activity has 
decreased significantly but is still elevated as compared to t = 0. Six days after induction of 
acute pancreatitis, amylase levels normalized. No difference between experimental groups 
was observed on any of the time points. Data are presented as mean +/- SEM.
Figure 6. Histology scores of the pancreas. Pancreas tissue was obtained during autopsy at 
day 6 after induction of pancreatitis. Tissue sections were scored for histopathological signs 
of pancreatitis according to the scheme in Table 1 (maximal score is 20). All animals showed a 
moderate to severe pancreatitis score. No differences in histology scores were found between 
the groups, indicating that the severity of the pancreatitis was similar in all animals (p=0.55). 
Data are presented as mean +/- SEM.
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Figure 7. Intestinal histopathology. Ileum and jejunum tissue samples were obtained during 
autopsy at day 6 after induction of pancreatitis. Tissue sections were scored for inflammatory 
and ischemic lesions according to the scheme in Table 2 (range 0-20). The scores of ileum and 
jejunum were added. Animals showed minimal intestinal histopathological changes and no 
differences in histology scores were found between the groups (p=0.52). Data are presented 
as mean +/- SEM.
Figure 8. Total bacterial count of the pancreas. Pancreatic tissue samples were obtained 
during autopsy at day 6 after induction of pancreatitis. Total 16S rRNA gene copies per gram 
pancreatic tissue are shown. No differences in bacterial counts were found between the 
groups (p=0.13). Data are presented as mean +/- SD.
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translocation was not measured directly in this study, we have analyzed a 
major consequence of this process, i.e. bacterial contamination of pancreatic 
tissue. No difference between the four groups in terms of rRNA gene copies 
per gram pancreatic tissue (p=0.13) was observed, as shown in Figure 8. So, 
if this form and extent of pancreatic contamination is the result of bacterial 
translocation, no difference between the four groups was found. 
DISCUSSION
The current study was performed to address the underlying mechanisms 
responsible for the high mortality rate and high incidence of non-occlusive 
bowel ischemia in patients who received the combination of probiotic 
prophylaxis and enteral nutrition in the PROPATRIA study.10 All animals 
developed a moderate to severe acute pancreatitis with a significant increase 
in serum amylase levels in the first 24 hours after induction of pancreatitis. No 
differences were found in terms of animal discomfort, bacterial translocation, 
bowel ischemia and mortality between the four experimental groups, whether 
or not probiotics and enteral nutrition were administered. With the results of 
the current study, with mortality rates in the same range as seen in previous 
experiments and probiotics having no adverse effect on morbidity and 
mortality and no interaction between probiotics and enteral feeding, no new 
insights were obtained in search for the underlying mechanisms responsible 
for the increased incidence of non-occlusive bowel ischemia and mortality in 
patients treated with probiotics and enteral nutrition. 
 Of all experimental models for acute pancreatitis, the current model is most 
robust and has the highest percentage of pancreatic necrosis with short- and 
long-term survival rates to make observation/intervention studies feasible. 
This model, in our hands, initially was associated with a mortality rate of 
approximately 30%.13 This was deemed unacceptably high and has led to 
some minor, but essential modifications in the model, leading to an improved 
survival rate of around 10% for all four groups. This finding may indicate that 
now too few animals developed a really severe pancreatitis with not enough 
mucosal damage and bacterial translocation to be detected in the different 
groups, as a consequence.
 Now that we have found no differences in the animal model, the question 
arises whether this experimental design can be extrapolated to a clinical 
study in human with four groups of 10 patients with predicted severe acute 
pancreatitis as a set up to investigate the possible rerlation between probiotics 
and enteral feeding. It is likely that such a clinical study would probably need 
much more patients to be randomized, otherwise no meaningful difference 
between groups can be shown and no clinically relevant conclusion can be 
drawn. So, is this experimental study seriously underpowered as a reason for 
not having shown any meaningful effect of intervention? In sharp contrast to 
the clinical reality, all animals were genetically nearly identical, were born, 
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fed and kept under identical conditions and received the same standardized 
experimental induction of pancreatitis. Probably, this has an impact on the 
number of rats needed per treatment arm (i.e., one could imagine that less 
animals are needed to observe differences between groups), although we have 
no clue about the influence of these factors on the number of rats needed to 
be randomized per arm.17 
 In human, prophylaxis – antibiotics, enteral feeding or probiotics – is 
expected to minimize bacterial translocation and to reduce late infection of 
pancreatic necrosis. This renders extrapolation of our findings in this rat model 
to clinical human pancreatitis to be seriously flawed. No biphasic pattern with 
the sequence of SIRS, recovery, ‘second hit’ with necrosis getting infected, 
leading to late mortality after having survived the first phase of SIRS is shown 
in rats and there is no pattern of intra- and juxtapancreatic necrosis. However, 
despite the abovementioned shortcommings, up to now, the current model is 
the best available model studying severe acute pancreatitis in rats.
 In order to resemble the situation during the PROPATRIA study in our model, 
we have used the identical mixture of probiotics (but from a newly produced 
batch) and identical enteral nutrition, Nutrison Multi Fibre.9 Although 
technically it would have been possible to administer the enteral nutrition 
continuously during seven days, we used a maximum period of 9 hrs enteral 
feeding per day. Consequently, animals were given access to conventional 
food during the remainder of the day. It is unlikely that this may have affected 
the results. 
 Another major difference with the clinical situation is the timing of 
administration of probiotics. As in the study of van Minnen et al, in the current 
study animals were pretreated with probiotics, while in PROPATRIA all patients 
received the first dose of probiotics when the pancreatitis was already ongoing 
for 24 to 72 hours.13 In a mouse model for acute pancreatitis, it has been shown 
that pretreatment with probiotics abolishes the intestinal barrier dysfunction, 
while treatment with probiotics does not.18 So the timing of administration 
of probiotics is essential for their effects. Although this relationship between 
timing of administration of probiotics and start of the pancreatitis has only 
been shown in experimental models, it is perceivable that the same holds for 
the human situation. 
 One of the most unexpected findings in the PROPATRIA trial which needs 
to be resolved, was the occurrence of non-occlusive mesenteric ischemia.10 It 
has been speculated that the combination of enteral nutrition and probiotics 
may have contributed to the occurrence of this otherwise rare complication 
of acute pancreatitis. In our rat model, we therefore paid particular attention 
to any potential ischemic lesions occurring along the complete length of the 
intestinal tract. Although small numbers per group, in both the surviving and 
the deceased animals no signs of transmural bowel ischemia was observed 
neither macroscopically nor histopathologically. 
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None of the previously published studies about probiotic prophylaxis and 
experimental pancreatitis have shown negative effects of probiotics, including 
the current study.13,14,19 Therefore, it is unlikely that future experimental animal 
studies will provide us with knowledge to understand any of the possibly 
negative effects of probiotics observed in the PROPATRIA study. 
 In summary, this experimental study in rats has not shown any effect of 
probiotics with or without enteral feeding on morbidity and mortality in rats 
subjected to acute pancreatitis. In accordance with previous experimental 
studies, no negative effects of probiotics in acute pancreatitis were shown. So, 
in conclusion, it is not likely that new in-vivo experimental studies will bring 
us closer to an explanation of the still unexplained findings in the PROPATRIA 
trial. With the current knowledge and techniques no explanation could be 
found for the increased mortality and incidence of bowel ischemia as found in 
enterally fed patients with predicted severe pancreatitis and prophylactically 
treated with probiotics in the PROPATRIA trial.  
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ABSTRACT
Background: We previously demonstrated that probiotic prophylaxis, in 
patients with predicted severe pancreatitis, did not prevent infectious 
complications but unexpectedly increased the risk of bowel ischemia and 
mortality. The suggestion that these negative findings are only observed in 
the presence of organ failure at the start of probiotic treatment has not been 
confirmed.
Methods: In a retrospective analysis, all patients with predicted severe acute 
pancreatitis without initial organ failure admitted to a medium care facility 
of a teaching hospital in Prague from January 2003 to December 2010 were 
included. All patients routinely received probiotic treatment with Probioflora. 
Total parenteral nutrition (TPN) was routinely started and shifted towards 
total enteral nutrition. Infectious complications, mortality and the incidence 
of bowel ischemia were recorded.
Results: 99 consecutive patients, mean age 56 years, were included. Infectious 
complications occurred in 42 patients (42%), consisting of bacteraemia (n=40), 
pneumonia (n=11) and infected necrosis (n=11). Bowel ischemia was detected 
in two patients (2%). Overall mortality was 8%. 
Conclusion: In this retrospective study no apparent positive or negative 
impact of probiotic treatment with Probioflora was demonstrated when 
administered to patients with predicted severe acute pancreatitis without 
initial organ failure. 
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INTRODUCTION
In 80% of patients, acute pancreatitis runs a mild course, but 20% of patients 
develop necrotizing pancreatitis.1 If pancreatic or peripancreatic necrosis 
becomes infected, intervention is generally required. This is associated with 
high morbidity and mortality.1 Next to infected necrotizing pancreatitis, other 
infectious complications, such as bacteraemia and pneumonia, are risk factors 
for mortality in acute pancreatitis.2 Therefore, any treatment regimen capable 
of lowering the infection rate in acute pancreatitis could potentially reduce 
both morbidity and mortality.
 Some authors propose that bacterial translocation from the small bowel is 
the main route of infection but others do not agree.3-6 Prophylactic measures 
using antibiotics or probiotics and early start of enteral feeding have been 
hypothesized to reduce the infection rate, each by different mechanisms. 
Several recent meta-analyses have found no beneficial effect of systemic 
antibiotic prophylaxis in terms of reducing infectious complications and 
mortality.7,8 In patients with acute pancreatitis, routine enteral nutrition, when 
compared to routine parenteral nutrition, is associated with a lower mortality. 
9,10 However, it is suggested that this difference is a reflection of the fact that 
patients with parenteral nutrition may suffer from gut failure.11 
 Several clinical studies have assessed the effect of probiotics prophylaxis 
with contradictory results. Some suggested that probiotics prophylaxis reduces 
the infection rate and the need for surgical intervention in patients with 
necrotizing pancreatitis.12 The unexpected outcome of the Dutch PROPATRIA 
study13 resulted in a premature termination of several randomized trials in 
which probiotics were administrated to patients with acute pancreatitis14,15 
including a termination of a prospective study with the same probiotics used 
as in the PROPATRIA study in the Faculty Thomayer´s Hospital, Prague, Czech 
Republic. 
 Although the use of probiotics in acute pancreatitis is still a delicate issue, 
the negative outcome of the PROPATRIA study requires elucidation of the 
mechanism responsible for the negative outcomes observed.16 Since the 
PROPATRIA publication, no new studies have been performed on probiotics in 
patients with severe pancreatitis. In 2010, we became aware of the fact that 
in the Faculty Thomayer´s Hospital, the use of probiotic treatment in patients 
with predicted severe pancreatitis had continued, but only in patients without 
initial organ failure. As a part of our mutual interest in the impact of probiotics 
on these patients we retrospectively analyzed these patient data with the aim 
to unravel the mechanism of probiotic-induced bowel ischemia. 
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MATERIALS AND METHODS
Patient selection
A retrospective analysis was performed including all consecutive patients with 
acute pancreatitis who were admitted to the Faculty Thomayer´s Hospital, 
between January 1st, 2003 and December 31st, 2010. All patients with predicted 
severe pancreatitis without initial organ failure were admitted to the medium 
care unit where they routinely received probiotic treatment. Patients with 
organ failure on hospital admission were admitted to the intensive care unit 
(ICU) where they did not receive probiotic treatment. These patients were 
excluded from analysis. The database of the medium care was searched for 
patients with the ICD-10 code for acute pancreatitis (K85,0).
Definitions
Acute pancreatitis was defined as acute upper abdominal pain with a serum 
amylase level at least three times higher than the upper limit of normal. 
Predicted severity of the pancreatitis was assessed by the Imrie score17 and 
the serum C-reactive protein level18. Patients with an Imrie score of 3 or more, 
or with C-reactive protein over 150 mg/L, both within 48 hours after hospital 
admission, were classified as ‘predicted severe acute pancreatitis’. In case of 
clinical deterioration a contrast-enhanced CT scan (CECT) was performed to 
detect pancreatic or peripancreatic necrosis.
Nutrition
Immediately after hospital admission, all patients (regardless of organ failure) 
received total parenteral nutrition (TPN). Within the first days after admission, 
a nasojejunal tube was inserted to administer probiotics and eventually enteral 
feeding as well. Total parenteral nutrition was provided for at least ten days, 
with, if tolerated, a gradual shift towards total enteral nutrition. Depending 
on the calculated dietary needs of the patient, enteral nutrition consisted of 
Nutrison standard, Nutrison Multi Fibre or Nutrison Protein Plus (all Nutricia, 
Prague, Czech Republic). Patients received enteral nutrition until all signs of 
pancreatitis (e.g., fluid collections) were resolved on CECT. Consequently, 
patients could be discharged from hospital while on total enteral nutrition. 
These patients were followed clinically and radiologically in the outpatient 
department for weeks to months.
Probiotics
Probiotics were administered upon admission to the medium care through 
a nasojejunal tube and continued until the last day of hospital admission. 
The probiotic mixture, containing 3.0*109 bacteria per gift, was administered 
twice daily and consisted of seven different probiotic strains (i.e., Lactobacillus 
acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Bifidobacterium 
bifidum, Bifidobacterium longum, Bifidobacterium lactis, and Streptococcus 
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termophilus; Probioflora, Goldim, Prague, Czech Republic). When patients 
developed organ failure and needed ICU treatment, they were transferred 
to the ICU and treatment with Probioflora was continued. As these patients 
did not have organ failure at the time the probiotics were started, they 
were included in the analysis, according to the intention-to-treat principle. 
After hospital discharge, patients were advised to continue the use of these 
probiotics, which in the Czech Republic are available over the counter. Since 
Probioflora was administered as part of a routine daily clinical practice in 
patients with abdominal diseases, including acute pancreatitis, no ethical 
approval for this retrospective study was required.
Procedures and definitions
On admission, standard laboratory tests and abdominal ultrasound were 
performed to establish the cause of the pancreatitis. In case of cholangitis 
and/or choledocholithiasis, endoscopic retrograde cholangiography (ERC) 
with endoscopic sphincterotomy (ES) was performed.
 Infection of (peri-)pancreatic necrosis was defined as a positive bacterial 
culture of necrotic tissue obtained during intervention (i.e., percutaneous 
catheter drainage (PCD) or open necrosectomy), gas in the fluid collection 
on CECT, or a positive bacterial culture obtained with fine-needle aspiration 
(FNA). In case of (suspected) infection, patients were treated with intravenous 
antibiotics. Intervention was performed if patients deteriorated in spite of 
maximum conservative treatment.  
 Single organ failure was defined as pulmonary failure (PaO2<60mm Hg, 
despite FiO2 of 0.30, or need for mechanical ventilation), circulatory failure 
(circulatory systolic blood pressure <90mm Hg, despite adequate fluid 
resuscitation, or need for inotropic support) or renal failure (creatinine level 
>177µmol/L after rehydration or need for hemofiltration or hemodialysis). 
Multiple organ failure was defined as failure of two or three organ systems 
at the same time. Disseminated intravascular coagulation (platelet count 
<100x109/L), severe metabolic disturbance (calcium level <1.87 mmol/L) and 
gastrointestinal bleeding (>500ml of blood/24 hr) were reported as systemic 
complications.19 For reasons of comparability of the data from this study with 
those of the PROPATRIA study13, infectious complications were defined as 
infected (peri-)pancreatic necrosis, bacteraemia, pneumonia, urosepsis and 
infected ascites.
Data collection
The following data were extracted from the patient records: co-morbidity, 
length and body weight, American Society of Anesthesiologists classification 
(ASA classification), etiology, day of onset of symptoms, day of hospital 
admission, length of hospital stay, need for ICU admission, relevant laboratory 
findings (i.e., amylase, lipase, C-reactive protein, white blood cell count, 
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blood glucose, liver enzymes, calcium, hematocrit, arterial oxygen pressure, 
base deficit, urea, serum albumin), bacterial cultures, outcome of fine-needle 
aspiration (FNA), findings on CECT scan, presence of cholangitis or cholecystitis, 
presence of (multiple) organ failure and systemic complications, performance 
of ERCP and ES, length of administration of enteral nutrition and probiotics, 
type of intervention, presence of infectious complications, presence of bowel 
ischemia and mortality.  
Statistical analysis
Absolute frequency and percentages were calculated for infectious 
complications, mortality and bowel ischemia. Normally distributed data are 
presented as means (±SD). Non-normally distributed data are presented as 
median with interquartile range (IQR: P25–P75). Statistical analyses were 
performed using SPSS® for Windows® version 16.0.2 (SPSS, Chicago, Illinois, 
USA). 
RESULTS
Baseline characteristics
From January 1st, 2003 to December 31st 2010, 99 consecutive patients with 
predicted severe pancreatitis without organ failure were admitted to the 
medium care unit. All these patients received enteral nutrition and Probioflora 
as described. Baseline characteristics are shown in Table 1. Male:female 
ratio was 1:1, with a median age of 56 years (IQR 44-68 years). Median time 
between onset of symptoms and hospital admission was 0 days (IQR 0-0 days), 
and since patients were immediately admitted to the medium care unit, the 
time between hospital admission and admission to the medium care was also 
0 days (IQR 0-2 days). The twice daily, single dose of Probioflora and enteral 
nutrition was initiated after a median of 4 days (IQR 2-8 days). CECT was 
performed after a median of 6 days (IQR 4-7 days) in hospital. 
Outcomes
Table 2 shows the patient outcomes. Sixty patients (60%) developed necrotizing 
pancreatitis, with a median CT severity index of 5 (IQR 3-6). Infectious 
complications were diagnosed in 42 patients (42%): bacteraemia in 40 patients 
(40%), pneumonia in 11 patients (11%) and infected necrosis in 11 patients 
(11%). No patients developed urosepsis or infected ascites. Severe systemic 
complications occurred in 48 patients (48%): severe metabolic disturbance 
in 47 patients (47%), disseminated intravascular coagulation in 11 patients 
(11%) and severe gastrointestinal bleeding in 2 patients (2%). New onset organ 
failure during hospital admission, but after administration of Probioflora, was 
reported in 27 patients: seven patients (7%) developed single organ failure 
and 20 patients (20%) developed multiple organ failure. 
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N=99
Age (years) 56 (44-68)
Sex (male) 58 (59%)
BMI (kg/m2)* 30.7 (5.9)
Cause of pancreatitis
Biliary
Alcohol
Other
51 (52%)
25 (25%)
23 (23%)
American Society of Anaesthesiologists classification 
I (healthy status)
II (mild systemic disease)
III (severe systemic disease)
25 (25%)
43 (43%)
31 (31%)
Severity of pancreatitis
Imrie score (first 48h)
Ranson score (first 48h)**
C-reactive protein (mg/L) (highest first 48h)**
3.1 (1.4)
3.8 (1.9)
221 (81)
Time from first symptoms to admission (days) 0 (0-0)
Time from admission to first dose (days) 4 (2-8)
Time from admission to enteral nutrition (days) 4 (2-8)
N=99
Contrast-enhanced CT
Necrotizing pancreatitis
<30% necrosis
>30% necrosis
No contrast-enhanced CT performed
CT severity index
60 (60%)
36 (36%)
24 (24%)
3 (3%)
5 (0-10)
Any infectious complication
Infected necrosis
Bacteraemia
Pneumonia
42 (42%)
11 (11%)
40 (40%)
11 (11%)
Percutaneous drainage 8 (8%)
Surgical intervention, any indication 9 (9%)
Necrosectomy 7 (7%)
Intensive care admission 16 (16%)
Intensive care stay (days) 25 (12-36)
Hospital stay (days) 19 (13-30)
OF during admission, any onset* 27 (27%)
MOF during admission, any onset* 20 (20%)
Bowel ischemia 2 (2%)
Mortality 8 (8%)
Table 1. Baseline characteristics of 
99 patients with predicted severe 
pancreatitis receiving probiotic 
treatment with Probioflora. 
Data are n (%), mean (SD), or 
median (IQR). Unless noted, data 
were available in all 99 patients. 
*Data available in 35/99 patients. 
**Data available in 98/99 patients. 
Table 2. Clinical outcome. Data are 
n (%), mean (SD), or median (IQR). 
OF: Organ failure. MOF: Multiple 
organ failure. *New onset (multiple) 
organ failure during hospital 
admission, but after administration 
of probiotics was started.
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16/99 patients (16%) who were admitted to the medium care unit needed 
transfer to the ICU because of development of organ failure. Overall median 
length of hospital admission was 19 days (IQR 13-30 days). Eight patients (8%) 
died. Except for one patient, all eight patients had new onset multiple organ 
failure during hospitalization and in 3/8 patients (38%) infected necrosis was 
diagnosed. In 6/8 patients (75%) autopsy was performed and no signs of bowel 
ischemia were detected.
Infectious complications
The pathogens isolated from the patients with infectious complications were 
mainly Staphylococcus spp. and Enterococcus spp. (Table 3). The overall median 
time between hospital admission and diagnosis of any infectious complication 
was 11 days (IQR 8-19 days). Median time between admission and diagnosis 
of bacteraemia was 9 days (IQR 6-15 days), pneumonia 7 days (IQR 3-13 days) 
and infected necrosis 19 days (IQR 13-31). In patients with infected necrosis, 
infection was diagnosed in 1/11 patients (9%) in the first week after admission, 
in 2/11 patients (18%) in the second week after admission, in 4/11 patients 
(36%) in the third week after admission and in 4/11 patients (36%) after three 
weeks of admission.
Bowel ischemia
Bowel ischemia was diagnosed in two patients who received Probioflora and 
enteral nutrition. As no data were available on histopathological examination, 
no specific cause for the bowel ischemia could be reported. 
 The first patient was a 51-year old male with an alcoholic pancreatitis 
without comorbidity. Open necrosectomy due to infected necrosis was 
performed in six separate procedures on day 34, 44, 52, 62, 90 and 109. During 
necrosectomy on day 62, multiple necrotic perforations of the descending 
colon were found. Ultimately, this patient recovered.
 The second patient who developed bowel ischemia was a 62-year old male 
with a history of gastro-esophageal reflux disease and axonal neuropathy, 
who was admitted with biliary pancreatitis. On day 38, a laparotomy was 
performed and a small part of the duodenum and the proximal jejunum were 
resected because of ischemic alterations at the site of the tip of the nasojejunal 
feeding tube. On day 42, an ischemic colitis was found during the second open 
procedure. The patient died on day 62 and no autopsy was performed.
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DISCUSSION
This cohort of patients with predicted severe pancreatitis without initial 
organ failure was analyzed retrospectively in order to obtain clues for the yet 
unknown mechanism behind probiotic-induced bowel ischemia, as shown 
in the PROPATRIA study. Although in the current study treatment of the 
patients was not state-of-the-art (e.g. initial total parenteral nutrition in every 
patient), we focused on potential negative effects of probiotic treatment with 
Probioflora and did not find an increased incidence of bowel ischemia and 
mortality. 
 This conclusion is based on comparison with the literature.13,20 Unfortunately, 
a direct comparison with the patients included in the PROPATRIA trial13 is not 
realistic given the major differences between both cohorts: 1) PROPATRIA 
included patients with initial organ failure whereas this study did not, 2) 
the mixture of probiotics used was different and 3) parenteral nutrition was 
administered routinely in the current study, whereas in PROPATRIA enteral 
nutrition was used.  
 In the current study, probiotics were administered after a median of four 
days of hospital admission. Administration of probiotics starting four days after 
admission is outside the time interval considered “the window for prophylaxis”, 
suggested to be as small as 48 hours. In a mouse model for acute pancreatitis, 
Rychter et al. showed that the effectiveness of probiotics strongly depends on 
the timing of administration; administration of probiotics before induction of 
pancreatitis prevents intestinal barrier dysfunction to occur, while administration 
started after induction of disease was ineffective in this respect.21 
Gram-positive bacteria
Staphylococcus spp.
Staphylococcus epidermidis
Staphylococcus hominis
Staphylococcus aureus
Enterococcus spp.
Corinebacterium spp.
Streptococcus spp.
26
9
6
6
5
4
3
Gram-negative bacteria
Enterobacter spp.
Klebsiella spp.
Escherichia coli
Pseudomonas spp.
Other gram-negative microorganisms*
17
10
5
4
6
Fungi o
Table 3. Pathogens isolated from 42/99 patients with an infectious complication. When 
different organisms were cultured from different sites of a single patient, all microorganisms 
are listed. If a single organism was cultured from different sites of a single patient, this 
organism was listed only once. *Acinobacter spp. (1), and Sphingobacter spp. (1).
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The percentage of infectious complications reported in this study (42%) 
is higher than reported in two large randomized controlled trials (30% and 
31%).13,22 The high rate of infections may be related to the prolonged use of 
TPN as this has been documented to increase the incidence of positive blood 
cultures.9 
 In the current study, ultimately 27 patients developed (late) organ failure, 
while receiving Probioflora and ultimately 16 of these patients were admitted 
to the ICU. In none of these patients with organ failure was bowel ischemia 
diagnosed. However, one has to bear in mind that there was no formal 
strategy to detect bowel ischemia in these patients. The overall incidence of 
bowel ischemia was 2% and mortality 8%. Both this frequencies are within 
the expected range as described in the literature in patients with predicted 
severe acute pancreatitis.20 The bowel ischemia, however, was diagnosed after 
several weeks after hospital admission (i.e. day 38 and day 62), whereas in 
the PROPATRIA study bowel ischemia was diagnosed within the first 2 weeks 
of admission. Furthermore, in PROPATRIA in all but one of the 9 patients who 
developed bowel ischemia already suffered from organ failure on the first or 
second day of admission. These findings might suggest that the patients in the 
current study may have suffered from another type of bowel ischemia and not 
specifically probiotic-related.
 In 2009, Besselink et al. discussed whether the negative outcome of the 
PROPATRIA study may be related to the presence of organ failure at the 
time the probiotics were administered.6 The post-hoc sub-group analysis of 
the PROPATRIA cohort showed that a higher degree of enterocyte damage 
occurred in patients who received probiotics when they already had organ 
failure. These findings may suggest that probiotics do not increase the 
incidence of bowel ischemia when administered to patients without early 
organ failure. Although the current study supports this hypothesis there is no 
clear mechanism available to explain these findings.
 In conclusion, this study describes the first analysis of a cohort of patients 
with predicted severe pancreatitis without initial organ failure treated with 
probiotic treatment with Probioflora after the unexpected outcome of the 
PROPATRIA study in 2008. Although we acknowledge that patient care was 
not conform current guidelines and comparison with the PROPATRIA study is 
not realistic, we could not find a clear positive or negative impact of probiotic 
treatment with Probioflora on the incidence of bowel ischemia and mortality 
in patients with predicted severe pancreatitis without organ failure. 
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ABSTRACT
Background: Diagnosing infected necrotizing pancreatitis (INP) may be 
challenging. The aim of this study was to determine the added value of routine 
fine needle aspiration (FNA) next to clinical and imaging signs of infection in 
patients who underwent intervention for suspected INP.
Methods: Post-hoc analysis of 208 consecutive patients from a prospective 
multicenter database who underwent intervention because of suspected 
INP. In retrospect, three groups were constructed based on the patients 
preoperative characteristics: clinical, imaging and FNA. Patients in the clinical 
group had clinical signs of infection but no gas on preoperative CT and no FNA 
performed prior to intervention. Patients in the imaging group had gas bubbles 
on the preoperative CT scan but no FNA performed and patients in the FNA 
group had a positive FNA prior to intervention. The reference standard for 
infection was the culture taken during the first intervention (either catheter 
drainage or necrosectomy).
Results: The initial intervention for INP was performed a median of 27 days 
(IQR 20-39 days) after admission, without difference between the three groups 
(P=0.15). Infection was confirmed in 80% of 92 patients of the clinical group, 
in 94% of 88 patients of the imaging group, and in 86% of 28 patients of the 
FNA group (P=0.07). Mortality was 19% without differences between groups 
(P=0.39). 
Conclusion: INP can generally be diagnosed based on clinical or imaging signs 
of infection. FNA can be performed on indication, in patients with unclear 
clinical signs and no imaging signs of INP.
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INTRODUCTION
Acute pancreatitis is the most common gastrointestinal condition requiring 
acute hospitalization in the United States.1 Twenty percent of patients develop 
necrotizing pancreatitis.2 The 2012 revised Atlanta classification defines 
necrotizing pancreatitis by the presence of either pancreatic parenchymal 
or only peripancreatic necrosis.3 In approximately 30% of these patients 
infection of the necrosis occurs (infected necrotizing pancreatitis, INP) which 
requires radiological or surgical intervention in the vast majority of patients.2,4 
Interventions in these often critically ill patients carry a morbidity of 50-
100% and a mortality of 15-25%.4-9 Therefore, many studies have focused on 
prevention of INP. Surprisingly, only few studies have addressed the topic of 
diagnosing INP. 
 Suspicion of infected necrosis can be based on clinical signs only (e.g., 
fever, organ failure), on imaging signs namely gas bubbles in peripancreatic 
collections on computed tomography (CT), on positive microbiological 
culture obtained by fine-needle aspiration (FNA), or on a combinations 
of these factors.10,11 Since the initial Atlanta classification12 in 1993, only 
one retrospective study reported on the incidence of gas in peripancreatic 
collections (24% of 42 patients) in relation to patient outcome in patients with 
necrotizing pancreatitis.10 On the other hand, several studies reported on the 
use of FNA in diagnosing infected necrosis.6,11,13-17 As a result of these studies, 
some authors propose routine FNA in patients with necrotizing pancreatitis, as 
reflected by the high use of FNA in the literature (40-100%).5,17-19 The accuracy 
of FNA to diagnose infected necrosis may be high (ranging from 67 to 98%)19-21, 
but, for several reasons, the added value of routine FNA may be limited7. First, 
with the current preferred approach of delayed intervention, even in case of 
infected necrosis, FNA has limited therapeutic implications.4,22 Second, false-
negative and false-positive (contamination) rates have been reported up to 
25% and 15%, respectively.7,18,23 Finally, although FNA is a considered to be a 
safe and minimally invasive procedure, it does carry a small risk of procedure-
related complications (e.g., bleeding, perforation, iatrogenic infection).24 
 The aim of this study was to determine the individual role and (added) 
value of clinical and imaging signs and, especially, FNA in diagnosing INP.
PATIENTS AND METHODS
Patients 
We performed a post-hoc analysis in a prospective database of 639 patients with 
necrotizing pancreatitis, included between March 2004 and November 2008 in 
all eight Dutch university medical centres and 13 large teaching hospitals of the 
Dutch Pancreatitis Study Group. This cohort has been described previously.4 
During the study period, all patients admitted with acute pancreatitis were 
registered in a prospective database.8,25 Patients were selected for the current 
study if they underwent intervention for suspected infection of peripancreatic 
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or pancreatic necrosis. Patients were excluded if intervention was performed 
for other indications than (suspected) infection (e.g., abdominal compartment 
syndrome, bleeding, bowel ischaemia or perforation). 
Definitions and groups
A definitive diagnosis of INP was established by a positive microbiological 
culture obtained at the first intervention (either via percutaneous drainage 
or surgical necrosectomy). For this post-hoc analysis, the intervention culture 
was considered to be the reference standard for infection, regardless of other 
subsequent cultures obtained by drainage or re-interventions. A positive 
FNA culture prior to intervention or the presence of gas in peripancreatic 
collections on CT was not considered definite proof for infection, being the 
diagnostic variables under study. However, in clinical practice, a positive FNA 
culture was indicative for infected necrosis. Patients without intervention for 
suspected infected necrosis were excluded from further analysis, since the 
reference standard was lacking in these patients. All included patients were 
divided in three groups: 1) clinical signs of infection (clinical group); 2) gas in 
peripancreatic collections on CT and clinical signs (imaging group); and 3) FNA 
and clinical signs (FNA group). 
 To facilitate the analysis between the study groups, patients who had 
both gas in peripancreatic collections on CT and in whom FNA cultures 
were performed (n=16) were included in the imaging group, because FNA 
requires an additional intervention whereas information on the presence of 
gas in peripancreatic collections can be derived from the CT that is already 
performed routinely. However, in the clinical situation, this positive FNA was 
not ignored and used in the diagnostic work-up to establish the diagnosis of 
infected necrosis, therefore an additional sensitivity analysis was performed 
to determine the impact of including these 16 patients in the FNA group. 
Treatment protocol
The treatment protocol has been described in detail previously.4 In short, 
patients received broad-spectrum antibiotics in case of (suspected) INP 
initially. In case of clinical improvement, the antibiotic treatment regimen 
was narrowed based on culture results (if available). The majority of patients 
received broad-spectrum antibiotics for several weeks. Due to the multicenter 
character of this study it was not possible to record the exact use of antibiotics 
in all patients. Intervention was postponed, if possible for at least four weeks 
after onset of symptoms, allowing for demarcation and encapsulation of 
the infected collection, so called walled-off necrosis. The minority of the 
present cohort (n=88) was included in the PANTER trial and was assigned to 
open necrosectomy (n=45) or to the step-up approach (n=43).8 Since 2006, a 
multidisciplinary expert panel, consisting of eight gastrointestinal surgeons, 
one gastroenterologist and three radiologists guided decisions on intervention. 
CHAPTER 5: THE ROLE OF ROUTINE FINE-NEEDLE ASPIRATION IN THE DIAGNOSIS 
OF INFECTED NECROTIZING PANCREATITIS
81
Patients with (suspected) INP were evaluated by the expert panel and the 
treating physician was informed about the individual recommendations of 
the members of the panel. Notably, in every case the ultimate decision for 
treatment and intervention was made by the treating physician. 
Clinical group
Patients who had no gas in peripancreatic collections on CT and in whom 
no FNA was performed, were classified as patients in whom the suspicion 
of INP was based on clinical signs. Unfortunately, no algorithm exists for 
establishing the diagnosis of infected necrosis only based on clinical signs and 
therefore it is not possible to provide clear cut-off points of vital, biochemical 
and mechanical outcome parameters to define infection. Usually, clinical 
deterioration was an important observation in patients with (suspected) 
infected necrosis. Examples of clinical signs are persisting sepsis, (new or 
prolonged) organ failure, increased need for cardiovascular and/or respiratory 
and/or renal support, leucocytosis, increased C-reactive protein levels and 
fever. Moreover, no other infectious focus must be found or held responsible 
for the clinical deterioration. However, since an experienced clinical judgment 
is needed in these complex and usually critically ill patients, in the majority of 
patients the decision to intervene was advised by the expert panel.
Imaging group
Patients with gas bubbles on CT were included in this group. CTs were performed 
at the discretion of the treating physician. One dedicated abdominal radiologist 
(TLB) reviewed all CTs, blinded for the clinical background and treatment.
Fine-needle aspiration group
With the policy of postponing intervention regardless the presence of 
(suspected) infection, routine FNA was not used routinely. The indication for 
performing FNA was left to the treating physician and therefore FNA was only 
performed in case of unclear clinical and radiological signs of infection. FNA 
was performed with ultrasound-guidance or CT-guidance. 
Data collection
The following data were extracted from the prospective database: patient 
demographics, patient history, American Society of Anesthesiologists (ASA) 
class, etiology, day of hospital admission, length of hospital stay, laboratory 
findings, CT findings from the initial hospital and second review by an 
experienced abdominal radiologist, presence of infectious complications, 
presence of (multiple) organ failure, clinical course, type of intervention(s), 
cultures from FNA and first intervention, and mortality.
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Statistical analysis
All patients were analyzed in the three predefined groups. Per group, all 
data were pooled and baseline characteristics were listed. Percentages were 
calculated for baseline characteristics and outcomes and all intervention 
cultures were compared. Continuous data were presented as mean ± standard 
deviation (SD) and non-normally distributed data were presented as median 
(interquartile range, (IQR)). Differences were compared with the Chi-square or 
Mann-Whitney U tests, as appropriate. A p-value of 0.05 or less was considered 
as statistically significant. All statistical analyses were performed using SPSS® 
for Windows® version 16.0.2 (SPSS, Chicago, Illinois, USA). 
RESULTS
Baseline characteristics
Of 639 consecutive patients with necrotizing pancreatitis, 208 patients 
(32%) underwent either percutaneous drainage or surgical necrosectomy for 
suspected INP, and could therefore be evaluated for the reference standard of 
infected necrosis. Median age was 60 years (IQR 48-69) with male:female ratio 
2:1. The clinical group consisted of 92 (44%) of 208 patients, these patients 
had neither gas bubbles on CT nor was FNA performed. Gas in peripancreatic 
collections on CT was seen in 88 (42%) of 208 patients (imaging group) 
and FNA was performed in 28 (13%) of 208 patients (FNA group). Baseline 
characteristics are shown in Table 1.
Timing of intervention
There was no difference in timing of the first intervention between the three 
groups. In the clinical group (n=92), intervention was performed at a median 
of 27 days (IQR 21-38 days) after hospital admission versus 31 days (IQR 22-
46 days) in the imaging group and 31 days (IQR 18-38 days) in the FNA group 
(P=0.15). 
 Gas in collections with necrosis (n=88) was seen after a median of 22 
days (IQR 13-37 days) after hospital admission and the first intervention was 
performed a median of 10 days later. The first FNA (n=28) was performed 
a median of 17 days (IQR 10-28 days) after hospital admission and the first 
intervention was performed a median of 14 days later. 
Diagnostic accuracy
Infected necrosis was documented by a positive culture of material obtained 
during the first intervention (i.e., the reference standard) in 74 (80%) of 92 
patients of the clinical group, in 83 (94%) of 88 patients of the imaging group, 
and in 24 (86%) of 28 patients of the FNA group (P=0.07). 
 In 19 of the 28 patients (68%) in the FNA group the FNA-cultures matched 
with the intervention cultures. In 8 (29%) of 28 patients, other (new) micro-
organisms were found during intervention culture, in these patients the FNA 
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culture was considered to be false-negative. In one patient (4%) a false-
positive culture was found. When all 44 patients who underwent FNA before 
intervention were analyzed (including all 16 patients with both gas bubbles 
and FNA), 27% of FNA cultures (12 out of 44 patients) did not match with 
cultures taken from the intervention, regardless of the presence of gas 
in peripancreatic collections on CT. In 11 (25%) of 44 patients other (new) 
microorganisms were found during intervention culture compared to the 
FNA culture was (median time between FNA and intervention 9 days, IQR 
5-20 days) and in 1 (2%) of 44 patients a positive FNA culture was found with 
subsequently a negative intervention culture. In this patient, the time interval 
Characteristic All patients
(n=208)
Clinical group
(n=92)
Imaging group
(n=88)
FNA group
(n=28)
Age – yr 60 (48-69) 58 (45-69) 61(51-72) 57 (43-64)
Male sex 142 (68) 60 (64) 60 (68) 22 (79)
Etiology
   Biliary
   Alcohol abuse
   Other
   Unknown
101 (49)
  44 (21)
18 (9)
45 (21)
36 (39)
30 (33)
6 (8)
20 (21)
49 (56)
10 (11)
7 (8)
22 (25)
16 (57)
4 (14)
5 (18)
3 (11)
ASA-class on admission  
   I (healthy status)
   II (mild systemic disease)
   III (severe systemic disease)
57 (27)
113 (54)
38 (18)
21 (23)
53 (59)
18 (18)
22 (25)
50 (57)
16 (18)
14 (50)
10 (36)
  4 (14)
Predicted severity of pancreatitis
    APACHE-II score on 
       admission
    APACHE-II score >8 on 
       admission
Imrie-score on admission
Imrie-score ≥3 on admission
    Highest CRP level in first 48h     
       of admission (mg/L)
    CRP >150 (mg/L)
8 (5-11)
95 (46)
4 (3-5)
158 (76)
295 (212-380)
179 (86)
9 (5-11)
47 (50)
4 (2-5)
69 (75)
289 (210-372)
77 (78)
8 (5-11)
42 (48)
3 (3-5)
67 (76)
289 (205-381)
77 (88)
6 (4-10)
6 (21)
4 (2-5)
22 (79)
335 (245-438)
25 (89)
CT-severity index 8 (6-10) 8 (4-10) 6 (6-10) 7 (6-8)
Pancreatic necrosis 156 (75) 66 (72) 70 (80) 20 (71)
Peripancreatic necrosis alone 52 (25) 26 (28) 18 (20) 8 (29)
Extent of pancreatic necrosis
   <30%
   30-50%
   >50%
102 (49)
53 (25)
53 (25)
40 (45)
28 (30)
24 (25)
46 (52)
17 (19)
25 (28)
16 (57)
8 (29)
4 (14)
Table 1. Baseline characteristics. Continuous variables are in median (interquartile range), 
percentages are in parenthesis. CRP: C-reactive protein, APACHE: Acute Physiology And 
Chronic Health Evaluation, ASA: American Society of Anaesthesiologists
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between FNA and intervention was five days. These data are shown in detail in 
Table 2.
Mortality
Overall mortality was 19% (40 out of 208 patients) without differences 
between the groups: 18% (17 out of 92 patients) in the clinical group, 17% (15 
out of 88 patients) in the imaging group, and 28% (8 out of 28 patients) in the 
FNA group (P=0.39). Mortality in all 44 patients who underwent FNA prior to 
intervention was 27% (12 out of 44 patients). 
Microbiology
In 184 (88%) of 208 patients infected necrosis was confirmed by culture taken 
at the first intervention. In 114 of these 184 patients (62%) the infection was 
monomicrobial whereas in 70 patients (38%) two or more bacteria/fungi were 
cultured. The mortality between these groups did not differ (18%, (21 out of 
114 patients) with monomicrobial culture vs. 21% (15 out of 70 patients) with 
polymicrobial culture, P=0.62). Escherichia coli was most frequently cultured 
(40%), followed by Staphylococcus spp. (28%) and Enterococcus spp. (25%). 
Yeasts were cultured in 9% of patients, predominantly Candida spp. No data 
were provided about the resistance pattern of micro-organisms cultured from 
the necrosis. 
DISCUSSION
This study suggests that the diagnosis of INP can be based on clinical and 
imaging signs in the majority of patients. FNA can be used selectively in 
patients in whom the clinical signs are unclear and have no imaging signs of 
infection.
 Routine use of FNA has previously been advocated in patients suspected 
of having INP.26,27 This recommendation dates from a time period where the 
diagnosis of infected necrosis demanded immediate surgical treatment or 
interventional drainage. In current series, however, intervention is usually 
postponed, if clinically possible, until the necrosis has become walled-off.4,6,22,28 
Thus, even after confirmation of the diagnosis of infected necrosis, intervention 
is postponed. This is reflected by our data showing that the median timing of 
intervention was 29 days (IQR 22-41 days), without difference between the 
groups. Apparently, FNA did not lead to earlier intervention, whereas mortality 
was comparable between groups. Notably, no mortality was observed in the 
11 patients with gas bubbles and/or positive FNA in whom intervention was 
postponed and ultimately waived because of successful conservative treatment.4 
These findings support the philosophy that the diagnosis of INP does not 
mandate an emergency intervention and are in line with previous studies.4,7,29 
Future studies should determine whether earlier intervention after positive 
FNA, without the current 10-14 days delay, can reduce morbidity or mortality.
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The presence of gas in peripancreatic collections is considered by many as 
pathognomonic for INP.11 Only three studies reported on the incidence of 
gas in peripancreatic collections.10,11,20 Two studies published prior to 1993 
included only a small number of patients (less than 30).11,20 The third study, 
describing 42 patients with pancreatic necrosis on CT, found gas bubbles in 
20 patients (48%).10 However, because no consecutive series was described, 
the actual incidence of gas bubbles in patients with necrotizing pancreatitis 
Patient FNA culture Sensitivity 
profile
Antibiotics 
started
 after 
culture
Intervention 
culture
Sensitivity 
profile
Antibiotics 
started 
after 
culture
Time 
between 
FNA and 
intervention 
(days)
1 Moraxella 
spp.
PENI IMIP, FLUCO No growth n.a. IMIP, FLUCO 5
2 C. albicans
E. faecium
VANCO, 
FLUCO
VANCO, 
FLUCO
C. albicans,
E. faecium,
P. aeruginosa
MERO, 
FLUCO
VANCO
MERO, 
FLUCO
1
3 H.  influenza missing missing S. salivarius,
Prefotella spp.
AUGM, 
PENI, 
COTRIM
missing 1
4 No growth n.a. missing Klebsiëlla spp. AUGM, 
CIPRO
MERO, 
CIPRO
5
5 P. mirabilis PENI, AUGM IMIP C. albicans
E. faecalis
AUGM, 
VANCO
IMIP 7
6 No growth n.a. none Enterococcus spp. VANCO VACO 8
7 E. cloacae missing MERO E. cloacae
E. faecium
missing VANCO, 
COTRIM
9
8 Streptococcus 
spp. 
Enterococcus 
spp.
missing VANCO, 
FLUCO, CEFTA
B. fragilis,
E. faecium
missing VANCO 11
9 No growth n.a. none Citrobacter spp.
E. faecalis
AUGM, IMIP IMIP, TEICO, 
FLUCO
15
10 No growth n.a. TAZO Stenotrophomonas 
spp.
TAZO, 
COTRIM
CLINDA, 
COTRIM
20
11 E. coli missing missing E. coli,
E. cloacae
Streptococcus spp.
missing missing 36
12 No growth n.a. none S. aureus FLUCLOX FLUCLOX 44
Table 2. Data of 12 patients with discrepancy between FNA culture and intervention 
culture. AUGM: Augmentin, CEFTA: Ceftazidim, CIPRO: Ciproxin, CLINDA: Clindamycine, 
COTRIM: Cotrimoxazol, FLUCO: Fluconazol, FLUCLOX: Flucloxacilline, IMIP: Imipenem, MERO: 
Meroponem, PENI: Penicilline, TAZO: Tazocin, TEICO: Teicoplanine, VANCO: Vancomycine, n.a.: 
Not applicable
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remained unclear. In the current study, only patients in whom an intervention 
was performed for suspected INP were included (208 out of 639 patients). 
Even though this was a selected subgroup of patients, it enabled us to compare 
the CT (and FNA) findings with the reference standard.
 Infection of necrosis can occur at any given time after onset of symptoms 
but has a peak incidence between the third and fourth week.30 Therefore, 
FNA performed early in the disease course often renders negative results. 
Moreover, negative FNA cultures are obviously only reliable for a short period 
of time. Cut-off points varying from 1-27 days have been reported19,21,31, but 
most of the studies do not actually report on the time between FNA culture 
and intervention.6,11,13-17
 The role of antibiotics in patients with suspected INP is still a topic of debate. 
In the current study, almost all patients with suspicion of infected necrosis 
received broad-spectrum antibiotics as part of the conservative treatment 
strategy. Consequently, outcome of FNA cultures may be influenced and 
false-negative FNA cultures could occur. This may be partly the reason for the 
high false-negative rate of 29%. Conversely, prolonged antibiotic treatment 
before intervention could result in a negative intervention culture and thus 
false-positive FNA cultures and false-positive gas bubbles in peripancreatic 
collections. Whether antibiotics substantially influenced the intervention 
cultures remains unclear, although it may partly explain the false-positive 
outcomes of both FNA and CT findings. 
 Our results show that in almost 40 per cent of patients with INP multiple 
micro-organisms were found at cultures taken from the first intervention 
and that in 27% of patients these findings did not (fully) correspond with the 
micro-organisms found with FNA culture. This may indicate that translocation 
of other intestinal micro-organisms occurred in the time period between FNA 
and intervention. These findings do not support the routine narrowing the 
antibiotic treatment based on FNA cultures. 
 This study has some limitations. First, since not all patients with necrotizing 
pancreatitis underwent a routine FNA and a subsequent intervention, this study 
cannot be seen as a purely diagnostic study. However, it seems rather unlikely 
that such a study will be ever performed given the clear ethical problems with 
such an approach. Second, both FNA and CTs were performed on the discretion 
of the treating physician. We cannot exclude that only patients without obvious 
clinical signs and no gas bubbles on CT scan underwent a FNA. This could lead 
to selection bias but has not further implications to the management of the 
individual patient. The main strength of this paper, however, lies in the use of 
a multicentre, prospective database specifically focussed on intervention in 
necrotizing pancreatitis in a consecutive series of patients. 
 In conclusion, this study showed that in the majority of patients INP can be 
diagnosed based on clinical and imaging signs and that FNA may be reserved 
for patients with unclear clinical signs without imaging signs of infection. 
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Although FNA may lead to an earlier diagnosis of INP, it is unclear whether this 
is of additional value. This could be addressed in future studies.
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ABSTRACT
Objective: To evaluate the role of percutaneous catheter drainage (PCD) in 
patients with (infected) necrotizing pancreatitis.
Methods: A systematic literature search was performed. Inclusion criteria: 
1) consecutive cohort of patients with necrotizing pancreatitis undergoing 
PCD as primary treatment of peripancreatic collections; 2) indication for PCD: 
(suspected) infected necrosis or symptomatic sterile pancreatic necrosis; 3) 
outcomes reported: percentage of infected peripancreatic collections, need 
for additional surgical necrosectomy, complications and mortality. Exclusion 
criteria: 1) cohorts of <5 patients; 2) cohorts including chronic pancreatitis; 
3) studies on a selected subgroup of patients with acute pancreatitis: 
‘pseudocysts’ or ‘pancreatic abscesses’ and/or exclusively sterile pancreatic 
necrosis; 4) cohort of patients in whom PCD was always combined with 
another minimally invasive strategy. 
Results: Eleven studies, including 384 patients, fulfilled the inclusion criteria. 
Only one study was a randomized controlled trial (RCT). Four studies reported 
on the presence of organ failure prior to PCD; in 67% of 116 patients. Infected 
necrosis was proven in 271/384 patients (71%). In 214/384 patients (56%) 
no additional surgical necrosectomy was required after PCD. Complications 
consisted mostly of internal and external pancreatic fistulas. Overall mortality 
was 17% (67/384 patients). Nine of eleven studies separately reported 
mortality in patients with infected necrosis undergoing PCD: 15% (27/105 
patients). 
Conclusion: This study reviewed the outcome of PCD in a mixed group 
of patients with both sterile and infected pancreatic necrosis, largely in 
retrospective studies. A considerable number of patients can be treated with 
PCD without the need for surgical necrosectomy. 
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INTRODUCTION
Around 20% of patients with acute pancreatitis develop necrosis of the 
pancreas or peripancreatic fat tissue with associated peripancreatic 
collections.1,2 Sterile necrosis can generally be managed conservatively and 
mortality is relatively low (12%).1,3 Approximately 30% (range 14-62%) of 
patients with necrotizing pancreatitis, however, develop secondary infection 
of peripancreatic collections which is associated with sepsis and organ failure 
and is indication for intervention.1
 For long, the first choice intervention in infected necrotizing pancreatitis 
has been surgical necrosectomy by laparotomy with the aim to remove all 
infected necrosis.4-6 This approach is associated with considerable morbidity 
(34-95%) and mortality (11-39%).1,7-9 Some patients with sterile necrosis will 
ultimately also undergo surgical necrosectomy in case of clinical deterioration 
(i.e. multiple organ failure) despite maximal supportive therapy on the basis 
of suspected infection. Others undergo necrosectomy because of persistent 
symptomatic external hepatobiliary or duodenal compression by peripancreatic 
collections.5
 In 1998, Freeny et al. first described a consecutive series of patients 
exclusively with infected pancreatic necrosis who were primarily treated with 
imaging-guided percutaneous catheter drainage (PCD), as an alternative to 
primary surgical necrosectomy.10 The rationale for PCD was to temporize sepsis 
and thereby postpone the need for surgical necrosectomy. In their retrospective 
cohort study, PCD was successful in postponing surgical intervention for a 
median of 4 weeks and even in obviating the need for surgical necrosectomy 
in almost half of the patients. In addition, PCD seems technically feasible in 
the vast majority of patients with necrotizing pancreatitis.11 In the last decade, 
several cohort studies on PCD and minimally invasive necrosectomy (e.g. 
percutaneous necrosectomy12, video-assisted retroperitoneal debridement 
(VARD)13,14, transluminal endoscopic necrosectomy15) have been published. 
Recently, a minimally invasive ‘step-up approach’ consisting of PCD as first 
step and, if necessary, followed by VARD has proven to be more effective than 
primary open necrosectomy in a randomised trial (PANTER trial).16 More than 
a third of patients with infected necrotizing pancreatitis had been successfully 
treated with PCD only.
 This systematic review focuses on PCD as primary treatment for (infected) 
necrotizing pancreatitis. Primary aim was to determine the proportion 
of patients that can be treated with PCD without the need for additional 
necrosectomy from the published literature.
METHODS
Study selection
A systematic literature search was performed in EMBASE, MEDLINE and the 
Cochrane libraries from January 1st, 1992 to May 31st, 2010. The search was 
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limited to this episode, because before 1992, no universally accepted definitions 
were available for acute pancreatitis and pancreatic collections, frustrating 
the comparison of studies on PCD. In 1992, the Atlanta symposium provided 
definitions for acute pancreatitis and the different local complications such 
as pancreatic necrosis, pseudocysts and pancreatic abscesses.17 Although it is 
recognized today that the Atlanta classification has considerable shortcomings 
and is currently under revision18,19, the definitions have been widely used in 
the literature since 1992. 
 The MEDLINE and EMBASE search-terms were “(radiologic OR percutaneous 
OR drainage) AND pancreatitis”. Search-terms for the Cochrane library were: 
“pancreatitis AND (radiologic OR percutaneous OR drainage)”, restricted to 
title, abstract, keywords and English language. From the studies identified by 
the initial literature search, all titles and abstracts were screened to select 
studies reporting on patients undergoing PCD of peripancreatic collections 
associated with pancreatitis. Subsequently, full-text papers of the selected 
studies were independently screened by three authors (MvB, HvS and TB) to 
assess eligibility. 
 Inclusion criteria were: 1) a consecutive cohort of patients with acute 
necrotizing pancreatitis (ANP) undergoing PCD as a primary treatment 
of peripancreatic collections; 2) indication for PCD: (suspected) infected 
necrosis or symptomatic sterile pancreatic necrosis (e.g. clinical deterioration 
or significant mechanical obstruction); 3) essential outcomes reported: 
percentage of infected peripancreatic collections, need for additional surgical 
necrosectomy, complications and mortality. 
 Exclusion criteria were: 1) very small cohorts (< 5 patients); 2) cohorts 
including chronic pancreatitis (and results for acute pancreatitis not reported 
separately); 3) studies on a selected subgroup of patients with acute pancreatitis, 
classified as ‘pseudocysts’ or ‘pancreatic abscesses’ (as defined by the Atlanta 
classification) or sterile pancreatic necrosis exclusively; 4) cohorts of patients 
undergoing minimally invasive surgical necrosectomy which included previous 
PCD and cases treated by PCD only were not separately reported. 
 All cross-references were screened for potential relevant studies not 
identified by the initial literature search. The final decision on eligibility was 
reached by consensus.
 
Data extraction
From the included articles the following variables were extracted (if available): 
number of patients with ANP undergoing PCD, etiology, predictive severity 
scores (e.g. Ranson score20, Acute Physiology And Chronic Health Evaluation 
[APACHE]-II score21) prior to PCD, percentage of patients with organ failure, CT 
severity scores (i.e. CT severity index [CTSI]22, modified CTSI23, and Balthazar 
grade24), percentage of patients with infected necrosis,  indication for PCD, 
time between hospital admission and PCD, drain size, total number of 
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drains placed, time to removal of drains, success of PCD (defined as survival 
without the need for additional surgical necrosectomy), total hospital stay, 
complications and mortality. 
RESULTS
Included studies
The results of the literature search are depicted in Figure 1. Of these 34 papers 
reporting on PCD of peripancreatic collections associated with pancreatitis, 23 
were excluded for the following reasons: cohort of less than 5 patients (n= 1)25, 
cohorts including patients with ‘pseudocysts’ (n= 1)26, ‘pancreatic abscesses’ 
(n= 3)27-29 or both (n= 1)30, cohorts including patients with sterile pancreatic 
necrosis only (n= 2)31,32, cohorts of mixed chronic and acute pancreatitis and 
outcomes not reported separately (n= 1)33, one or more essential outcome not 
reported (n= 6)34-39, PCD in combination with transgastric drainage (n= 2)40,41 and 
cohorts where primary PCD was part of a ‘step-up’ approach in which PCD was 
always followed by minimally invasive surgical necrosectomy (n= 6)42-47. Finally, 
eleven studies were included in the current systematic review.10,16,48-56 Nine 
studies were retrospective, non-controlled case-series10,48,50-56, one study was 
Figure 1. Study selection
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a prospective, non-controlled case-series49 and one study was a multicentre 
RCT16 (Oxford, level 4 evidence and level 1b evidence, respectively).57 Study 
characteristics of the eleven included studies are summarized in Table 1.
Patient characteristics
The pooled data from the 11 studies included in this study, comprised a total 
of 384 patients undergoing PCD as primary treatment for (suspected) infected 
necrosis or symptomatic sterile pancreatic necrosis (range of number of 
patients per study 8-80). Patient characteristics are summarized in Table 2.
 Etiology of ANP was reported in seven studies and five other studies reported 
data on clinical details and CT severity (Table 2). In these 11 studies, various 
predictive severity scores and CT severity scores were used. Four studies (116 
patients) reported on percentage of patients suffering from organ failure prior 
to PCD. Seventy-eight of 116 patients (67%) ,had organ failure (34 patients 
with single and 44 with multiple organ failure) prior to PCD. Out of the total of 
384 patients, 271 patients (71%) had infected peripancreatic necrosis, defined 
as the presence of gas in the peripancreatic collection on CT or as a positive 
culture at fine needle aspiration in all studies. For PCD both the Seldinger and 
the Tandem trocar techniques were used and the majority of the radiological 
interventions were CT-guided. The size of the drains used, however, ranged 
from 8 to 28 French (2.7 to 9.3 mm). 
Outcome
Table 3 shows outcomes as reported in the studies. Whenever possible, 
outcomes for infected and sterile necrosis are presented separately. The 
success rate of PCD, defined as the percentage of patients surviving without 
additional surgical necrosectomy, was 214/384 patients (56%). Eight studies 
reported specific data on patients with infected necrosis (n= 166): 87/166 
patients (52%) recovered after PCD only. Five series reported on the time 
between insertion and removal of drains, varying from 16 to 98 days. 
Additional surgical necrosectomy was needed in 133/384 patients (35%). 
The remaining 9% (37 patients) were considered unfit for surgery or died 
before necrosectomy could be performed. The time interval between first 
PCD and surgery was reported in six series and ranged from 18 to 109 
days. In those studies reporting on the number of catheters placed (7 studies), 
two or more catheters were usually placed per patient, with a maximum of 
14 catheters.54 No accurate mean number of procedures can be presented, 
since most series do not provide these data. Generally, drains were 
flushed with saline every eight hours and were replaced when occluded. 
In the one RCT on this subject a median of 1 catheter was placed with a 
median size of 14 French. Ultimately, drains were upgraded or replaced in 11 
patients (26%).16
 The complication rate was described in all but one series. One-hunderd 
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Author Year 
published
Country Study design Study 
period
Inclusion criteria Technique used
Freeny10 1998 United 
States
Retrospective, 
non-controlled 
case-series
1991
-
1995
-  medically uncontrolled sepsis CT-guided drainage, 10-28 
Fr drains
Gambiez48 1998 France Retrospective, 
non-controlled 
case-series
1990
-
1995
-  secondary outbreak or 
persistence (>7 days) of signs 
of sepsis unexplained by a 
source of infection other than 
abdominal abscess
-  organ failure despite medical 
treatment
-  bacterial proof of infection
CT-guided drainage
Fotoohi49 1999 United 
States
Retrospective, 
non-controlled 
case-series
1988
-
1997
- sepsis
- pain
- biliary obstruction
CT-guided drainage, Seldinger 
/ Trocar technique used, 8-24 
Fr drains
Baril50 2000 United 
States
Retrospective, 
non-controlled 
case-series
1993 
- 
1997
-  (suspected) pancreatic or 
peri-pancreatic sepsis
CT-guided drainage, Seldinger 
technique used, 10-12 Fr 
drains
Cheung51 2005 Hong Kong Retrospective, 
non-controlled 
case-series
2001
-
2002
-  deteriorated clinical condition
-  symptomatic pancreatic 
collections
CT-guided drainage, 20 Fr 
drains
Navalho52 2006 Portugal Retrospective, 
non-controlled 
case-series
1993
-
2003
-  infected pancreatic necrosis US / CT-guided drainage, 
Trocar technique used, 12-14 
Fr drains
Lee53 2008 Korea Prospective, 
non-controlled 
case-series
2000
-
2004
-  infected pancreatic necrosis CT-guided drainage, 14 Fr 
drains stepwise dilated to 20 
Fr drains
Bruennler54 2008 Germany Retrospective, 
non-controlled 
case-series
1992
-
2004
-  infected pancreatic necrosis CT-guided drainage, Seldinger
Mortele55 2009 United 
States
Retrospective, 
non-controlled 
case-series
n.r -  infected pancreatic necrosis
-  suspected pancreatic necrosis, 
raised by fever, elevated 
WBC, or general clinical 
deterioration refractory to 
standard medical care
CT-guided drainage, Seldinger 
/ Trocar technique used, up to 
14 Fr drains
Rocha56 2009 United 
States
Retrospective, 
non-controlled 
case-series
2001
-
2005
n.r. n.r.
Van 
Santvoort16
2010 The 
Netherlands
RCT 2005
-
2008
-  infected pancreatic necrosis
-  persistent sepsis or progressive 
clinical deterioration despite 
maximal support on ICU, 
without documentation of 
infected necrosis
US / CT-guided, Seldinger 
technique used, minimal drain 
size 12 Fr
Table 1. Study characteristics of the included studies on percutaneous catheter drainage as primary 
treatment  for necrotizing pancreatitis. n.r.: Not reported, WBC: White Blood cell Count, ICU: 
Intensive Care Unit, RCT: Randomized Controlled Trial, CT: Computed Tomography, US: Ultrasound, 
Fr: French.
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Study No. of 
patients
Etiology Predictive 
severity 
scores
Organ 
failure
CT severity 
scores
Infected (peri)- 
pancreatic collections
Freeny10
1998
34 7/34 alcoholic
12/34 biliary
15/34 other
n.r. n.r. CTSI:
mean 8.2
34/34 (100%)
Gambiez48
1998
10 n.r. Ranson: 
mean 3.4
5/10 
(50%)
Balthazar:
Gr. D: 16
Gr. E: 37
3/10 (33%)
Fotoohi49
1999
60 20/60 alcoholic
6/60 biliary
34/60 other
n.r. n.r. n.r. 44/60 (73%)
Baril50
2000
38 n.r. n.r. n.r. n.r. 25/38 (66%)
Cheung51
2005
8 1/8 alcoholic
5/8 biliary
2/8 other
Ranson: 
 mean 5.9
(range 3-9)
n.r. n.r. 4/8 (50%)
Navalho52
2006
30 9/30 alcoholic
17/30 biliary
4/30 other
n.r. n.r. n.r. 30/30 (100%)
Lee53
2008
18 n.r. n.r. n.r. n.r. 18/18 (100%)
Bruennler54
2008
80 32/80 alcoholic
26/80 biliary
22/80 other
Ranson:
median 2
(range 0-4)
APACHE:
median 18
(range 1-38)
65/80 
on ICU
CTSI:
median 6
(range 4-10)
52/80 (65%)
Mortele55
2009
35 8/35 alcoholic
12/35 biliary
15/35 other
Atlanta: 
mean 0.92
(range 0-3)
16/35 
(46%)
Modified CTSI:
mean 9.4
(range 8-10)
13/35 (37%)
Rocha56
2009
28 n.r. n.r. 21/28 
(75%)
n.r. 9/28 (32%)
van Santvoort16
2010
43 3/43 alcoholic
26/43 biliary
14/43 other
APACHE:
mean 15
MODS:
median 2
(range 0-9)
SOFA:
median 3
(range 0-11)
36/43
(84%)
CTSI:
median 8
(range 4-10)
39/43 (91%)
Table 2. Patient characteristics of the included studies on percutaneous catheter drainage as 
primary treatment for necrotizing pancreatitis. n.r.: Not reported, Ranson: Severity score for 
acute pancreatitis20, Atlanta: Severity score for acute pancreatitis17, APACHE: Acute Physiology 
and Chronic Health Evaluation21, CTSI: Computed Tomography Severity Index22, Modified 
CTSI: Modified Computed Tomography Severity Index23, Balthazar: CT severity score for acute 
pancreatitis24, ICU: Intensive Care Unit
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Study No. of 
patients
Time admission 
until PCD
(days)
Successful 
PCD 
Need for 
additional 
surgery
Time between 
PCD and 
necrosectomy
(days)
Patients with 
one or more 
complications
Mortality
Freeny10
1998
34 Mean 9
(1-48)
16 (47%)
All IPN
18 (53%)
All IPN
Mean 32
(6-78)
9 (26%) 4 (12%)  
All IPN
Gambiez48
1998
10 Mean 17
(10-25)
3 (30%)
IPN: 0/3
SPN: 3/7
7 (70%)
IPN: 3/3
SPN: 4/7
n.r. 6 (60%) 2 (20%)  
IPN: 2/3
SPN: 0/7
Fotoohi49
1999
60 n.r. 54 (90%) 3 (5%) n.r. 6 (10%) 3 (5%)
Baril50
2000
38 n.r. 30 (79%)
IPN: 18/25
SPN: 12/13
7 (18%)
IPN: 6/25
SPN: 1/13
n.r. 1 (3%) 2 (5%)
IPN: 2/25
SPN: 0/13
Cheung51
2005
8 Mean 55
(21-154)
IPN: 30
SPN: 81
3 (38%)
IPN: 1/4
SPN: 2/4
5 (63%)
IPN: 3/4
SPN: 2/4
 Mean 70
(1-161)
IPN: 59
SPN: 88
4 (50%) 1 (13%) 
IPN: 1/4
SPN: 0/4
Navalho52
2006
30 Mean 18 19 (63%)
All IPN
10 (33%)
All IPN
Mean 18 n.r. 5 (17%) 
All IPN
Lee53
2008
18 Median 10
(1-58)
14 (78%)
All IPN
3 (17%)
All IPN
n.r. 2 (11%) 1 (6%) 
All IPN
Bruennler54
2008
80 Median 3.5 
(1-40)
38 (48%) 24 (30%) n.r. 23 (29%) 27 (34%)
Mortele55
2009
35 Mean 11
(2-33)
IPN: 12
SPN:10
17 (49%)
IPN: 6/13
SPN: 11/22
13 (37%)
IPN: 7/13
SPN: 6/22
Mean 69
(3-445)
IPN: 42
SPN: 101
4 (11%) 6 (17%) 
IPN: 1/13 
SPN: 5/22
Rocha56
2009
28 n.r. 5 (18%) 17 (61%) Median 109
(1-600)
3 (11%) 8 (29%) 
IPN: 4/9
SPN 4/19
van 
Santvoort16
2010
43 Median 30
(11-71)
15 (35%)
IPN:13/39
SPN: 2/4
26 (60%)
IPN: 25/39
SPN: 1/4
Median 10
(1-52)
17 (40%) 8 (19%)
IPN: 7/8
SPN: 1/8
Table 3. Outcome of the included studies on percutaneous catheter drainage as primary 
treatment for necrotizing pancreatitis. n.r.: Not reported, PCD: Percutaneous catheter 
drainage, IPN: Infected pancreatic necrosis, SPN: Sterile pancreatic necrosis, MOF:Multiple 
organ failure
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and three complications occurred in 75/354 patients (21%). The majority of 
complications were pancreatico-cutaneous and pancreatico-enteric fistulas 
(n= 53, 51% of all 103 complications). In total, nine other procedure-related 
complications were described. This included four bleeding complications of 
which two were self-limiting, and two consisted of massive bleeding due to 
puncture of the splenic artery. These two patients suffered from subsequent 
hemorrhagic shock and died. One colonic perforation, which required 
surgical intervention, was reported. The remaining four complications were 
considered minor and consisted of transient abdominal pain (n= 1), self-
limiting pneumothorax (n= 1) and catheter dislodgement (n= 2). 
 The mortality rate was 17% (67 of 384) across studies. Nine of eleven 
studies reported the mortality for PCD in patients with infected necrosis: 15% 
(27 of 175 patients). In these studies, mortality for PCD in patients with sterile 
necrosis was 15% as well (10 of 69 patients). 
DISCUSSION
This study reviewed the outcome of PCD in a mixed group of patients with both 
sterile and infected pancreatic necrosis, by enlarge in retrospective studies. The 
bundle of data, including the PCD step-up arm of the only RCT on the subject, 
supports the conclusion that a considerable number of patients can be treated 
with PCD without the need for surgical necrosectomy. Approximately half of 
the patients were treated with PCD, without the need for further surgical 
necrosectomy. In patients who did require surgical intervention, PCD allowed 
for postponing additional intervention for several weeks. 
 The across study mortality was 17% (reported in eleven studies), and 15% 
in patients with infected necrosis (reported in nine studies). Although not all 
studies provided data on mortality of patients with infected necrosis, mortality 
of 15% is similar to numbers reported for open “conventional” and minimally 
invasive necrosectomy. A recent review (1994-2008) of 11 series with more 
than 100 patients undergoing open necrosectomy demonstrated a mean 
mortality of 19%.58 The same study reported 19% mortality in their series of 
137 patients undergoing minimally invasive necrosectomy. Furthermore, in 
the one RCT on this subject mortality in the ‘step-up’ arm was 19% and multi 
organ failure was present in 35% of patients prior to intervention.16 
 Over the last two decades, PCD is increasingly used as primary minimally 
invasive treatment for necrotizing pancreatitis with proven or suspected 
infection. The rationale of PCD treatment is to improve the clinical condition 
of these usually seriously ill patients by drainage of “infected fluid (pus) under 
pressure” to either postpone surgical intervention or to even obviate the need 
for surgical necrosectomy. Postponing surgical intervention has been shown to 
improve outcome in patients needing necrosectomy for infected necrosis.59 In 
2000, Büchler et al. proposed that (surgical) intervention should be restricted 
to patients with infected peripancreatic or pancreatic necrosis.4 This has 
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resulted in a much more critically ill group of patients undergoing intervention. 
The indication for PCD, however, differed between the 11 included series. 
Although all 384 patients suffered from necrotizing pancreatitis, only 71% 
indeed had infected peripancreatic collections proven by bacterial culture. 
Other indications for intervention were symptomatic ‘organized necrosis’ and 
‘severe clinical deterioration despite maximum conservative treatment’. These 
last two indications are not very well-defined and one may question whether 
these patients could not have been successfully treated conservatively. 
 In the pooled data of this systematic review, the percentage of patients 
with one or more complications was 21%, with only nine reported procedure-
related complications. Series on surgical necrosectomy report a considerable 
higher complication rate, ranging from 34% to 68%.3,60,61 Furthermore, in the 
current study, only 15% of patients developed a pancreatic fistula, compared 
to 22-47% in the studies on surgical necrosectomy.62-64 However, mostly only 
early complications were described in the included studies. Except for the 
only RCT16, no follow-up was reported in other studies and as a result, late 
complications (e.g. pseudocysts, pancreatic duct amputations, pancreatic 
insufficiency and chronic pancreatitis) were likely missed. In the PANTER 
trial, a 6-months complication rate of 30% was reported in the step-up arm, 
consisting of incisional hernias (7%), endocrine insufficiency (16%) and need 
for pancreatic enzyme suppletion (7%).16 These results indicate that late 
complications do occur, while only short-term complications were reported in 
ten of the eleven included studies. 
 It is conceivable, that drain placement into a sterile peripancreatic collection 
can introduce bacteria resulting in secondary infection. Walser et al. showed 
that initially culture negative collections more frequently become infected 
after percutaneous drainage (13/22, 59%), than after simple fine needle 
aspiration (3/15, 20%, p < 0.03).31 Not all such infections can be classified 
as iatrogenic, as sterile necrosis could become ‘spontaneously’ infected due 
to bacterial translocation through the bowel wall or by systemic infection.65 A 
recent randomized study found an increased risk of developing infected necrosis 
by routine prolonged percutaneous catheter drainage of sterile peripancreatic 
collections (11/20, 55%) as compared to conservative treatment (4/20, 20%, p 
= 0.048).32,66 None of the studies included reported on the rate of iatrogenic 
infection, but underreporting is likely to have occurred.
 In the current study, almost a half of the patients still needed surgical 
necrosectomy after PCD. Although PCD may have ameliorated the patient’s 
condition and may have improved outcome, it may also have caused unnecessary 
delay in a subgroup that is better off with primary surgical intervention. This 
review, however, does not allow for detecting and classifying this specific 
subgroup.   
 The size of the drains used varied from 8 to 28 French and in only one study 
the drainage tract was stepwise dilated.53 Occluded or dislocated drains were 
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replaced by the interventional radiologist in all series. There is a tendency over 
time to use large bore catheters with a lower rate of catheter occlusion and 
need for replacement. In the future, it would be interesting to evaluate whether 
the use of large-size catheters will reduce the need for catheter replacement.
 In most series, catheters were flushed daily with saline, in general every eight 
hours. The daily flushing in combination with the frequent need for catheter 
replacement makes PCD a relatively intensive and time-consuming therapy 
for the patient, surgeon and interventional radiologist.67 However, in the RCT, 
56% of patients in the step-up arm only needed one catheter placement with a 
median size of 14 French.16
 In this review, studies reporting on PCD as part of a step-up approach for 
minimally invasive necrosectomy were not included  in order not to mix the 
effects and complications of drainage only with those of minimally invasive 
necrosectomy (with or without videoscopic assistance) only.42-46 With minimally 
invasive necrosectomy, not only the fluid compartment will be drained by the 
catheter, but also the remaining necrotic debris will be removed. This technique 
is becoming increasingly popular over the last decade.
 A limitation of the current systematic review is that many of the included studies 
were small and retrospective. Moreover, in some series essential data were not 
presented (e.g. total number of interventions, outcome related to infectious 
status of collections, percentage of patients with organ failure at time of PCD). 
A formal assessment of methodological quality could not be performed because 
the papers did not provide enough detailed information for such an assessment.68 
This makes comparison with studies reporting on open necrosectomy even more 
difficult. It is likely that the success of PCD with the need for further surgery is 
overestimated  due to selection bias in the overall results of this review, as success 
rate was 56% compared with 35% in the one RCT. Nevertheless, many patients 
with (suspected) infected necrotizing pancreatitis can recover with PCD as first 
and only intervention.
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ABSTRACT
Objective: Endoscopic transpapillary stenting (ETS) of the pancreatic duct 
facilitates ductal outflow and may reduce time to pancreatic fistula closure. 
However, data on the feasibility of ETS in patients with necrotizing pancreatitis 
are scarce.
Background: Pancreatic fistulas often occur after intervention in necrotizing 
pancreatitis and frequently close only after months of conservative treatment. 
Methods: From a prospective cohort of patients with acute pancreatitis 
admitted in 15 hospitals (2004-2007), all patients who underwent ETS or 
conservative treatment for a pancreatic fistula were identified. Safety, 
feasibility, and outcome of ETS were evaluated. Furthermore, a literature 
review was performed for similar studies in necrotizing pancreatitis.
Results: Out of 731 patients with acute pancreatitis, 19 patients were treated 
with ETS and 16 patients were treated conservatively for a pancreatic fistula. 
Fistula closure was achieved in 16 of 19 patients (84%) in the ETS group and in 
8 of 12 patients (75%) in the conservative group (P=0,175). The median time 
to fistula closure following ETS was 71 days (IQR 34 – 142) compared to 120 
days (IQR 51 – 175 days) in the conservative group (P=0,130). Complications 
were observed in 6 patients A total of 10 studies reporting the results of 281 
patients with stent placement for pancreatic fistulas were included in the 
literature review. Fistula closure was achieved in 200 patients (71%). Stent-
related complications were reported in 9% of patients.
Conclusion: ETS seems a feasible and safe alternative to conservative 
treatment in patients with pancreatic fistulas after intervention for necrotizing 
pancreatitis.
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INTRODUCTION
Infection of pancreatic necrosis occurs in around 30% of patients with 
necrotizing pancreatitis and is considered an indication for intervention1. 
Surgical necrosectomy and percutaneous catheter drainage are the most 
frequently used techniques to debride and drain the infected collections. The 
drains are generally kept in place until the spontaneous production decreases 
or the collected fluid becomes clear after postprocedural lavage. A subset of 
patients will, however, have continued spontaneous production of clear fluids 
from the drain, indicative of a pancreatico-cutaneous fistula.2-5 The estimated 
incidence of persisting pancreatic fistulas varies from 17 to 76% after 
intervention for necrotizing pancreatitis.6-9 Pancreatic fistulas are associated 
with considerable morbidity such as metabolic and nutritional disturbances, 
prolonged hospitalization and even with mortality.7
 Pancreatic fistulas most often are treated conservatively, although the time 
for a pancreatic fistula to resolve spontaneously usually takes more than 3 
months and in some cases even over a year.10 If conservative treatment fails, 
ultimately, a pancreaticojejunostomy may be indicated.6,11 
 Over the years, several groups of investigators have proposed endoscopic 
transpapillary stenting (ETS) as an alternative strategy for the management 
of pancreatic duct (PD) injuries.12-17 ETS decreases intraductal pressure, 
which facilitates drainage of pancreatic secretions to the duodenum instead 
of through the fistula. Most series describe the results of ETS in patients with 
fistulas after pancreatic surgery for suspected malignancy or for pseudocysts 
complicating chronic pancreatitis. However, performing an endoscopic 
intervention in a critically ill patient with necrotizing pancreatitis and 
concomitant papillary edema, pancreatic ductal or duodenal obstruction by 
pancreatic collections may be technically challenging and may potentially 
even worsen clinical outcome. 
 Only limited data are available on ETS and conservative treatment of fistulas 
in patients with necrotizing pancreatitis and little is known about the safety 
of ETS in critically ill patients13. We therefore evaluated the feasibility and 
clinical outcome of ETS and conservative treatment in patients with pancreatic 
fistulas after intervention for necrotizing pancreatitis from a prospective 
multicenter database. In addition, we performed a literature review for similar 
studies reporting the result of ETS and conservative treatment in patients with 
acute necrotizing pancreatitis.
METHODS
Design
This was a retrospective analysis of a prospective database of 731 patients 
with a primary episode of acute pancreatitis admitted to the 15 centers of 
the Dutch Pancreatitis Study Group between March 2004 and March 2007. 
The ethical review board of each participating hospital approved the protocol 
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for prospective data collection and all patients or their legal representatives 
gave written informed consent for inclusion in the database. The baseline 
characteristics and outcome of this cohort have previous been reported.18-20
Patient selection
All patients who underwent percutaneous drainage and/or surgical treatment 
for (suspected) infected necrotizing pancreatitis and subsequently developed 
a pancreatic fistula were included in this study. Patients were identified by 
screening all case record forms, endoscopic retrograde pancreaticography 
(ERP) and other imaging reports of the patients in the database. No strict 
criteria existed for the indication to perform ERP in patients with a pancreatic 
fistula in the participating hospitals. The decision to perform ETS depended on 
hospital policy and endoscopic skills of the gastroenterologists.  
 A pancreatico-cutaneous fistula was defined as output via an operatively 
or percutaneously placed catheter (or drainage canal after removal of drains 
or from a surgical wound) of any measurable volume with an amylase content 
greater than 3 times the serum amylase activity. A pancreatico-abdominal 
fistula was defined as the presence of ascites with amylase content greater 
than 3 times the serum amylase activity. These definitions were adapted from 
the International Study Group on Pancreatic Fistula criteria.2 
Technique of Endoscopic Transpapillary Stenting 
ERP was performed to locate the site of PD injury or disruption, as 
demonstrated by contrast leakage from the pancreatic duct (Fig. 1). In 
presence of a downstream obstruction or disruption of the PD, a guide wire 
was inserted and, if possible, a stent was placed. The preferred position was 
a bridging stent to bypass or cover the PD disruption, and thereby restore the 
flow of pancreatic secretions. In all patients, bridging of the leakage site was 
attempted. If bridging was not possible, an internal stent was placed with the 
proximal tip of the stent in the collection and the distal tip through the papilla 
(Fig. 2). Finally, if neither a bridging stent nor an internal stent could be placed, 
a short transpapillary stent was placed to reduce intraductal pressure. 
Outcome and data collection
Data on patient demographics and clinical outcome were available from 
the prospective database. The outcomes of the study were procedure-
related complications during ETS, any deterioration in clinical condition after 
ETS or ERCP, and successful fistula treatment after ETS or after conservative 
treatment. Successful fistula treatment was defined as total resolution 
of fistula output and absence of large fluid collections on follow-up 
computed tomography (CT) after removal of all drains without the need for 
additional interventions. 
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Figure 1: Endoscopic retrograde pancreatography (ERP) of a patient with ductal leakage from 
the head of the pancreas. A percutaneous catheter drain is visible. 
Figure 2: Computed Tomography (CT) of a patient that underwent surgical necrosectomy 
with postoperative lavage (2 large bore transabdominal drains visible). An internal 
stent is visible with the proximal tip of the stent in the collection and the distal tip through 
the papilla.
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Follow-up
Peripancreatic fluid collections can develop, persist or even return after initial 
fistula resolution. Therefore, follow-up imaging (US, CT or MRI) was used for the 
assessment of long-term outcome of fistula resolution. All available imaging 
6 months, 1 year and 2 years after initial fistula resolution were reviewed by 
a single experienced radiologist (T.L.B.) for the presence of persistent fluid 
collections (PFCs). 
Literature review
A MEDLINE search was performed for similar studies reporting the results 
of endoscopic stenting or conservative treatment for pancreatic fistulas in 
patients with acute pancreatitis. Search terms were “pancreatic fistula” OR 
“duct disruption”. Cross references were searched in the studies found. Only 
studies published in the English language were included. Studies reporting 
the results of surgery for pancreatic fistulas were excluded. All studies 
reporting the result of transgastric or transduodenal endoscopic treatment for 
pancreatic pseudocysts or pancreatic fluid collections instead of endoscopic 
transpapillary treatment for pancreatic fistulas were also excluded.
Statistics
Descriptive statistics were performed and data are presented as numbers 
with subsequent percentages. Non-normally distributed data are presented as 
median with interquartile range (IQR). Univariate logistic regression analysis 
was performed to assess potential association of each of the variables with 
the use of ETS or conservative treatmet. P<0.05 was considered statistically 
significant. Significant variables were explored using a multivariate regression. 
For outcome, categorical variables were compared using Fisher’s exact test and 
in case of continuous measures, differences were tested using Mann-Whitney 
U test. All statistical analyses were performed using SPSS for Windows version 
15.0 (SPSS Chicago, Chicago, IL).
RESULTS
Acute pancreatitis cohort
Between March 2004 and March 2007, 731 patients with a first episode of 
acute pancreatitis were included. From 203 patients with severe pancreatitis, 
129 patients (64%) suffered from organ failure and 98 patients (48%) 
developed infected necrosis. In 115 patients (57%) either percutaneous 
drainage, necrosectomy or both was performed because of (suspected) 
infected necrotizing pancreatitis. In 64 patients (56%) percutaneous drainage 
was performed, 43 of these patients underwent subsequent necrosectomy and 
51 patients underwent a primary necrosectomy (without previous drainage). 
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Pancreatic fistula cohort
From these 115 patients, 35 patients (30%) with a pancreatic fistula after 
radiologic and/or surgical intervention for necrotizing pancreatitis were 
identified. Nineteen patients were treated with ETS and 16 patients were 
treated conservatively (see Table 1 for baseline characteristics). An overview 
of all patients with ETS and conservative treatment are given in Tables 2 and 
3. Univariate logistic regression analysis was performed to assess potential 
association of each of the variables with ETS or conservative treatment. The 
patients in the conservative group were older with a median age 61 years 
compared with 46 years in the ETS group (P=0,028). One patient had a 
pancreatico-abdominal fistula; the remaining 34 patients had a pancreatico-
cutaneous fistula. A PD injury or disruption was confirmed by contrast 
leakage during ERP in 18 of 19 patients treated with ETS (95%). Concomitant 
obstruction of the PD was observed in 10 of 19 patients (53%). The median 
fistula output was approximately 150 (IQR 200-300) mL/day for the ETS group 
and 250 (IQR 75-338) mL/day for the conservative group. These 19 patients 
were treated in 6 of 15 participating hospitals. Of 19 patients with a pancreatic 
fistula treated with ETS, 12 patients (63%) had recovered from (multi)organ 
failure. Three patients were admitted to the intensive care unit (ICU) due 
to multiorgan failure at the time of ETS. From 16 patients with conservative 
treatment, 9 patients (56%) suffered from (multi)organ failure at any moment 
during admission. 
 In 24 patients, ETS for a pancreatic fistula was attempted and succeeded 
in 19 patients (79%). The median duration of conservative treatment before 
ETS was 34 days (IQR 18-92). The remaining 5 patients, in whom ETS was not 
possible, were treated conservatively. ETS failed in these patients because 
cannulation of the PD was not possible due to papillary oedema (n=4) and 
due to a complete stop of the PD (n=1). In 13 patients (68%) a PD stent could 
be placed during the initial procedure (Table 4). In 4 patients (21%), a second 
procedure was required and 2 patients (11%) required 3 procedures. Bridging 
of the PD disruption was achieved in only 4 of 19 patients (21%). In the 
remaining 15 patients, 6 patients received an internal stent and 9 patients a 
short transpapillary stent. 
Complications
Complications occurred in 6 patients after stent placement. Migration of 
the stent occurred in 4 of 19 patients (21%) and clogging in 2 of 19 patients 
(11%). In 3 of 4 patients with a migrated stent, a new stent was placed. In the 
fourth patient, the fistula had resolved at the time the stent migration was 
discovered. The clogged stents were both exchanged during subsequent ERPs. 
In 1 patient in whom ETS was attempted but failed, a clinical deterioration was 
observed with an increase in abdominal pain during 1 day and a transient rise 
in inflammatory markers.
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Patient characteristics ETS 
(N=19)
Conservative (N=16) P**
Male gender 11 (37) 8 (50) 0,435
Age (yr) 46 (32-61) 61 (52-70) 0,028
CT severity index 7 (4-9) 8 (6-10) 0,182
Persistent organ failure during admission# 15 (79) 9 (56) 0,156
Pancreatic parenchymal necrosis 14 (74) 15 (94) 0,147
Peripancreatic necrosis/collections only* 5 (26) 1 (6) 0,147
Infected necrosis 13 (68) 12 (75) 0,668
Time from onset of symptoms to intervention for 
infected necrosis (d)
26 (11-67) 22 (12-35) 0,227
Type of initial intervention 0,067
      Surgical necrosectomy 11 (58) 14 (88)
      Percutaneous catheter drainage 8 (42) 2 (13)
Octreotide therapy 5 (26) 5 (33) 0,656
Sphincterotomy 8 (42) 5 (31) 0,509
Time from intervention to ERP (d) 34 (18-92) -
Type of fistula 1,000
      Pancreatico-cutaneous 15 (94) 16 (100)
      Pancreatico-abdominal 1 (6) 0 (0)
Location of PD disruption 0,178
      Head 2 (11) 4 (25)
      Body 7 (37) 4 (25)
      Tail 9 (47) 1 (6)
      Normal pancreatic duct 1 (5) 0 (0)
      Not identified 0 (0) 7 (44)
Pancreatic duct obstruction 10 (53) -
Fistula output (mL/d) 150 (200-300) 250 (75-338) 0,350
Data are n (%) or median (interquartile range). CT = computed tomography ERP = endoscopic 
retrograde pancreatography PD = pancreatic duct ETS = endoscopic transpapillary stenting 
*No pancreatic parenchymal necrosis. #Organ failure more than 48hrs. **Univariate logistic 
regression analysis was used to test for differences between groups. 
Table 1: Baseline characteristics
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Outcome
Fistula closure (ie, complete resolution of the fistula without need for other 
interventions) was achieved in 16 of 19 patients (84%) in the ETS group and in 
8 of 12 patients (75%) in the conservative group (P=0,175). In the ETS group, 
1 patient required a pancreaticojejunostomy for fistula closure 118 days after 
ETS. Two patients died prior to fistula closure, 18 and 22 days after stent 
placement. These were 2 patients suffering from severe multiorgan failure that 
started before any intervention and persisted throughout the disease course. In 
the conservatively treated patients, 4 patients (25%) underwent an additional 
intervention to achieve fistula closure. Pancreaticojejunostomy was performed 
in 3 patients and 1 patient underwent endoscopic transgastric drainage of the 
collection. The median time to fistula closure after ETS was 71 days (IQR 34 
– 142) compared to 120 days (IQR 51 – 175 days)] in the conservative group 
(P=0,130). The association between age, ETS or conservative treatment and 
time to fistula resolution was explored using multivariate linear regression. 
Adjusting for the effect of age did not change outcome of fistula closure or 
time to fistula resolution.
 In the ETS group, the time to fistula closure was not associated with the 
number of days between intervention for necrotizing pancreatitis and ETS. 
Neither was it associated with the position of the endoprothesis (transpapillary, 
bridging or internal) or the presence of a PD stenosis (data not shown). 
Follow-up
The presence of PFCs was investigated in all surviving patients that underwent 
imaging (US, CT or MRI) during follow-up. Six months after initial fistula 
resolution, PFCs were seen at imaging in 6 of 15 patients (40%) after ETS and 
in 8 of 13 patients (62%) after conservative treatment (P=0,449). After 1 year, 
1 patient in the ETS group had died due to metastatic disease. One year and 2 
ETS characteristics N = 19
Number of ETS attempts for stent placement (median) 1 (1-3)
Stent position
    Bridging 4 (21)
    Transpapillary 9 (47)
    Internal 6 (32)
Diameter stent (Fr) 7 (5-10) 
Length stent (cm) 7 (3-15) 
Table 4: Characteristics of endoscopic stent placement (ETS) for pancreatic fistulas in patients 
with necrotizing pancreatitis.
Data are n (%) or median (range). 
120
years after fistula resolution, PFCs were noticed in 3 of 14 patients (21%) after 
ETS and in 7 of 13 patients (54%) after conservative treatment (P=0,120).
Literature review
After reviewing 58 potential relevant manuscripts, 10 articles with a total of 
281 patients (including the present series) with stent placement for pancreatic 
fistulas were selected.12-15,17,21-24 An overview is given in Table 5. Only the results 
for patients with acute pancreatitis are given (as far as these results could 
be deducted from the articles). Twenty-five complications were reported 
in the studies, although the pancreatitis severity of most patients was not 
described in detail. Time to fistula closure ranged from a median of 2 days to 
4 months between studies and within the individual studies a wide range of 
time to closure was observed (similar to our findings). A direct comparison of 
results between studies is unfortunately seriously hampered due to lack of 
homogeneity. The study by Boerma and colleagues is most similar to this study. 
This study, like our study, included only patients with necrotizing pancreatitis 
and a pancreatic fistula after necrosectomy. In this study, however, only 
patients with a pancreatic obstruction underwent endoscopic stenting. The 
overall reported rate of fistula closure after stent placement in the studies 
retrieved varied between 58 and 100%. 
 In addition, the literature was searched for studies reporting the result of 
conservative treatment for pancreatic fistulas in patients with necrotizing 
pancreatitis. After an extensive MEDLINE and cross-reference search, only a 
single study was identified.10 Sikora and colleagues reported on 156 patients 
with acute severe pancreatitis that underwent percutaneous drainage or 
surgical intervention. Out of the 81 surviving patients, 43 developed a 
pancreatic fistula (53%) and were managed conservatively. In 38 patients 
(88%) fistula closure was achieved after a median of 70 days (28 – 424 
days). However, from these 38 patients with spontaneous closure, 3 patients 
underwent cystogastrostomy (n=3) or cystojejunostomy (n=4) at a later stage 
for treatment of pseudocysts.
DISCUSSION
This is the largest series on ETS and conservative treatment for pancreatic 
fistulas after surgical or radiological intervention in patients with necrotizing 
pancreatitis. Although ETS was performed selectively and not in a prospective 
manner, our results suggest that ETS is feasible, relatively safe and might form 
an alternative for conservative treatment in critically ill patients. 
 Previous studies have described the results of ETS for pancreatic fistulas, 
as is presented in the literature review. Most studies report a high rate of 
successful fistula closure after endoscopic stenting. The results, however, 
are difficult to compare. The studies differ in several aspects. First of all, 
most studies also included patients with pancreatic fistulas after surgery for 
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pancreatic cancer or chronic pancreatitis. Second, the definition of a pancreatic 
fistula varied between studies. Third, the timing and indication for endoscopic 
treatment differed or were not reported. Fourth, the patient characteristics of 
patients with acute pancreatitis (eg, presence of necrosis or organ failure) are 
not given. Finally, the position of the stent (transpapillary, internal or bridging) 
was not reported in most studies. 
 Kozarek et al reported in 1997 that transpapillary stenting can effectively 
close pancreatic fistulas within a week.12 In 9 retrospectively identified 
patients with ductal injury after surgery for chronic and acute pancreatitis, 
8 fistulas were closed within a week. One stent occlusion and one stent 
migration were described. These promising results unfortunately have not 
been reproduced by other case series. Howard et a. described 7 patients 
with different types of pancreatic fistulas and treatment with transpapillary 
stenting.14 ETS was successful in all patients, although patients with complete 
ductal disruption were not deemed amenable for ETS and only patients 
with partial ductal disruption were included. No complications of ETS 
were reported. Telford et al described results in 43 patients identified with 
pancreatic ductal disruption of different etiology.15 Four patients experienced 
a clinical deterioration after stent placement, although stent occlusion was 
not documented. The study by Boerma et al is the only study, next to the 
present series, that solely included patients with necrotizing pancreatitis that 
had undergone surgical necrosectomy.13 After ETS, after a median of 10 days, 
fistula production stopped in all 13 patients. All patients, however, that were 
treated with endoscopic stenting had a ductal obstruction and all stents were 
placed through the obstruction. This might have shortened overall time to 
fistula closure compared with the present series. In the present study, fistula 
closure was achieved in approximately 80% of patients. The median time to 
fistula closure, however, was more than 2 months after stent placement. Our 
results differ from some of the results reported. The observed difference 
may be explained by the fact that we only included patients that underwent 
intervention for suspected infected necrosis. In these patients, the ductal 
anatomy of the pancreas was severely disrupted as is reflected by the high 
rate of ductal obstruction, ductal disconnection and the median CT severity 
index (CTSI). CTSI was 8 or higher in 50% of patients. A CTSI of 8 correlates 
with at least 30% lack of enhancement of pancreatic parenchyma (along with 
the presence of 2 or more peripancreatic collections).25 As a result of the 
disrupted anatomy, in only 4 patients a bridging stent could be positioned. The 
transpapillary or internal stent placed in the remaining 15 patients lowers the 
pancreatic intraductal pressure, but probably does not entirely reduce flow 
of pancreatic juices into the pancreatic fluid collections. As a consequence, 
complete closure of the fistula will still take considerable time. A bridging stent 
has been correlated with a more favourable outcome.15 In this study, outcome 
for patients with a bridging stent was similar to results after transpapillary or 
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an internal stent, although patient numbers in the current study probably are 
too small to formally compare the outcome for the different stent positions. 
 Despite many challenging factors most often encountered in critically ill 
patients with necrotizing pancreatitis, no complications such as bleeding or 
perforation directly related to ETS were noted in this study. Several other 
complications did occur, such as occlusion and migration of stents. Notably, 
these events did not result in clinical deterioration. 
 In this study, we used the adapted definition for pancreatic fistula as 
proposed by the International Study Group on Pancreatic Fistula (ISGPF) that 
was designed for pancreatic resections.2 Fistulas after pancreatic resections 
represent failure of a healing or sealing of a pancreatic-enteric anastomosis. 
We defined a pancreatic fistula after intervention for necrotizing pancreatitis 
as output via a percutaneous drain (or drainage canal after removal of drains 
or from a surgical wound) of any measurable volume of fluid with an amylase 
content greater than 3 times the serum amylase activity. We feel this definition 
is more appropriate for patients with necrotizing pancreatitis. 
 From the number of patients with a pancreatic fistula in the study cohort, the 
incidence of pancreatic fistulas after intervention for necrotizing pancreatitis 
cannot accurately be deducted. The physicians decided to perform ETS at their 
own discretion and the conservatively treated patients were identified from 
the ERP reports, imaging reports and case record forms. It is possible that 
some patients with a pancreatic fistula may have gone unnoticed.
 This study has several shortcomings. It was a retrospective analysis and 
ETS was not performed according to a standardized protocol. Conservative 
treatment before ETS differed among centers. For example, 4 patients received 
octreotide and 8 patients underwent a biliary sphincterotomy during early 
ERCP when signs of an impacted stone or significant cholestasis were present. 
It is unlikely that these differences in conservative treatment strategies 
may have influenced outcome of ETS because in most patients conservative 
treatment was attempted for more than 3 weeks. More importantly, selection 
of patients for ETS and conservative treatment very likely influenced the time 
to fistula resolution. It is possible that some of the patients undergoing ETS 
would have had spontaneous closure of their fistula in the same time period 
with conservative treatment. On the other hand, it is also very much possible 
that some conservative treated patients would have had earlier resolution if 
they were treated with ETS. The overall median time to fistula closure did not 
differ significantly between groups. If ETS really shortens time to fistula closure 
can only be answered in a comparative, preferably randomized, design. Such a 
study is needed, but unfortunately difficult to perform. 
 In conclusion, this study suggests that endoscopic transpapillary treatment 
in patients with pancreatic fistulas after intervention for infected necrotizing 
pancreatitis is a feasible and a safe alternative to conservative treatment. 
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ABSTRACT
Objectives: To determine the risk of recurrent biliary events in the period 
after mild biliary pancreatitis but prior to interval cholecystectomy and to 
determine the safety of cholecystectomy during the index admission.
Summary of background data: Although current guidelines recommend to 
perform cholecystectomy early after mild biliary pancreatitis, consensus on 
the definition of early (i.e. during index admission or within the first weeks 
after hospital discharge) is lacking. 
Methods: We performed a systematic search in Pubmed, Embase and Cochrane 
for studies published from January 1992 to July 2010. Included were cohort 
studies of patients with mild biliary pancreatitis reporting on the timing of 
cholecystectomy, number of re-admissions for recurrent biliary events prior to 
cholecystectomy, operative complications (e.g. bile duct injury, bleeding) and 
mortality. Study quality and risks of bias were assessed.
Results: After screening 2413 studies, eight cohort studies and one randomized 
trial describing 998 patients were included. Cholecystectomy was performed 
during index admission in 483 patients (48%) without any reported re-
admissions. Interval cholecystectomy was performed in 515 patients (52%) 
after 40 days (median; interquartile range 19-58 days). Prior to interval 
cholecystectomy, 95 patients (18%) were re-admitted for recurrent biliary 
events (0% vs. 18%, P<0.0001). These included recurrent biliary pancreatitis 
(n=43, 8%), acute cholecystitis (n=17) and biliary colics (n=35). Patients 
who had an endoscopic retrograde cholangiopancreatography had fewer 
recurrent biliary events (10% vs. 24%, P=0.001), especially less recurrent 
biliary pancreatitis (1% vs. 9%). There were no differences in operative 
complications, conversion rate (7%) and mortality (0%) between index and 
interval cholecystectomy. Because baseline characteristics were only reported 
in 26% of patients, study populations could not be compared.
Conclusions: Interval cholecystectomy after mild biliary pancreatitis is 
associated with a high risk of re-admission for recurrent biliary events, 
especially recurrent biliary pancreatitis. Cholecystectomy during index 
admission for mild biliary pancreatitis appears safe but selection bias could 
not be excluded.
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INTRODUCTION
The incidence of acute biliary pancreatitis is increasing worldwide, possibly due 
to an increase in obesity with associated increased risk of gallstone disease.1,2 
In the US alone, the annual costs of acute pancreatitis currently exceed $2.2 
billion.3 Although 20% of patients develops severe pancreatitis, associated 
with high morbidity and mortality, in 80% of patients the pancreatitis remains 
mild.4 
 It is generally accepted that patients with severe biliary pancreatitis should 
undergo cholecystectomy when signs of inflammation have resolved (i.e. 
interval cholecystectomy).5 After mild biliary pancreatitis current international 
guidelines advice ‘early’ cholecystectomy.6-8 The definition of ‘early’, 
however, varies greatly between guidelines. The International Association of 
Pancreatology (IAP) recommends that all patients with gallstone pancreatitis 
should undergo cholecystectomy as soon as the patient has recovered from 
the attack8, while the American Gastroenterological Association7 and the 
British Society of Gastroenterology6 recommend cholecystectomy within 
a 2-4 weeks interval after discharge. This lack of consensus is also reflected 
by several audits from the UK9-11, Germany12, Italy13 and a large database 
study from the USA14. The differences between these guidelines are most 
likely caused by a lack of randomized controlled studies on this topic. The 
rationale of early cholecystectomy is to reduce the risk of recurrent biliary 
events (e.g. recurrent biliary pancreatitis, acute cholecystitis, symptomatic 
choledocholithiasis, biliary colics). This may be essential, as a recurrent attack 
of biliary pancreatitis could be severe and thus life threatening.15 
 In case of clinical equipoise, the situation where no clear therapeutic 
recommendation can be made, many clinicians routinely perform interval 
cholecystectomy, because this does not stress the usually already busy 
emergency theatre list, and for reimbursement reasons.12 Therefore, it is 
essential to quantify the risks involved with interval cholecystectomy as 
compared to cholecystectomy during index admission (index cholecystectomy) 
and to grade the current evidence on this topic. 
 We performed the first systematic review on timing of cholecystectomy after 
mild biliary pancreatitis, and focused on: 1) the risk of recurrent biliary events 
in the period between discharge after mild biliary pancreatitis and interval 
cholecystectomy, and 2) the safety of index versus interval cholecystectomy 
after mild biliary pancreatitis.
METHODS
Systematic literature search
A systematic literature search was performed in the Pubmed, Embase and 
Cochrane Library databases from January 1st, 1992 to July 31st, 2010. We 
adhered to the 2009 PRISMA statement.16 The search was limited to this 
episode, as before 1992 no universally accepted terms were available for acute 
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pancreatitis and its clinical course. In 1992, the Atlanta symposium provided 
clear definitions of the disease and its complications.17 Although the Atlanta 
classification is currently under revision, the definitions have been widely 
used in the literature since 1992. 
 The MeSH headings “cholecystectomy” and “pancreatitis” were used, and 
the search was restricted to English literature. From the studies identified, 
all titles and abstracts were screened to select those reporting on the timing 
of cholecystectomy in patients with mild biliary pancreatitis. Subsequently, 
full-text papers of the selected studies were independently screened by two 
authors (MvB and MB) for eligibility. When multiple articles were published by 
the same study group and no difference in study period was described, only 
the most recent paper was selected for this systematic review.
Inclusion and exclusion criteria
Inclusion criteria were: 1) cohort of patients undergoing cholecystectomy 
after mild biliary pancreatitis (i.e. either index or interval cholecystectomy); 2) 
information on the following essential outcomes: time between recovery from 
acute pancreatitis and cholecystectomy, number of recurrent biliary events 
prior to cholecystectomy, complications during the cholecystectomy (e.g. bile 
duct injury, bleeding) and mortality.
 Exclusion criteria were: 1) cohorts with fewer than five patients; 2) 
cohorts including severe pancreatitis without reporting the results for mild 
pancreatitis separately; 3) cohorts without reporting on essential outcomes; 
4) cohorts in which patients underwent index cholecystectomy during the 
initial attack of acute pancreatitis (i.e. prior to recovery); the rationale for this 
being that the IAP guideline advices cholecystectomy only after recovery of 
biliary pancreatitis.8
 All references of the included studies were screened for potential relevant 
studies not identified by the initial literature search. The final decision on 
eligibility was reached by consensus between the two screening authors.
Data extraction
From the included studies, the following variables were extracted (if available): 
definition of mild biliary pancreatitis, number of patients undergoing 
cholecystectomy after mild biliary pancreatitis, number of endoscopic 
retrograde cholangiography (ERC) and endoscopic sphincterotomy performed, 
time between first hospital admission and cholecystectomy, reasons for 
delay of surgery, number of re-admissions during time between first hospital 
admission and cholecystectomy, total number of recurrent biliary events (i.e. 
biliary pancreatitis, acute cholecystitis and biliary colics) requiring re-admission 
during time between first hospital admission and cholecystectomy, conversion 
to open cholecystectomy, complications and mortality. If reported, follow-up 
and data of patients with recurrent biliary pancreatitis after cholecystectomy 
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were extracted. The authors of included studies were contacted if one of these 
variables could not be extracted from the original article. We defined ’index 
cholecystectomy’ as cholecystectomy during the initial hospital admission 
for acute biliary pancreatitis. Interval cholecystectomy was defined as 
cholecystectomy during a new hospital admission for cholecystectomy, usually 
performed at least one week after discharge. 
Assessment of study quality 
We performed a quality assessment of the included studies with two 
previously validated checklists that scored the methodological quality of 
non-randomized studies.18,19 Downs et al described a checklist with 27 items 
(one point for each item) which can be used for quality assessment for both 
randomized and non-randomized studies.18 The MINORS checklist, described 
by Slim et al, contains eight items for non-comparative studies and 12 items 
for comparative studies (maximum of two points for each item).19 In both lists 
a low score reflects a high risk of bias, whereas a high score reflects a low risk 
of bias. To facilitate comparison of both lists, each score was converted to a 
score on a 0-10 scale. Randomized controlled trials were only assessed with 
the checklist of Downs et al. No studies were excluded on the basis of their 
score. Baseline characteristics were assessed to determine whether selection 
bias might have played a role in the timing of cholecystectomy (i.e. less sick 
patients undergoing index cholecystectomy more frequently). Finally, we 
assessed reasons for delay of cholecystectomy.
Statistical analysis
All data were pooled. Total number of readmissions due to recurrent biliary 
events was calculated, as well as every recurrent biliary event apart and 
compared between the patients with early cholecystectomy and interval 
cholecystectomy. Regarding the number of recurrent biliary events prior to 
cholecystectomy, comparison was made by patients with or without ERC prior 
to cholecystectomy. Baseline characteristics were listed, as well as the number 
of complications occurred. Mortality and conversion rates were calculated and 
compared between patients with early and interval cholecystectomy.
 Non-normally distributed data were presented as median (interquartile 
range). Proportions were compared by the chi-square test or the Fisher exact 
test, as appropriate. All statistical analysis were performed using SPSS® for 
Windows® version 16.0.2 (SPSS, Chicago, Illinois, USA). Two-sided P<0.05 was 
considered statistically significant.
RESULTS
Included studies
The results of the literature search are depicted in Figure 1. The initial search 
yielded 2413 potentially relevant papers. After screening titles and abstracts for 
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relevance, 38 remaining papers were further assessed for eligibility. Although 
all 38 papers reported on the timing of cholecystectomy in biliary pancreatitis, 
29 were excluded for the following reasons: cohort of patients not reporting 
on the incidence of recurrent biliary events prior to cholecystectomy (n=9)15,20-
27, cohorts of patients with mixed severe and mild acute biliary pancreatitis 
and outcomes not reported separately (n=6)11,28-32, cohorts of patients without 
data on the period between index admission and cholecystectomy (n=5)10,33-
36, cohorts where no separate results were described for patients with acute 
biliary pancreatitis (n=4)37-40, cohorts in which patients were operated during 
the initial attack of pancreatitis (n=3)41-43, cohorts with fewer than five patients 
per study group (n=1)44 and cohorts without documentation of essential 
outcomes (n=1)45. Finally, nine studies were included in the current systematic 
review.9,46-53 Six studies were retrospective cohort studies9,48-51,53, two studies 
were prospective cohort studies47,52 and one study was a randomized controlled 
trial46 (level 4 evidence, level 4 evidence and level 1b evidence, respectively54). 
 In the one randomized trial, Aboulian et al randomized between 
cholecystectomy during the initial attack of pancreatitis versus cholecystectomy 
after recovery but during index admission.46 Based on our exclusion criteria we 
included only the latter arm.
Figure 1: PRISMA flowchart systematic review of timing of cholecystectomy after mild biliary 
pancreatitis.
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Study Country Year Definition of mild acute biliary pancreatitis
Schachter52 Israel 2000 Acute abdominal pain with elevated serum and/or urine levels of amylase (>700 
IU/L serum, normal 70-220; urine >1500 IU/L, 
normal <1000). Imaging confirmation of gallstones. Ranson ≤3.
McCullough50 Canada 2003 Lipase >400 U/L. Radiographic confirmation of gallstones (US, CT, ERC). No necrosis 
on CT, no ICU stay.
Cameron9 UK 2004 Acute upper abdominal pain, serum amylase >500 IU/l (normal 30-110)
Gallstones demonstrated on US or ERC. No description of a severity score. 
Griniatsos48 UK 2005 Generalized or upper abdominal pain and tenderness, elevation of serum amylase 
level more than three times the normal. Documented gallstones and absence of 
other factors known to cause acute pancreatitis. Modified Imrie score <3 within 48h 
after admission.
Clarke47 USA 2008 Elevation of  lipase 3 times or more the normal level. Gallstones on US.
Ranson ≤3, no required emergent operative intervention for management of the 
biliopancreatic process. 
Ito49 USA 2008 Abdominal pain and tenderness, together with elevations in serum amylase and/or 
lipase concentration (at least 3 times the upper limit of normal). 
Documentation of gallstones or choledocholithiasis on imaging studies. No necrosis 
on CT scan.
Nebiker51 Switzerland 2008 Acute abdominal pain with a threefold increase of serum amylase activity. 
Detection of gallstones on US, MRCP or ERC. Modified Ranson score ≤3, no necrosis 
on CT.
Sinha53 India 2008 Serum amylase level more than two times the normal, increase ALT to three or more 
times the normal. US features of pancreatic edema and cholelithiasis with or without 
CBD stones. Ranson ≤4.
Aboulian46 USA 2010 Upper abdominal pain, nausea, vomiting, epigastric tenderness, absence of ethanol 
use, elevated amylase level to at least twice the upper limit of normal. Imaging 
confirmation of gallstones. 
Ranson ≤3, clinical stability with admission to a non-monitored ward bed, absence 
of acute cholangitis, low suspicion for a retained CBD stone.
Table 1. Characteristics of the included studies.
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Study Number of 
patients
Time between 
discharge and 
cholecystectomy 
(range/SD) (days)
Re-admissions for 
recurrent biliary 
events (%) (N= 
biliary pancreatitis, 
cholecystitis, colics)
Conversion 
to open 
cholecystectomy
(%)
Complications Reasons 
for delay in 
surgery
Index
cholec.
Interval
cholec.
Index
cholec.
Interval
cholec.
Index
cholec.
Interval
cholec.
Index
cholec.
Interval
cholec.
Index
cholec.
Interval
cholec.
Schachter52 - 19 - >56 - 0 - 2
(11%)
- 0 All study-
related
McCullough50 74 90 0 mean 40 
(+/- 69)
0 18 (20%)
(3,5,10)
9
(12%)
8
(9%)
11 16 All hospital-
related
Cameron9 - 58 - mean 93
median 68
(5-720)
- 11 (19%)
(4,3,4)
- 7
(12%)
- 0 nr
Griniatsos*48 - 20 - median 14
(7-14)
- 0 - 0 - 1 All hospital-
related
Griniatsos*48 - 24 - median 60
(47-91)
- 1 (4%)
(1,0,0)
- 0 - 1 16 hospital-
related, 4 delay 
of clinical 
improvement,
4 severe 
comorbidity
Clarke47 110 92 0 mean 23
(+/- 10)
0 8 (9%)
(7,1,0)
nr nr 4 5 All study-
related
Ito49 162 119 0 median 45
(4-436)
0 39 (33%)
(16,6,17)
20
(12%)
8
(7%)
37 34 nr
Nebiker51 32 67 0 >14 0 15 (22%)
(9,2,4)
2
(6%)
2
(3%)
2 5 All hospital-
related
Sinha53 81 26 0 >42 0 3 (12%)
(3,0,0)
0 0 0 0 All patient-
related
Aboulian46 24 - 0 - 0 - 0 - 0 - -
TOTAL 483 515 0 Median 
40
0 95 (18%) 
(43,17,35)
31 
(9%)#
27 (6%) 17 
(4%)
29 (6%) -
Table 2: Patient outcomes of the included studies.
*In one study two different groups of interval cholecystectomy were described. #Percentages only calculated 
for the studies that reported this endpoint. SD: Standard deviation, nr: Not reported
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Baseline characteristics
The pooled data comprised of 998 patients undergoing cholecystectomy after 
mild biliary pancreatitis (range per study: 19-281 patients). The definitions 
of mild biliary pancreatitis per study are shown in Table 1. In the nine 
studies, 15 cohorts with different timing of cholecystectomy were described. 
One study described two different cohorts of patients undergoing interval 
cholecystectomy (Table 2).48 Relevant baseline characteristics (i.e. age and ASA 
classification) were only reported both in two studies, including 263 patients 
(26%). A total number of 483 of 998 patients (48%; described in six different 
cohorts), underwent cholecystectomy during index admission. In the remaining 
nine cohorts, 515 of 998 patients (52%) underwent interval cholecystectomy at 
a median of 40 days (interquartile range 19-58 days) after discharge. Six studies 
(645 patients) reported on gender and age. The male:female ratio was 1:2, 
with a median age of 56 years (interquartile range 53-60 years). Eight studies, 
including 13 different cohorts and 796 patients, reported on the number of 
patients who underwent pre-operative ERC: 308 patients (39%). Not all eight 
studies reported numbers on the use of endoscopic sphincterotomy implicitly. 
Four studies described the use of intra-operative cholangiography.9,46,48,50 
 
Re-admission prior to cholecystectomy
Table 2 shows outcomes as reported in the included studies. The re-
admission rate between discharge and interval cholecystectomy was 95/515 
(18%). Recurrent biliary pancreatitis occurred in 43/515 patients (8%), 
acute cholecystitis in 17/515 patients (3%) and biliary colics requiring re-
admission in 35/515 patients (7%). No new episodes of biliary events prior to 
cholecystectomy were reported in the patients undergoing cholecystectomy 
during index admission (18% vs. 0%, P<0.0001). Details about the severity of 
recurrent biliary pancreatitis could only be retrieved for 3/43 patients: two 
patients suffered from severe recurrent biliary pancreatitis49 and one patient 
suffered from a mild recurrent biliary pancreatitis48. 
Outcome of cholecystectomy
Eight studies, including 796 patients, reported on the conversion rate. Overall, 
conversion to open cholecystectomy occurred in 58 patients (7%), without 
differences between index and interval cholecystectomy. Major reasons for 
conversion were intra-abdominal adhesions, however, no exact data about 
the distribution of the conversions among the two groups could be retrieved. 
One study did not distinguish between laparoscopic and conventional 
cholecystectomy.47 Although complications were described in all timing 
cohorts, not all studies described the number of patients with complications, 
but only the number of complications. For this reason, no overall complication 
rate could be calculated. A total number of 116 different complications were 
described, including three common bile duct injuries, without mortality. Again, 
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Table 3: Patient outcomes in patients with or without ERC undergoing delayed 
cholecystectomy. 
Table 4: Quality assessment of the included studies with two different scoring lists.
*In one study two different groups of interval cholecystectomy were described. nr: Not 
reported. ERC: Endoscopic retrograde cholangiography. ES: Endoscopic sphincterotomy.
*All scores are 0-10, with 10 reflecting the highest methodological score.
Study N ERC/ES
(%)
Re-admissions after 
previous ERC/ES
(biliary pancreatitis, 
cholecystitis, colics)
Re-admissions without 
previous ERC/ES
(biliary pancreatitis, 
cholecystitis, colics)
Schachter52 19 100% 0 0
McCullough50 90 63% nr nr
Cameron9 58 64% (0,nr,nr) ≥4
(4,nr,nr)
Griniatsos*48 20 0% 0 0
Griniatsos*48 24 0% 0 1 (4%)
(1,0,0)
Clarke47 92 nr nr nr
Ito49 119 47% 14 (12%)
(2,5,7)
25 (21%)
(4,1,10)
Nebiker51 67 36% 0 15 (22%)
(9,2,4)
Sinha53 26 0% 0 3 (12%)
(3,0,0)
TOTAL 515 40% 14 (10%) 
(2,5,7)
≥48 (24%)
(31,3,14)
Study MINORS 
checklist*
Checklist for (non-) 
randomized trials*
Schachter52 3.8 3.7
McCullough50 6.7 5.9
Cameron9 5.6 5.9
Griniatsos*48 6.7 6.7
Clarke47 6.7 6.7
Ito49 7.5 6.3
Nebiker51 7.5 6.7
Sinha53 6.3 5.2
Aboulian46 - 8.9
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the exact type of complications and distribution among the two groups could 
not be extracted from the included studies.
Role of endoscopic sphincterotomy / ERC
Table 3 provides an overview of re-admissions for biliary events in relation to 
the use of ERC. Re-admission after previous ERC occurred in 14/136 patients 
(10%), due to recurrent biliary pancreatitis in two patients, acute cholecystitis 
in five patients and biliary colics in seven patients. Notably, of 197 patients 
without previous ERC, 48 (24%) were re-admitted. These re-admissions were 
due to recurrent biliary pancreatitis (n=31), acute cholecystitis (n=3) and biliary 
colics (n=14). ERC protected against re-admissions (10% vs. 24%, P=0.001). 
Recurrent pancreatitis after cholecystectomy
Only two out of nine studies (n=157) reported follow-up after cholecystectomy.9,51 
Cameron et al9 reported one case of recurrent biliary pancreatitis (2%), 223 days 
after cholecystectomy and Nebiker et al51 reported one case (1%) of recurrent 
biliary pancreatitis, five years after cholecystectomy. In both patients a common 
bile duct stone was found. These patients suffered from mild pancreatitis and 
recovered uneventfully. It is unclear whether these patients had undergone 
index or interval cholecystectomy. The overall risk of recurrent pancreatitis after 
cholecystectomy in the pooled data was therefore 2/157 (1%). 
Assessment of study quality 
Table 4 shows the converted quality scores on a 0-10 scale. The randomized 
trial scored high46, five studies scored moderate47-51, two studies scored 
moderate to low9,53 and one study scored low52. Reasons for delay of surgery 
were reported in 338/515 patients (66%) and were due to patient-related 
affairs (both patient-preferred delay and comorbidity, 34 patients, 10%), 
hospital-logistics (193 patients, 57%) and study design (111 patients, 33%). 
Two prospective cohort studies stated explicitly that cholecystectomy had 
intentionally been postponed because of the study design.47,52 
DISCUSSION
This first systematic review on the timing of cholecystectomy after mild biliary 
pancreatitis found high re-admission rates (18%) for interval cholecystectomy. 
As morbidity was comparable between index and interval cholecystectomy, it 
seems that cholecystectomy during index admission should be the preferred 
strategy for patients with mild pancreatitis. However, as baseline characteristics 
were often not provided we cannot be sure whether the two groups are truly 
comparable. Selection bias might have played a role, e.g. patients with more 
co-morbidity might have undergone interval cholecystectomy.
 Why do clinicians perform interval cholecystectomy so often? Lankisch et 
al sent a questionnaire to 190 German gastroenterologists and found that 
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lack of operation room availability and budgetary restraints were the reason 
that only 23% of patients had undergone cholecystectomy during the initial 
hospital admission for mild biliary pancreatitis.12 These arguments have been 
challenged by a recent paper, concluding that cholecystectomy during index 
admission is both feasible and cost neutral.10
  For long, surgeons have legitimated the choice for interval cholecystectomy 
by the belief that cholecystectomy during index admission would be associated 
with difficult dissection due to edema caused by pancreatitis, which could 
lead to more surgical complications and ‘unnecessary’ conversions. In contrast 
to this belief, in 107 patients with mild biliary pancreatitis, Sinha et al found 
that difficult dissection of Calot’s triangle occurred more frequently in interval 
cholecystectomy as compared to index cholecystectomy (42% vs. 12%, 
P<0.001).53 
 Since the majority of patients apparently do not suffer from recurrent biliary 
events necessitating re-admission, one might ask “How detrimental are these 
recurrent biliary events? Why not only perform cholecystectomy in case of re-
admission?” Furthermore, although cholecystectomy is considered definitive 
treatment, still 1% to 8.7% of patients suffer from recurrent biliary pancreatitis 
after cholecystectomy.13 Nevertheless, 4-50% of cases of recurrent biliary 
pancreatitis are severe which might lead to mortality, although fortunately 
not reported in this review.15,55 Since recurrent biliary pancreatitis occurred in 
8% of patients in the interval cholecystectomy group, we feel this is a strong 
argument in favor of cholecystectomy during index admission.
 It is generally accepted that patients with mild biliary pancreatitis without 
signs of (potential) cholangitis do not benefit from endoscopic sphinterotomy.4 
In this review, however, ERC was performed in 39% of all patients, but no 
explicit data on the number of endoscopic sphincterotomies performed 
during ERC or the presence of cholangitis could be extracted from the included 
studies. Recurrent biliary complications occurred in 10% of patients with and 
in 24% of patients without ERC. This difference was mainly due to a difference 
in recurrent biliary pancreatitis (2% of patients with ERC vs. 16% of patients 
without ERC). So, although ERC prevents recurrent pancreatitis to a large 
extent, it does not prevent against acute cholecystitis and biliary colics (8% 
with ERC vs. 9% without ERC). These numbers support the finding of a recent 
non-systematic review; ERC decreases the incidence of common bile duct 
stones-related complications, but will not prevent gallbladder stones-related 
complications, like biliary colics and acute cholecystitis.56 Although in this 
review the percentage of patients with pre-operative ERC seems to be very 
high, it is important to realize that with lower incidence of the protective ERC 
the incidence of recurrent biliary events, especially biliary pancreatitis, could 
well have been even higher. 
 The results of the included studies are possibly flawed by selection bias, 
because the choice for index or interval cholecystectomy was to a large extent 
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based on clinical arguments. There may also have been publication bias, as a 
result of underreporting by doctor or patient of biliary colics in general or as 
a reason for readmission. Another limit of this systematic review is the fact 
that most included studies were of moderate to low methodological quality. 
Furthermore, no adequate follow-up after cholecystectomy was reported in 
most studies. Although follow-up is not necessarily needed in a comparative 
study of pre-operative readmissions for biliary events, it would give us a better 
insight of postoperative complications and recurrent biliary events after 
removal of the gallbladder. 
 Only one randomized trial, by Aboulian et al, was included in this review.46 
The primary endpoint of this trial was length of hospital stay. The study was 
stopped at interim analysis for a one day shorter hospital stay after early 
cholecystectomy with no difference in secondary endpoints (e.g. conversion 
rate, complication rate and mortality). We did not include the early group 
of this RCT, because we did not study cholecystectomy during pancreatitis 
but cholecystectomy after pancreatitis. There may be risks involved with 
performing cholecystectomy in the first 48-72 hours of pancreatitis, regardless 
of the clinical condition of the patient.57 Of all patients with predicted mild 
pancreatitis, some 15% of patients will progress to severe pancreatitis.58,59 
Performing a cholecystectomy in patients with severe pancreatitis may be 
unsafe.5 As in other studies41-43, no life-threatening complications or mortality 
were noted, but with only 25 patients in the early group these numbers might 
have been too small to detect these complications.46 Furthermore, the authors 
mainly included young Hispanic females, a population that may be of lower risk 
of complications than many populations with mild pancreatitis worldwide.60 
Although interval cholecystectomy is clearly associated with an undesirable 
high rate of readmissions, the included studies were of insufficient quality 
to exclude selection bias. Therefore, randomized controlled studies should 
confirm the efficacy and safety of cholecystectomy during index admission for 
mild biliary pancreatitis. 
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Summary and general 
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This thesis has focused on questions remaining after two pivotal multicenter 
randomized controlled trials, (RCT) conducted by the Dutch Pancreatitis Study 
Group (DPSG). Both trials had a major impact on clinical care for patients with 
severe forms of acute pancreatitis. The first trial, PROPATRIA (probiotics in 
pancreatitis trial, 2004-2007), has given rise to an intensive discussion on 
ethical, procedural and methodological aspects of randomized trials in the 
Netherlands.1 The outcome of the study was dramatic and fully unexpected, 
since mortality was higher in the patients prophylactically treated with 
probiotics compared to the placebo group, whereas probiotics did not reduce 
infectious complications. Even more, bowel ischemia was diagnosed in 6% of 
patient in the probiotic group vs. 0% in the placebo group. From that moment 
on, probiotics were not considered harmless anymore, especially not when 
administrated in critically ill patients. However, except for several speculations, 
the underlying mechanism for mortality and bowel ischemia remained unclear. 
The second multicenter RCT of the DPSG was the PANTER trial (pancreatitis, 
maximal necrosectomy versus minimally invasive step-up approach, 2005-
2008) and showed that the step-up approach (percutaneous catheter drainage 
(PCD), if needed, followed by minimally invasive necrosectomy) was superior 
to open surgical necrosectomy in terms of major and minor complications 
and cost efficiency.2 Furthermore, it showed that a third of patients with 
(suspected) infected necrosis could be successfully treated by PCD alone, 
without the need for additional surgical necrosectomy. 
 Crucial questions remained after finishing the PROPATRA and PANTER trials. 
The first part of this thesis focuses on the interaction between probiotics 
and enteral nutrition in order to unravel the mechanism responsible for the 
increased mortality and bowel ischemia in patients treated with probiotics in 
the PROPATRIA trial. The second part of this thesis focuses on how to accurately 
diagnose infection and how to design further interventional treatment 
strategies in acute pancreatitis, having found that after PANTER, “drainage 
first” is the new paradigm in treatment of infected necrosis in severe acute 
pancreatitis.  
Part I – Interaction between probiotics and enteral nutrition in 
acute pancreatitis
For long, probiotics were thought to be harmless food supplements. The 
PROPATRIA trial, however, showed that a specific mixture of six probiotic 
strains (Ecologic 641) could be harmful to critically ill patients with severe 
pancreatitis.1 A causal relation between administration of probiotics and 
non-occlusive bowel ischemia (NOMI) has not been established yet. It has 
been hypothesized, however, that non-occlusive bowel ischemia could have 
been induced by probiotics by generating potentially cytotoxic fermentation 
products. 
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In Chapter 2, we used a dynamic, computer-controlled model for simulating 
in vivo conditions of the stomach and small bowel (TIM-1 model). We were 
particularly interested in whether the composition of enteral nutrition could 
have any influence on the intraluminal metabolic activity of Ecologic 641. Each 
experiment with TIM-1 lasted six hours, reflecting the slow intestinal transit 
time clinically observed in very ill patients. Enteral nutrition was continuously 
administered directly into the duodenum. Probiotics and placebo both were 
also administered into the duodenum, but as in a single shot. Bile salts and 
pancreatic enzymes were added or left out, depending on the experimental 
design. We found that in the presence of pancreatic enzymes, significantly 
more acid was produced. In the presence of pancreatic enzymes, lactic acid 
production is increased, whereas in the addition of bile salts lactic acid 
production is decreased. Addition of fibre-enriched enteral nutrition resulted 
in a higher lactic acid production compared to protein-enriched enteral 
nutrition. In the presence of fibre-enriched enteral nutrition, short-chain 
fatty acid production was increased compared to protein-enriched enteral 
nutrition. It was concluded that the metabolic activity of the probiotic mixture 
is maximal in the presence of both pancreatic enzymes and fibre-enriched 
enteral nutrition in the duodenum. 
 In 2008, van Minnen et al. described the effects of pretreatment with 
Ecologic 641, a probiotic mixture of six different probiotic strains, on bacterial 
translocation and mortality in an experimental rat model.3 Pretreatment 
with probiotics led to a better survival and lower bacterial translocation 
than observed in rats treated with placebo. A major difference with the 
PROPATRIA trial was the timing of administration of probiotics. In patients, the 
pancreatitis was already ongoing, whereas in rats administration was given 
prophylactically in the true sense, so prior to onset of the pancreatitis. In this 
series of experiments described in Chapter 3,  the same experimental rat model 
for severe necrotizing pancreatitis as described by van Minnen et al. was used 
and the clinical situation was mimicked  as closely as possible.2,3 Animals were 
allocated to four experimental groups: 1) acute pancreatitis with administration 
of saline and placebo, 2) acute pancreatitis with administration of saline and 
probiotics, 3) acute pancreatitis with administration of fibre-enriched enteral 
nutrition and placebo, and 4) acute pancreatitis with administration of fibre-
enriched enteral nutrition and probiotics. Based on clinical, biochemical, 
histological and bacteriological findings, no causal relationship between 
NOMI and the combination of administrated fibre-enriched enteral nutrition 
and probiotics and no reduction of bacterial translocation to the pancreas in 
animals treated with probiotics could be found.
 Since 2008, after the outcome of the PROPATRIA trial, no new clinical 
studies have been published about probiotic prophylaxis in patients with 
acute pancreatitis. In 2010, we became aware of a hospital, the Faculty 
Thomayer´s Hospital, Prague, Czech Republic, where administration of 
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probiotics in combination with enteral nutrition was continued in patients 
with acute pancreatitis, without organ failure. In Chapter 4, we describe a 
retrospective analysis of all these patients and concluded that in this study, 
no negative impact of probiotic prophylaxis, bowel perfusion and/or mortality 
was observed in this group of patients with predicted severe pancreatitis 
without organ failure. Furthermore, no reduction of infectious complications 
was observed when compared to the literature.
 In summary, the unfavorable outcome of the PROPATRIA trial was 
investigated with focus on a potential negative interaction between probiotics 
and enteral nutrition in acute pancreatitis as the driving force behind the 
excess mortality. Neither in vitro, nor in vivo studies in rats could detect a 
negative interference between probiotics, intraluminal conditions and enteral 
feeding. As a consequence, no support could be lent to the hypothesis that 
the combination of the three above mentioned factors leads to excessive 
oxygen consumption, mucosal hypoxemia, mucosal damage and bacterial 
translocation. This series of experiments, therefore, provide no clue as to 
whether the experimental prophylactic administration of probiotics has 
started a cascade of events leading to local mucosal hypoxia and NOMI. The in 
vitro experiments and the studies in rats have not brought us any closer to an 
explanation for the higher death rate in the PROPATRIA trial for patients who 
received probiotics to lower the infection rate. The analysis of the data from 
Prague, although performed in patients who did not suffer from early organ 
failure, showed no positive or negative effect of probiotics on the number 
of infectious complications. Furthermore, no increased mortality and bowel 
ischemia were found. These findings are comparable to another study by 
Besselink et al, in which negative effects of probiotics were only observed in 
patients with (multiple) organ failure. In PROPATRIA, it is important to note 
that NOMI was a post-hoc outcome measure and has not been part of the 
study hypothesis. As a consequence we have not systematically looked for the 
presence or absence of NOMI in both groups. Since NOMI is not necessarily 
a lethal complication and can escape to detection when not systematically 
searched for, a clear association between probiotics, NOMI and death cannot 
be confirmed based on the combined findings of the PROPATRIA trial and the 
studies that have been described in this thesis.
 
Part II – Diagnosis of infection and interventional strategies in 
acute pancreatitis
In the Chapters 5, 6, 7 and 8 several aspects of (surgical) intervention were 
studied to investigate the role of PCD only in the treatment of infected 
necrosis. We performed these additional studies, since accurate diagnosis 
of infection remained a key issue in our trial and in intervention studies of 
others. The potential of percutaneous drainage turned out to be the most 
prominent finding of the PANTER trial, fistula formation was a frequently 
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observed complication and timing of cholecystectomy was an important topic, 
once pancreatitis had been survived.
 About 20% of patients with acute pancreatitis develop pancreatic or 
peripancreatic necrosis (i.e. necrotizing pancreatitis). In a third of these patients 
infection of the necrosis occurs, and in the vast majority of these patients an 
intervention (i.e., catheter drainage, endoscopic or surgical necrosectomy) 
is required.4 Even with an intervention, morbidity and mortality still ranges 
between 50-100% and 15-25%, respectively.6-9 In the last decades, many 
studies have focused on prevention of infection of the necrosis, however only 
a few studies addressed the topic of diagnosing infection of the necrosis. In 
general, infection of the necrosis is suspected based on positive tissue cultures 
(e.g., obtained by fine-needle aspiration, FNA), gas bubbles in fluid collections 
on contrast-enhanced computer tomography (CECT), and by clinical signs (e.g. 
fever, leucocytosis, organ failure). In Chapter 5, we have tried to study the role 
of each of these methods for diagnosing infection in a post-hoc analysis of a 
prospective cohort of 639 patients with necrotizing pancreatitis.5 We selected 
all 208 patients who underwent an intervention for infected necrotizing 
pancreatitis to study the meaning of strictly clinical parameters, imaging 
modalities and FNA for the confirmation of infection. In general, interventions 
were postponed as long as possible, preferably more than four weeks after 
onset of symptoms, allowing demarcation of the necrotic cavity and ultimately 
reducing the complication rate. Even in case of proven infection, interventions 
were postponed, whenever possible. It was concluded that in the majority 
of patients infected necrosis can be diagnosed based on clinical and imaging 
signs and that FNA may be reserved for patients with unclear clinical signs 
with absence of imaging signs of infection. 
 For decades, the only interventional strategy for patients with (suspected) 
infected necrosis was open surgical necrosectomy. However, this procedure is 
associated with a mortality of 30% and a morbidity of up to 95%. Furthermore, 
a high incidence of long term pancreatic insufficiency is reported in patients 
who undergo open necrosectomy.10-12 Since the late eighties, less invasive 
interventions have gained popularity in the treatment of infected necrotizing 
pancreatitis. The breakthrough occurred in the late nineties, when PCD as 
primary treatment of infected necrotizing pancreatitis was first described.13 
Since then, many studies reported on minimally invasive strategies for 
infected necrotizing pancreatitis. The hypothesis of PCD is to treat infected 
necrosis as an abscess and drain the infected fluid (i.e., pus) under pressure 
to enable the patient’s immune system to cope with the infected focus and to 
leave the necrotic material for the patient to deal with. Successful drainage 
of the infected fluid under pressure will ameliorate sepsis and improve the 
patient’s clinical condition. If necrosectomy is still needed after PCD, PCD 
may have postponed the need of surgical intervention, allowing for further 
encapsulation of the necrotic collections and improvement of the patient’s 
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clinical condition. In Chapter 6, we described the results of the first systematic 
review on the role of PCD in the treatment of (suspected) infected necrotizing 
pancreatitis and concluded that a considerable number (percentages ranging 
from 18 to 90%) of patients could be treated with PCD only, without the need 
for additional surgical necrosectomy. How to select patients for PCD and how 
predict which (group of) patients will react favorably to PCD as the first step, 
could not be concluded from the systematic review.
 A well-known complication after surgical necrosectomy or PCD in patients 
with (suspected) infected necrotizing pancreatitis is a pancreatico-cutaneous 
fistula. Incidences of persisting pancreatic fistulas range from 17% to 76% 
and are associated with metabolic and nutritional disturbances, prolonged 
hospitalization and even with mortality.14-17 Usually, these fistulas are treated 
conservatively, however, endoscopic transpapillary stent placement (ETS) is 
suggested to be a safe and feasible alternative.18-20 The rationale of ETS is to 
reduce intraductal pressure, facilitating drainage of pancreatic secretions to 
the duodenum instead of through the fistula. In Chapter 7, we compared the 
outcome of 35 patients with persisting pancreatic fistula after intervention for 
(suspected) infected necrotizing pancreatitis who were treated conservatively 
or with ETS. In 5 patients who were ultimately treated conservatively, ETS 
was not successful. In the majority of patients (84%) with persisting fistula, 
complete resolution of the fistula was achieved with ETS only. In the patients 
who were treated conservatively, 25% needed additional intervention for 
fistula closure. Median time to fistula closure was 71 days in the ETS group 
and 120 days in the conservative group. It was concluded that ETS may be a 
safe and feasible alternative to conservative treatment.
 Current guidelines advocate early cholecystectomy after an episode of 
mild biliary pancreatitis. However, there is no consensus on the definition of 
“early”: within two or four weeks after hospital discharge or even during index 
admission.4,21-23 The DPSG analyzed all patients with mild biliary pancreatitis 
from the PROPATRIA trial and found that 34/249 patients (14%) suffered 
from recurrent biliary events prior to cholecystectomy.24 In Chapter 8 
we describe a systematic review of the literature and focused primarily 
on the risk of recurrent biliary events in the period between discharge 
after mild biliary pancreatitis and interval cholecystectomy, and secondary 
on the safety of index versus interval cholecystectomy after mild 
biliary pancreatitis. Overall, 39% of patients underwent a pre-operative 
endoscopic retrograde cholangiography (ERC). Re-admission rate in the 
group of patients who underwent delayed cholecystectomy was 18%, of 
whom around 40% suffered from recurrent biliary pancreatitis. None of the 
patients who underwent cholecystectomy during index admission suffered 
from recurrent biliary complications prior to cholecystectomy. No differences 
in conversion rate and complications were found between groups. To 
reduce recurrent biliary complications after an episode of mild biliary 
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pancreatitis, it is suggested to minimize the period between cholecystectomy 
and hospital discharge from the index admission.
Conclusions and ways to proceed
Part I – Interaction between probiotics and enteral nutrition in 
acute pancreatitis
The first part of this thesis was dedicated to the question: how to explain the 
unexpected findings of the PROPATRIA trial? A question that was frequently 
brought up was: “have we challenged the small bowel in these very sick patients 
too much by administrating the combination of enteral feeding and probiotics 
in the lumen of the proximal small bowel and could this have induced high 
oxygen consumption leading to local hypoxia with non-occlusive small bowel 
ischemia?”. If this would have been the case, can the observation of bowel 
ischemia in 9 patients serve as an explanation for the excess mortality in the 
experimental group in the PROPATRIA trial?1 This concept was the focus of 
several studies in this thesis and has also been addressed in part in the work of 
Paul van Minnen, Harro Timmermans, Marc Besselink and Femke Lutgendorff. 
Besselink et al. showed that probiotics may increase mucosal damage in the 
subgroup of patients with predicted severe acute pancreatitis and organ 
failure, whereas no increased mucosal damage was found in patients without 
organ failure.25 Although this analyses was performed in a small subgroup 
of patients of the PROPATRIA trial (115 patients without and 26 with organ 
failure), these results point out that the presence of organ failure might be the 
key factor in the search for answers after the PROPATRIA trial. Unfortunately, 
the studies described in this thesis did not have given us real new clues to how 
the excess mortality has been brought about. Earlier experimental studies by 
our group, specifically those conducted by Femke Lutgendorff, have shown 
that probiotics, when administered prior to onset of acute pancreatitis, have a 
positive impact on small bowel mucosa, in line with the theoretical concept of 
how probiotics are supposed to improve small bowel function and transport.26,27 
In addition, the available clinical data do not provide us with a mechanism to 
hold the probiotics, the enteral feeding or the combination responsible for the 
unexpected findings in the PROPATRIA trial. A comment has to be made here 
that the results of neither in vitro studies, nor experimental studies in animals 
can be extrapolated to the situation in human, and as a consequence, our 
findings are all indirect data on pathophysiological mechanisms playing a role 
in patients with acute pancreatitis. 
 As shown in Chapter 2, In TIM-1 some potential harmful metabolites for 
the intestinal mucosa are produced in the presence of fibre-enriched enteral 
nutrition and pancreatic enzymes, however, the collected samples should be 
further used in Caco-2 cell culture experiments to focus on the cytotoxicity 
of these samples on bowel mucosa. Furthermore, each single probiotic strain 
of Ecologic 641 should be investigated in TIM-1 to find out what strain is 
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responsible for what metabolite. For better understanding of the findings in TIM-
1, future studies should also focus on whether the intraluminal concentration of 
pancreatic enzymes is increased or decreased in patients with (severe) acute 
pancreatitis, since only a few small studies showed conflicting results.28,29 
However, since no major differences in acid production were found between 
experiments with different intraluminal conditions in TIM-1, it is unlikely that 
in future in vitro experiments the mechanism responsible for the increased 
mortality and bowel ischemia as shown in the PROPATRIA trial will be found. 
When focusing on experimental studies in rats, none of the studies performed 
after the PROPATRIA trial have shown negative effects of probiotics and the 
results described in Chapter 3 did not show any negative effect of probiotics 
and enteral nutrition. Therefore, it is unlikely that future experimental animal 
studies will provide knowledge to understand the potential negative effects of 
probiotics. 
 As shown in Chapter 4, in patients in Prague with predicted severe pancreatitis 
without organ failure at the time the first dose of multispecies probiotic 
prophylaxis and enteral nutrition was administered, no negative effects of 
probiotics were found. However, as in PROPATRIA, no positive impact on the 
number of infectious complications was observed. Although this monocenter 
study suggests that this specific probiotic mixture was probably not harmful 
to patients with pancreatitis without organ failure, one should notice that a 
relatively small cohort of patients was described in a retrospective manner using 
a different multispecies probiotic product as used in PROPATRIA. Because of the 
shortcomings, a direct comparison with PROPATRIA is difficult to make. 
 So we are left with the following conclusions. In this thesis, no clear new 
insights have been gained to unravel the puzzling findings of the PROPATRIA 
trial. We have to accept that current knowledge and current techniques to study 
phenomena at the level of the small bowel are potentially suboptimal. It will be 
very difficult to design further studies to unravel the mechanism of NOMI and its 
local and systemic consequences. This leaves us with the dilemma: do we need 
to proceed and design further studies or do we accept the fact that we have not 
been able to find the answer to the questions remaining after the PROPATRIA 
trial?
 Scientifically, the next logical step would be to repeat the PROPATRIA trial 
investing in the same group of patients as participated in the PROPATRIA 
trial, in order to determine the reproducibility of the initial findings. Apart 
from strong ethical objections and reluctance to embark on such a study, a 
clinically meaningful study hypothesis would be lacking, since reduction of 
infectious complications in predicted severe acute pancreatitis was the primary 
outcome measure in the PROPATRIA study. In that respect, the outcome of 
the study was negative and therefore there is no scientific basis for repeating 
the study.  
 Is there still a (minute) possibility that there is no causal relation between the 
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excess mortality and the administration of probiotics in predicted severe acute 
pancreatitis? Probably not. We only found confirmation that (certain) probiotics 
are probably not harmful in the subgroup of patients with acute pancreatitis 
without organ failure, but we were unable to construct the mechanism by which 
probiotics, in extreme conditions of organ failure, can potentially induce NOMI. 
The fact that the mechanism was not found does obviously not necessarily mean 
that such a mechanism does not exist. The PROPATRIA trial was powered for 
infectious complications as the primary outcome measure and underpowered 
for mortality, but, again, this should not be a reason to dismiss the increased 
mortality in the study as coincidence. 
 Since it is not likely that new in vitro and in vivo experimental studies will bring 
us closer to an explanation of the still unexplained findings in the PROPATRIA 
trial, and that no new clinical randomized controlled trial will be performed 
in the near future, we can only accept that with the current knowledge and 
techniques no explanation could be found for the increased mortality and 
incidence of bowel ischemia in enterally fed patients with predicted severe 
pancreatitis and prophylactically treated with probiotics in the PROPATRIA trial. 
Part II – Diagnosis of infection and interventional strategies in 
acute pancreatitis
In the last decades, minimally invasive procedures have become the new 
standard practice of care. For long, open necrosectomy has been the gold 
standard for treatment of (suspected) infected necrosis, however, the PANTER 
trial showed that even in a complicated disease as severe acute pancreatitis, 
minimally invasive intervention strategies are superior to conventional 
strategies.2 Furthermore, the need for invasive diagnostic procedures to 
determine infection of necrosis could be disputed. With the policy of the 
PANTER trial to postpone surgical intervention for as long as possible, the second 
part of this thesis gives answers on: how to accurately diagnose infection in 
patient with suspected infected necrosis; if infection is suspected, what is the 
role of PCD compared to open surgical necrosectomy; and how to treat long 
lasting pancreatic fistulas after drainage procedures in acute pancreatitis? 
Furthermore, we focused on the optimal timing of cholecystectomy after mild 
biliary pancreatitis. These questions remained after finishing the PANTER and 
PROPATRIA trials. With a combined database of both studies, patients were 
selected to answer these questions, together with systematic reviews of the 
literature. The following conclusions can be drawn from this thesis:
1)  With the policy of postponing intervention in patients with (suspected) 
infected necrotizing pancreatitis, FNA is of limited value and should only 
be used in patients with unclear clinical signs without radiological signs 
of infection.
2)  In patients with infected necrotizing pancreatitis, a considerable number 
of patients can be treated with PCD only, without the need for surgical 
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necrosectomy. Therefore, PCD should be the first step as interventional 
treatment strategy.
3)  Persistent pancreatic fistulas after interventional treatment of (infected) 
necrotizing pancreatitis could be safely treated by ETS as alternative to 
conservative treatment.
4)  In patients with mild biliary pancreatitis, the period between hospital 
discharge from the index admission and the cholecystectomy should be 
minimized to lower recurrent biliary complications prior to cholecystectomy. 
As identified in Chapter 5 and 6, with the policy of postponing intervention for 
as long as possible, FNA is of limited value. However, there may be a subgroup 
of patients with early signs of infected necrotizing pancreatitis that may benefit 
from an early intervention, and in particularly PCD because of the minimally 
induced immunological response compared to surgical necrosectomy. In this 
subgroup of patients, PCD should only be performed when the pancreatic 
necrosis is infected. Without radiological signs and unclear clinical signs, FNA 
may play a more prominent role in the diagnostic work-up. In the near future, 
the POINTER trial (postponed or immediate drainage of infected necrotizing 
pancreatitis) will investigate what the optimal timing for intervention will be in 
patients with (suspected) infected necrotizing pancreatitis and what the role of 
FNA will be in early diagnosing infection. 
 As identified in Chapter 7, a well-known complication of surgical or radiological 
intervention in infected necrotizing pancreatitis is a persisting pancreatic 
fistula. It is shown that ETS is a safe and alternative treatment to conservative 
treatment. Future randomized studies should investigate whether ETS must be 
considered to be a useful alternative to conservative treatment or must be the 
gold standard for persisting pancreatic fistulas. Besides duration of closure of 
the fistula, quality of life and cost-efficacy should be investigated. 
 As identified in Chapter 8, cholecystectomy after an episode of mild 
biliary pancreatitis should be performed as soon as possible after recovery, 
since a prolonged period between the initial episode of biliary pancreatitis 
and cholecystectomy is associated with a higher recurrence of biliary 
complications. Studies included in the systematic review were of medium 
methodological quality, therefore the PONCHO trial was conducted to 
investigate whether early cholecystectomy should be preferred above 
delayed cholecystectomy. The results of the PONCHO trial (trial number 
ISRCTN72764151) are expected in 2014. The optimal timing of cholecystectomy 
in patients with severe biliary pancreatitis remains unclear, however, 
scarce evidence suggests that early cholecystectomy is associated with an 
increased number of infectious complications.30,31 After determination of the 
optimal timing of cholecystectomy in patients with mild biliary pancreatitis, 
future studies should focus on the optimal timing of cholecystectomy in patients 
with severe biliary pancreatitis. 
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Chapter 10
Nederlandse samenvatting
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In dit proefschrift ligt de focus op vraagstukken die zijn overgebleven na het 
uitvoeren van twee belangrijke, multicentrische, gerandomiseerde studies 
door de Pancreatitis Werkgroep Nederland. Beide studies hebben een grote 
invloed gehad op de behandeling van patiënten met een ernstige vorm van 
acute pancreatitis. De eerste studie, PROPATRIA (probiotica en pancreatitis 
trial, 2004-2007), heeft geleid tot een uitgebreide disussie over de ethische, 
procedurele en methodologische aspecten van gerandomiseerde studies 
in Nederland.1 De resultaten van PROPATRIA waren dramatisch en volledig 
onverwacht, aangezien het toedienen van probiotica niet resulteerde in een 
verlaging van het aantal infectieuze complicaties, maar wel in een verhoogde 
mortaliteit onder patiënten die profylactisch probiotica kregen toegediend. 
Daarnaast werd bij 6% van de patiënten die probiotica kreeg toegediend 
darmischemie gediagnosticeerd, tegenover 0% in de groep patiënten met 
placebo. Vanaf toen bleek dat probiotica ook schadelijk kunnen zijn, zeker 
wanneer deze worden toegediend aan ernstig zieke patiënten. Echter, ondanks 
de vele speculaties is het onderliggende mechanisme voor de verhoogde 
mortaliteit en darmischemie vooralsnog onbekend.
 De tweede multicentrische, gerandomiseerde studie van de Pancreatitis 
Werkgroep Nederland was de PANTER studie (pancreatitis, maximale 
necrosectomie tegenover minimaal invasieve step-up benadering, 2005-
2008).2 Deze studie liet zien dat de step-up benadering (percutane catheter 
drainage (PCD), eventueel gevolgd door een minimaal invasieve necrosectomie) 
superior was ten opzichte van de open chirurgische necrosectomie op 
het gebied van majeure en mineure complicaties en kosteneffectiviteit. 
Daarnaast werd duidelijk dat een derde van alle patiënten met verdenking 
op geïnfecteerde necrose succesvol behandeld kan worden met alleen PCD, 
zonder dat aanvullende chirurgische necrosectomie nodig is.
 Na afloop van beide studies bleven nog een aantal cruciale vragen 
onbeantwoord. Het eerste deel van dit proefschrift richt zich met name op 
de interactie tussen probiotica en enterale voeding. In dit deel wordt getracht 
het mechanisme te ontdekken dat verantwoordelijk is voor de verhoogde 
mortaliteit en incidentie van darmischemie bij patiënten die probiotica kregen 
toegediend tijdens de PROPATRIA studie. Het tweede deel van dit proefschrift 
richt zich op hoe de diagnose “geïnfecteerde necrose” gesteld kan worden 
en welke verdere interventiestrategieën er zijn in de behandeling van acute 
pancreatitis. Dit alles met in het achterhoofd dat na de PANTER studie 
PCD de eerste keus van interventie is in de behandeling van geïnfecteerde 
pancreasnecrose.  
Deel I – Interactie tussen probiotica en enterale voeding tijdens 
acute pancreatitis
Van oudsher worden probiotica gezien als ongevaarlijke voedingssuplementen. 
Echter, de PROPATRIA studie liet zien dat een speciale mix van zes probio-
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ticsstammen (Ecologic 641) wel degelijk schadelijk kan zijn wanneer dit wordt 
toegediend aan ernstig zieke patiënten met acute pancreatitis.1 Het bestaan 
van een causaal verband tussen de toediening van probiotica en het ontstaan 
van niet-obstructieve darmischemie is vooralsnog niet bewezen. Wel bestaan 
er verschillende theorieën, zoals dat de darmischemie veroorzaakt zou zijn 
door het vrijkomen van fermentatieproducten die mogelijk cytotoxisch zijn. 
 In Hoofdstuk 2 wordt een dynamisch, computer-gestuurd model 
beschreven voor het simuleren van de verschillende condities van de maag en 
de dunne darm (TIM-1 model). Wij stelden ons de vraag of de samenstelling 
van de gebruikte sondevoeding invloed heeft gehad op de intraluminale 
activiteit van de probioticastammen in Ecologic 641. Elk experiment met 
TIM-1 duurde 6 uur, aangezien deze duur het meest overeenkomt met de 
langzame passagetijd van het maagdarmstelsel bij ernstig zieke patiënten. 
De sondevoeding werd met een constante snelheid geïnjecteerd in het 
duodenum. De probiotica en het placebo werden in een eenmalige dosis 
ook geïnjecteerd in het duodenum. Afhankelijk van het experiment werden 
galzouten en pancreasenzymen toegevoegd of weggelaten. We vonden dat de 
aanwezigheid van pancreasenzymen resulteerde in een hogere interluminale 
productie van zuur. Door aanwezigheid van pancreasenzymen werd de 
lactaatproductie vergroot, maar de toevoeging van galzouten zorgde voor 
een daling hiervan. Het gebruik van vezelrijke voeding zorgde ook voor een 
hogere lactaatproductie vergeleken met eiwitrijke voeding. Er werden meer 
korte-keten vetzuren geproduceerd wanneer vezelrijke voeding werd gebruikt 
ten opzichte van eiwitrijke voeding. Er werd geconcludeerd dat de metabole 
activiteit van de probiotica maximaal is wanneer zowel pancreasenzymen als 
vezelrijke voeding aanwezig zijn in het duodenum. 
 In 2008 schreven van Minnen en collega’s over de effecten van 
voorbehandeling met Ecologic 641 op bacteriële translocatie en mortaliteit 
in een ratmodel voor acute pancreatitis.3 Voorbehandeling met probiotica 
resulteerde in een vermindere mortaliteit en minder bacteriële translocatie ten 
opzichte van ratten die placebo kregen toegediend. Echter, een groot verschil 
met de PROPATRIA studie was de timing van toediening van de probiotica. Bij 
patiënten was de pancreatitis al aan de gang, terwijl bij ratten de probiotica 
een aantal dagen voorafgaand aan de pancreatitis werden toegediend. In 
Hoofdstuk 3 wordt hetzelfde experimentele ratmodel beschreven zoals van 
Minnen en collega’s gebruikt hebben, waarbij getracht is de klinische situatie 
zo goed mogelijk na te bootsen.1,3 De dieren werden in vier experimentele 
groepen ingedeeld: 1) acute pancreatitis met toediening van fysiologisch zout 
en placebo, 2) acute pancreatitis met toediening van fysiologisch zout en 
probiotica, 3) acute pancreatitis met toediening van vezelrijke sondevoeding 
en placebo, 4) acute pancreatitis met toediening van vezelrijke sondevoeding 
en probiotica. Er werd gescoord op klinische, biochemische, histologische 
en bacteriologische parameters, waarbij geen causaal verband kon worden 
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aangetoond tussen niet-obstructieve darmischemie en de toegediende 
combinatie van vezelrijke sondevoeding met probiotica. Daarnaast werd geen 
vermindering van bacteriële translocatie gezien bij de dieren die werden 
voorbehandeld met probiotica.
 Nadat de resultaten van de PROPATRIA studie in 2008 bekend werden 
gemaakt, is er sindsdien geen klinische studie meer gepubliceerd over het 
gebruik van probiotica bij patiënten met acute pancreatitis. In 2010 ontdekten 
wij dat er in een ziekenhuis in Praag (Faculty Thomayer’s Hospital, Tsjechië) 
nog steeds patiënten met acute pancreatitis zonder orgaanfalen probiotica 
en enterale voeding kregen toegediend. In Hoofdstuk 4 beschrijven we een 
retrospectieve analyse van al deze patiënten en kwamen tot de conclusie dat 
in deze studie geen negatieve effecten van probiotica werden gezien op de 
darmperfusie en mortaliteit bij patiënten met voorspeld ernstige pancreatitis 
zonder orgaanfalen. Daarnaast werd wederom geen daling gezien van het 
aantal infectieuze complicaties ten opzichte van de bestaande literatuur.
 Samenvattend kan gesteld worden dat in dit eerste deel van het proefschrift 
de focus ligt op het vinden van het mechanisme dat mogelijk heeft gezorgd 
voor de verhoogde mortaliteit bij patiënten met acute pancreatitis die 
behandeld zijn met probiotica en enterale voeding. Zowel in vitro als in vivo 
studies hebben geen negatieve interactie tussen probiotica, intraluminale 
condities en enterale voeding kunnen aantonen. Daarom kan de theorie dat 
de combinatie van de drie hierboven genoemde factoren heeft geleid tot 
een toegenomen zuurstofverbruik, mucosale hypoxie, mucosale schade en 
bacteriële translocatie niet worden ondersteund. 
 Deze serie experimenten geven geen nieuwe inzichten voor de theorie 
dat de toediening van probiotica heeft geleid tot een cascade van events, 
resulterend in locale mucosale ischemie en niet-occlusieve darmischemie.  De 
in vitro experimenten en de studie met ratten heeft ons niet dichterbij een 
verklaring gebracht voor de verhoogde mortaliteit in de PROPATRIA studie 
bij patiënten die probiotica kregen toegediend om het aantal infectieuze 
complicaties te verminderen. De analyse van de data uit Praag liet geen 
positief of negatief effect zien op het percentage infectieuze complicaties 
bij patiënten met acute pancreatitis zonder orgaanfalen. Daarnaast werd 
geen verhoging van mortaliteit of percentage darmischemie gezien. Deze 
bevindingen komen overeen met een andere studie van Besselink en 
collega’s, waarin de negatieve effecten van probiotica alleen werden gezien 
bij patiënten met (multi-)orgaanfalen. Hierbij moet worden opgemerkt dat in 
PROPATRIA niet-occlusieve darmischemie een post-hoc eindpunt was en niet 
een onderdeel van de studiehypothese. Om deze reden is tijdens de studie 
niet systematisch gekeken naar de aan- of afwezigheid van non-occlusieve 
darmischemie. Hierbij is het ook belangrijk te vermelden dat non-occlusieve 
darmischemie geen letale complicaties is en daarom onopgemerkt kan blijven 
wanneer er niet systematisch naar gezocht wordt. Gebaseerd op bovenstaande 
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feiten, de resultaten van de PROPATRIA studie en de studies beschreven in 
dit proefschrift kan er daarom niet bevestigd worden dat er een associatie is 
tussen de toediening van probiotica, non-occlusieve darmischemie en sterfte.
Deel II – Diagnose van infectie en interventie strategieën bij 
acute pancreatitis
In de Hoofdstukken 5, 6, 7 en 8 worden een aantal aspecten van (chirurgische) 
interventies bestudeerd bij patiënten met acute pancreatitis. Deze studies zijn 
verricht omdat een accurate diagnose van geïnfecteerde necrose een zeer 
belangrijke factor is in de PANTER studie en in verschillende interventiestudies, 
zoals beschreven in de literatuur. Daarnaast wilden we de precieze waarde van 
PCD bepalen bij de behandeling van geïnfecteerde necrose. De PANTER studie 
liet al de potentie van PCD zien, maar een veel voorkomende complicatie na 
interventie is het ontstaan van een pancreasfistel. Als laatste is de timing 
van cholecystectomie na biliaire pancreatitis een belangrijk onderwerp bij 
patiënten die een episode van acute pancreatitis overleefd hebben. 
 Ongeveer 20% van de patiënten met acute pancreatitis ontwikkelt 
(peri-) pancreatische necrose (necrotiserende pancreatitis). In een derde 
van deze patiënten treedt infectie van de necrose op, waarna het overgrote 
deel van deze patiënten een interventie moet ondergaan (bijv. PCD en/of 
endoscopische of chirurgische necrosectomie).4 Zelfs als deze groep patiënten 
een interventie ondergaat, wordt er een morbiditeit van 50-100% gevonden en 
een mortaliteit van 15-25%.5-9 In de laatste jaren is er veel onderzoek verricht 
naar de preventie van infectie van de necrose. Echter, er is weinig onderzoek 
bekend over de diagnostiek bij verdenking op geïnfecteerde necrose. Over 
het algemeen wordt aan geïnfecteerde necrose gedacht wanneer een 
weefselkweek (bijv. verkregen door fijne-naald aspiratie (FNA)) positief is, 
bij de aanwezigheid van gasbellen in vochtcollecties op een CT-scan met 
contrast, en bij verschillende klinische kenmerken (bijv. koorts, leucocytose 
of orgaanfalen). In Hoofdstuk 5 hebben we getracht om middels een post-
hoc analyse van een prospectief cohort van 639 patiënten met necrotiserende 
pancreatitis de waarde van elk van bovenstaande methodes te onderzoeken 
bij het diagnosticeren van geïnfecteerde necrose.5 In totaal werden 208 
patiënten geanalyseerd welke allen een interventie hebben ondergaan voor 
verdenking op geïnfecteerde necrotiserende pancreatitis, om zo de waarde 
van puur alleen de klinische parameters te bestuderen in de bevestiging van 
de diagnose “infectie”, evenals de waarde van beeldvorming en FNA. Over het 
algemeen werden de interventies voor verdenking op geïnfecteerde necrose 
zo lang mogelijk uitgesteld, waarbij de voorkeur uitging naar meer dan vier 
weken na ontstaan van de symptomen van acute pancreatitis, om zo de 
necrotische holte beter te laten demarceren, met het uiteindelijke doel om 
het aantal complicaties te verlagen. Zelfs al was er een zeer sterke verdenking 
op infectie, of zelfs bewezen geïnfecteerde pancreasnecrose, dan nog werd 
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geprobeerd de interventie zo lang mogelijk uit te stellen. Deze studie laat zien 
dat in het merendeel van de patiënten infectie van de (peri-)pancreatische 
necrose gediagnosticeerd kan worden op basis van de klinische beoordeling 
van de patient, in combinatie met goede beeldvorming. FNA hoeft alleen 
gebruikt te worden bij patiënten zonder duidelijke klinische en radiologische 
kenmerken van infectie.
 Jarenlang was open chirurgische necrosectomie de enige toegepaste 
interventie bij patiënten met verdenking op geïnfecteerde necrose. Echter, 
deze procedure is geassocieerd met een mortaliteit die kan oplopen tot 35% 
en een morbiditeit tot 95%. Daarnaast werd er op de lange termijn na open 
necrosectomie een hoge incidentie van pancreasinsufficiëntie gevonden.10-12 
Sinds eind jaren tachtig wonnen minder invastieve interventies steeds meer 
populariteit bij de behandeling van geïnfecteerde necrotiserende pancreatitis. 
De doorbraak kwam pas eind jaren negentig, toen PCD als primaire 
behandeling voor patiënten met geïnfecteerde necrotiserende pancreatitis 
werd beschreven.13 Vanaf dat moment zijn er veel studies beschreven 
over minimaal invastieve behandelingen bij patiënten met verdenking op 
geïnfecteerde necrose. De gedachte geïnfecteerde PCD is om de geïnfecteerde 
necrose te behandelen als een abces en om het geinfecteerde vocht (pus) 
te draineren. Op deze manier wordt het immuunsysteem van de patiënt 
geholpen met het infectieuze focus, waarna het overgebleven necrotische 
materiaal door het lichaam zelf opgeruimd kan worden. Een succesvolle 
drainage van het geïnfecteerde vocht zal de sepsis verminderen en daarmee 
de klinische conditie van de patiënt verbeteren. Wanneer daarna onverhoopt 
necrosectomie alsnog nodig blijkt te zijn, dan heeft PCD de chirurgische 
interventie in ieder geval deels uitgesteld, waardoor er een betere afkapseling 
van de necrotische collectie heeft kunnen plaatsvinden. In Hoofdstuk 6 
worden de resultaten van de eerste systematische review naar de rol van PCD 
bij behandeling van (verdenking op) geïnfecteerde necrotiserende pancreatitis 
beschreven. Er werd geconcludeerd dat een aanzienlijk aantal patiënten 
(percentages varierend tussen 18-90%) behandeld kan worden met alleen 
PCD, zonder dat er een aanvullende chirurgische necrosectomie nodig is. Uit 
deze systematische review is helaas niet gebleken welke patiënten vooraf 
geselecteerd moeten worden voor PCD en welke groep patiënten na PCD 
alsnog necrosectomie moet ondergaan. 
 Een beruchte complicatie na chirurgische necrosectomie en/of PCD bij 
patiënten met (verdenking op) geïnfecteerde necrotiserende pancreatitis is 
een pancreatico-cutane fistel. De incidentie van deze complicatie varieert 
tussen de 17-67% en is geassocieerd met een verstoring in het metabolisme 
en de voedingsstatus, een toegenomen lengte van de ziekenhuisopname, en 
zelfs met sterfte.14-17 Normaal gesproken worden deze fistels conservatief 
behandeld, echter, van endoscopische transpapillaire stentplaatsing (ETS) 
wordt gedacht dat het een veilig en goed uitvoerbaar alternatief is voor 
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conservatieve behandeling.18-20 De gedachte achter ETS is dat het de intraductale 
druk vermindert, waardoor het de drainage van pancreassecreties richting 
het duodenum fasciliteert in plaats van drainage door de fistel. In Hoofdstuk 
7 worden de resulaten beschreven van 35 patiënten die conservatief en/of 
met ETS zijn behandeld voor een persisterende pancreasfistel, ontstaan na 
interventie voor (verdenking op) geïnfecteerde necrose. In de meerderheid 
van de patiënten met een persisterende pancreasfistel (84%) trad complete 
verdwijning van de fistel op met alleen ETS. Vijf patiënten, bij wie ETS 
niet succesvol was, werden uiteindelijk conservatief behandeld. Van de 
patiënten die conservatief werden behandeld, onderging uiteindelijk 25% een 
aanvullende interventie om de fistel op te heffen. De mediane duur tot het 
droogvallen van de fistel was 71 dagen in de groep patiënten die ETS onderging 
en 120 dagen in de groep patiënten die conservatief werd behandeld. Er werd 
geconcludeerd dat ETS een veilig en goed uitvoerbaar alternatief is voor 
conservatieve therapie.
 Huidige richtlijnen adviseren vroege cholecystectomie na een episode van 
milde biliaire pancreatitis. Echter, in de literatuur bestaat geen consensus over 
de definitie van “vroeg”: binnen 2 tot 4 weken na ziekenhuisontslag óf tijdens 
dezelfde opname (indexopname).4,21-23 De Pancreatitis Werkgroep Nederland 
analyseerde alle patiënten met milde biliaire pancreatitis uit de PROPATRIA 
studie en vond dat 34/249 patiënten (14%) recidiverende klachten van 
biliaire aard ondervonden voordat een cholecystectomie was uitgevoerd.24 In 
Hoofdstuk 8 beschrijven we een systematische review van de literatuur, waarbij 
we onderzochten wat het risico is op recidiverende klachten van biliaire aard 
in de wachttijd tussen ziekenhuisontslag na een episode van milde biliaire 
pancreatitis en een uitgestelde cholecystectomie. Tevens onderzochten we of 
vroege cholecystectomie even veilig is als een uitgestelde cholecystectomie. 
In totaal onderging 39% van de patiënten een pre-operatief endoscopisch 
retrograad cholanchiogram. Het percentage heropname in de groep patiënten 
die een uitgestelde cholecystectomie onderging was 18%, waarbij 40% 
van deze patiënten een recidief biliaire pancreatitis kreeg. Geen van de 
patiënten die tijdens de indexopname een cholecystectomie onderging had 
recidiverende klachten van biliaire aard voorafgaand aan de cholecystectomie. 
Er werd geen verschil gezien in het aantal conversies en complicaties tussen 
de groepen. Er werd geconcludeerd dat een verkorting van de wachttijd tot 
cholecystectomie bij patiënten met een milde biliaire pancreatitis zal leiden 
tot minder heropnames voor klachten van biliaire aard. 
Conclusies en toekomst perspectief
Deel I – Interactie tussen probiotica en enterale voeding tijdens 
acute pancreatitis
Het eerste deel van dit proefschrift is toegespitst op de vraag: is er een 
verklaring voor de onverwachte resultaten van de PROPATRIA studie? Een 
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veelgestelde vraag is: “hebben we teveel gevraagd van de dunne darm in 
deze ernstig zieke patiënten door het toedienen van probiotica en enterale 
voeding in het lumen van het proximale deel van de dunne darm? Heeft dit 
geleid tot een verhoogd zuurstofverbruik met daardoor locale hypoxie en 
uiteindelijk niet-occlusieve darmischemie?” Als dit daadwerkelijk zo zou zijn, 
kan de darmischemie, zoals gezien bij negen patiënten in de probiotica-arm 
van de studie, dan fungeren als oorzaak en uitleg voor de verhoogde sterfte 
in deze experimentele groep van de PROPATRIA studie?1 Dit concept is de 
focus geweest van verschillende studies in dit proefschrift, maar ook al deels 
onderzocht door Paul van Minnen, Harro Timmermans, Marc Besselink en 
Femke Lutgendorff. Besselink en collega’s hebben laten zien dat probiotica 
meer mucosale schade kunnen veroorzaken in een subgroep patiënten met 
voorspeld ernstige pancreatitis en orgaanfalen, terwijl er geen mucosale 
schade werd gevonden bij patiënten zonder orgaanfalen.25 Alhoewel deze 
analyse was verricht in een kleine subgroep patiënten uit de PROPATRIA 
studie (115 patiënten zonder orgaanfalen en 26 patiënten met orgaanfalen), 
wijzen de resultaten uit dat de aanwezigheid van orgaanfalen misschien wel 
de belangrijkste factor is in de zoektocht naar antwoorden na de PROPATRIA 
studie. Helaas hebben de studies in dit proefschrift ons geen nieuwe duidelijke 
aanwijzingen gegeven wat de verhoogde mortaliteit in de PROPATRIA 
studie heeft veroorzaakt. Eerder uitgevoerde experimentele studies door 
de Pancreatitis Werkgroep Nederland, met name de studies van Femke 
Lutgendorff, hebben laten zien dat probiotica, welke voorafgaand aan een 
episode van acute pancreatitis werden toegediend, een positief effect hadden 
op de mucosa van de dunne darm. Dit komt ook overeen met het theoretische 
concept waarbij probiotica geacht worden de functie en het transport van de 
dunne darm positief te beïnvloeden.26,27 Tevens geven de beschikbare klinische 
data ons ook geen nieuwe aanwijzingen voor een mechanisme waarbij de 
probiotica, de enterale voeding, of de combinatie hiervan verantwoordelijk 
is voor de onverwachte resultaten van de PROPATRIA studie. Hierbij moet wel 
vermeld worden dat noch de resultaten van de in vitro studies, noch van de 
experimentele dierenstudies geëxtrapoleerd kunnen worden naar de humane 
situatie, en daarom al onze bevindingen alleen maar indirecte data zijn over de 
pathofysiologisce mechanismen die tijdens een episode van acute pancreatitis 
een rol spelen.
 Zoals te lezen is in Hoofdstuk 2, worden er in TIM-1 potentieel schadelijke 
metabolieten voor de darmmucosa geproduceerd in de aanwezigheid van 
vezelrijke voeding en pancreasenzymen. Echter, de verzamelde monsters uit 
TIM-1 moeten verder onderzocht worden in Caco-2 celkweek experimenten 
om te onderzoeken wat daadwerkelijk de cytotoxiciteit is van deze samples 
op de darmmucosa. Als aanvulling zou elke probioticastam van Ecologic 641 
onderzocht moeten worden in TIM-1 om te weten te komen welk metaboliet 
door welke stam wordt geproduceerd. Om de resultaten van TIM-1 beter 
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te begrijpen, is het noodzakelijk om duidelijk te krijgen of de intraluminale 
concentratie van pancreasenzymen tijdens een episode van (ernstige) 
pancreatitis verhoogd of verlaagd is, aangezien de beschikbare studies 
tegengestelde resultaten laten zien.28,29 Echter, omdat in TIM-1 er geen grote 
verschillen in zuurproductie werden gevonden tussen de experimenten met 
varierende intraluminale condities, is het niet te verwachten dat aanvullende 
in vitro experimenten het mechanisme zullen verklaren dat verantwoordelijk 
is voor de verhoogde mortaliteit en darmischemie in de PROPATRIA studie.
 Wanneer we kijken naar experimentele studies met ratten, heeft na de 
PROPATRIA studie tot op heden geen enkele studie een negatief effect van 
probiotica laten zien. Daarnaast laat de studie beschreven in Hoofdstuk 3 ook 
geen negatieve effecten van probiotica en enterale voeding zien. Daarom geldt 
ook voor toekomstige dierexperimentele studies dat het niet te verwachten is 
dat deze inzicht zullen geven in de mogelijk negatieve effecten van probiotica.
 Bij de groep patiënten in Praag met voorspeld ernstige pancreatitis zonder 
orgaanfalen op het moment dat de eerste dosis probiotica en enterale voeding 
werd toegediend, werden geen negatieve effecten van probiotica gevonden. 
Daarnaast werd, net als in de PROPATRIA studie, geen positief effect gevonden 
op het aantal infectieuze complicaties. Alhoewel deze monocenter studie 
suggereert dat een specifieke probioticamix niet schadelijk is voor patiënten 
met voorspeld ernstige pancreatitis zonder orgaanfalen, moet wel opgemerkt 
worden dat een relatief klein cohort patiënten wordt beschreven en het 
een retrospectieve analyse betreft. Tevens werd een andere probioticamix 
gebruikt dan bij de PROPATRIA studie. Vanwege deze tekortkomingen is een 
directe vergelijking met de PROPATRIA studie zeer lastig.
 De volgende conclusies kunnen worden getrokken. Dit proefschrift heeft 
geen duidelijke nieuwe inzichten opgeleverd waarmee de resultaten van de 
PROPATRIA studie verklaard kunnen worden. We moeten accepteren dat 
de huidige kennis en technieken mogelijk suboptimaal zijn om specifieke 
mechanismen op het level van de dunne darm te onderzoeken. Daarom 
zal het erg moeilijk zijn om nieuwe studies te ontwikkelen waarmee het 
mechanisme van niet-occlusieve darmischemie en de daarbijbehorende locale 
en systemische effecten adequaat onderzocht kan worden. Hierdoor staan 
we voor het volgende dilemma: moeten we doorgaan met het ontwikkelen 
en uitvoeren van studies naar niet-occlusieve darmischemie of moeten we 
accepteren dat we momenteel niet in staat zijn om een antwoord te vinden op 
de vragen die ontstaan zijn na de PROPATRIA studie?
 Wetenschappelijk gezien zou het herhalen van de PROPATRIA studie een 
logische vervolgstap zijn, waarbij dezelfde groep patiënten als tijdens de 
PROPATRIA studie geïncludeerd zou moeten worden. Alleen op deze manier 
kan bepaald worden of de gevonden resultaten reproduceerbaar zijn. Naast 
zeer sterke ethische bezwaren en terughoudendheid om weer zo een studie 
uit te voeren, ontbreekt er ook een zinnige studiehypothese. Bij de PROPATRIA 
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studie was vermindering van het aantal infectieuze complicaties bij patiënten 
met voorspeld ernstige pancreatitis de primaire uitkomstmaat. Echter, er werd 
geen effect gezien op het precentage infectieuze complicaties, waardoor er 
geen wetenschappelijke basis is om de studie te herhalen.
 Bestaat er nog de mogelijkheid dat er geen relatie bestaat tussen de 
verhoogde mortaliteit en de toevoeging van probiotica bij patiënten met 
voorspeld ernstige pancreatitis? Waarschijnlijk niet. We hebben alleen een 
bevestiging gevonden dat (bepaalde) probioticastammen waarschijnlijk niet 
schadelijk zijn in een subgroep patiënten met acute pancreatitis zonder 
orgaanfalen, maar we zijn helaas niet in staat om het mechanisme na te 
bootsen waarin probiotica in extreme condities, zoals bij patiënten met 
orgaanfalen, mogelijk niet-occlusieve darmischemie kunnen veroorzaken. Het 
feit dat dit mechanisme niet gevonden is, betekent niet dat dit mechanisme 
ook niet bestaat. Het aantal te includeren patiënten in de PROPATRIA studie 
was berekend om een verschil in infectieuze complicaties te vinden en niet 
een verschil in mortaliteit. Echter, dit mag niet de reden zijn om de verhoogde 
mortaliteit in de PROPATRIA studie te beschouwen als een toevalsbevinding.
 Omdat het niet te verwachten is dat nieuwe in vitro en in vivo studies ons 
dichterbij een uitleg zullen brengen voor de onverwachte resultaten van de 
PROPATRIA studie, en omdat er geen nieuwe gerandomiseerde studie in de 
nabije toekomst uitgevoerd zal worden, moeten we accepteren dat met de 
huidige kennis en technieken we geen verklaring kunnen vinden voor de 
verhoogde mortaliteit en incidentie van darmischemie bij enteraal gevoede 
patiënten met voorspeld ernstige pancreatitis die profylactisch behandeld zijn 
met probiotica in de PROPATRIA studie. 
Deel II – Diagnose van infectie en interventie strategieën bij 
acute pancreatitis
In de laatste jaren zijn minimaal invasieve procedures de nieuwe standaard 
geworden in de gezondheidszorg. Lang gold open necrosectomie als de gouden 
standaard voor de behandeling van (verdenking op) geïnfecteerde necrose. 
Echter, de PANTER studie heeft laten zien dat, zelfs bij gecompliceerde ziektes 
zoals ernstige acute pancreatitis, minimaal invasieve interventiestrategieën 
superior zijn ten opzichte van conventionele strategieën.2 Daarnaast wordt 
ook de behoefte aan invasieve diagnostische middelen bij het diagnosticeren 
van geïnfecteerde necrose betwist. Met in het achterhoofd de policy van de 
PANTER studie om chirurgische interventie zo lang mogelijk uit te stellen, 
beantwoordt het tweede deel van dit proefschrift de volgende vragen: hoe 
kan accuraat de diagnose geïnfecteerde necrose gesteld worden, wat is de 
rol van PCD vergeleken met open chirurgische necrosectomie bij verdenking 
op geïnfecteerde necrose, en hoe moeten persisterende pancreasfistels 
behandeld worden bij patiënten die een interventie hebben ondergaan na 
acute pancreatitis? Daarnaast hebben we gekeken naar de optimale timing van 
CHAPTER 10: NEDERLANDSE SAMENVATTING
 
169
cholecystectomie na een episode van milde biliaire pancreatitis. Deze vragen 
persisteerden na de PANTER en PROPATRIA studies. Met een gecombineerde 
database van beide studies werden patiënten geselecteerd om deze vragen 
te beantwoorden, samen met systematische reviews van de literatuur. De 
volgende conclusies kunnen getrokken worden uit het tweede deel van dit 
proefschrift:
1)  Met de policy van het uitstellen van interventie bij patiënten met (verdenking 
op) geïnfecteerde necrotiserende pancreatitis is de toegevoegde waarde 
van FNA laag. FNA moet alleen gebruikt worden bij patiënten bij wie er op 
basis van klinische en radiologische tekenen nog onduidelijkheid bestaat 
over de aanwezigheid van geïnfecteerde necrose. 
2)  Bij patiënten met geïnfecteerde necrotiserende pancreatitis kan een 
aanzienlijk deel behandeld worden met alleen PCD, zonder dat er 
aanvullende chirurgische necrosectomie nodig is. Daarom moet PCD de 
eerste keus van interventie zijn bij verdenking op geïnfecteerde necrose. 
3)  Persisterende pancreasfistels, ontstaan na een interventie ten behoeve 
van (geïnfecteerde) necrotiserende pancreatitis, kunnen veilig behandeld 
worden met ETS als alternatief voor conservatieve behandeling. 
4)  Bij patiënten met een milde biliaire pancreatitis moet de tijd tussen 
ziekenhuisontslag na indexopname en cholecystectomie zo kort mogelijk 
gehouden worden om het aantal recidiverende klachten van biliaire aard te 
minimaliseren. 
Zoals beschreven in Hoofdstuk 5 en 6, is met het zo lang mogelijk uitstellen 
van een interventie FNA een onderzoek geworden met gelimiteerde waarde. 
Echter, het is mogelijk dat een subgroep patiënten met vroege tekenen van 
geïnfecteerde necrotiserende pancreatitis wel degelijk baat heeft bij een 
vroege interventie. Hierbij moet dan gedacht worden aan PCD, aangezien 
dit een veel minder heftige immuunrespons veroorzaakt vergeleken met 
chirurgische necrosectomie. In deze subgroep patiënten zou PCD alleen 
geïnitieerd zijn wanneer er duidelijk bewijs is van geïnfecteerde necrose. 
Bij onduidelijke radiologische en klinische kenmerken van geïnfecteerde 
necrose kan FNA alsnog een belangrijke rol innemen in de diagnostiek 
naar geïnfecteerde necrose. In de nabije toekomst zal de POINTER studie 
(uitgestelde of vroege drainage bij patiënten met geïnfecteerde necrotiserende 
pancreatitis) uitwijzen wat de optimale timing is voor interventie bij patiënten 
met (verdenking op) geïnfecteerde necrotiserende pancreatitis en wat de rol 
is van FNA bij het vroeg diagnosticeren van infectie.
 Een persisterende pancreasfistel is een beruchte complicatie van 
chirurgische of radiologische interventie bij patiënten met geïnfecteerde 
necrotiserende pancreatitis. In Hoofdstuk 7 is beschreven dat ETS een 
veilige en goed uitvoerbare behandeling is als alternatief voor conservatieve 
behandeling. Toekomstige gerandomiseerde studies moeten uitwijzen of 
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ETS de gouden standaard moet worden voor peristerende pancreasfistels of 
alleen beschouwd mag worden als een veilig alternatief voor conservatieve 
behandeling. Naast de duur voor het droogvallen van de pancreasfistel moet 
ook onderzocht worden wat de kwaliteit van leven is voor patiënten en moet 
gekeken worden naar de kosten-effectiviteit.  
 In Hoofdstuk 8 staat beschreven dat cholecystectomie na een episode 
van milde biliaire pancreatitis zo snel mogelijk na herstel van de pancreatitis 
uitgevoerd moet worden, aangezien een uitgestelde cholecystectomie 
na milde biliaire pancreatitis is geassocieerd met een hoger recidief van 
biliaire complicaties. Omdat de studies die in de systematische review zijn 
geïncludeerd van matige methodologische kwaliteit zijn, is de PONCHO studie 
opgestart om te onderzoeken of vroege cholecystectomie geprefereerd 
moet worden boven uitgestelde cholecystectomie. De resultaten van de 
PONCHO studie (studienummer ISRCTN72764151) worden in de loop van 
2014 verwacht. De optimale timing van cholecystectomie na een episode van 
ernstige biliaire pancreatitis blijft vooralsnog onduidelijk, echter het schaarse 
bewijs dat beschikbaar is suggereert dat een vroege cholecystectomie na 
ernstige biliaire pancreatitis is geassocieerd met een verhoogd percentage 
infectieuze complicaties.30,31 Nadat bewezen is wat de optimale timing is voor 
cholecystectomie na een episode van milde biliaire pancreatitis, moeten 
toekomstige studies zich richten op de optimale timing van cholecystectomie 
na ernstige biliaire pancreatitis. 
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Dankwoord
Tijdens mijn promotieonderzoek heb ik met vele mensen samengewerkt. Met 
de één wat intensiever dan met de ander, maar uiteindelijk heeft iedereen 
zijn of haar steentje bijgedragen aan dit proefschrift. Zonder de bijdrage van 
de mensen om mij heen was het nooit gelukt om tot dit eindresultaat te 
komen. Daarom wil ik hen allen bedanken die dit proefschrift mogelijk hebben 
gemaakt. Naar een aantal mensen wil ik graag wat extra woorden van dank 
uitspreken.
Prof. dr. H.G. Gooszen, geachte promotor, professor, ik weet nog de dag dat 
ik voor het eerst tegenover u zat op uw kamer om over wetenschappelijk 
onderzoek te praten. Al snel opperde u om aan de slag te gaan op het 
datacentrum van de Pancreatitis Werkgroep Nederland en ik viel met mijn 
neus in de boter. Kort nadat ik mij gemeld had op het datacentrum werden 
de resultaten bekend van PROPATRIA, waarna ik uiteindelijk werd aangesteld 
op het POSTPATRIA project. De verhuizing van Utrecht naar Nijmegen had wat 
voeten in de aarde, maar u heeft zich altijd vol  ingezet om dit project tot een 
goed einde te brengen. U heeft mij het vertrouwen gegeven dat ik nodig had. 
Ik kreeg de volledige vrijheid bij het opzetten van mijn experimenten en ik 
hoop dat ik het vertrouwen heb waargemaakt met dit proefschrift. De laatste 
loodjes waren zwaar en soms had ik wat aanmoediging nodig, maar uiteindelijk 
hebben we het POSTPATRIA project tot een goed einde kunnen brengen. U 
was ook altijd geinteresseerd naar mijn leven naast het onderzoek, iets wat ik 
altijd erg gewaardeerd heb. En ja, professor, Tijn slaapt nog steeds onder het 
mooie lakentje. Volgens mij kan ik me geen betere promotor wensen. Ik wil u 
bedanken voor alles wat u de afgelopen jaren voor mij heeft gedaan en ik ben 
oprecht trots dat u mijn promotor bent. 
Prof. dr. ir. G.T. Rijkers, geachte promotor, beste Ger, vanaf moment één 
was je mijn vraagbaak voor het experimentele deel van dit proefschrift. Ik 
zie ons nog samen naar een vergadering van de proefdiercommissie gaan 
om het pancreatitismodel toe te lichten. Ook de vele meetings bij TNO om 
te discussiëren over de TIM-resultaten staan me nog goed bij. Je hebt me 
enorm op weg geholpen in de wereld van de experimentele wetenschap en 
mij bijgestaan waar nodig gedurende mijn promotietraject. Hier ben ik je 
erg dankbaar voor. Je aanstelling aan de Roosevelt Academie als hoogleraar 
en daarmee ook je vertrek uit Nijmegen heeft ervoor gezorgd dat we elkaar 
wat minder vaak zagen, maar telefonisch en per mail hebben we altijd goed 
contact gehouden. Het hoogleraarschap is je van harte gegund en het is me 
een genoegen dat ik onder jou mag promoveren. 
Dr. M.G. Besselink, gachte copromotor, beste Marc, wat heb ik een 
bewondering voor je. Jouw enthousiasme en doorzettingsvermogen waren 
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een grote inspiratiebron voor me. Ik vraag me nog steeds af hoe je het steeds 
voor elkaar kreeg, maar zonder uitzondering kreeg ik altijd binnen 24 uur alle 
toegestuurde documenten terug met zinvolle opmerkingen en aanpassingen. 
Ik kon met alles bij je terecht, op elk moment van de dag. Jij was degene die me 
onder jouw vleugels nam na mijn eerste schreden in het datacentrum. Je nam 
me op sleeptouw en enthousiasmeerde me voor veel studies die uiteindelijk 
allemaal in dit proefschrift terecht zijn gekomen. Vanaf dag één heb ik 
ongelooflijk veel van je opgestoken en wat ben ik blij dat jij mijn compromotor 
bent. Heel veel dank voor jouw begeleiding, je tomeloze enthousiasme en 
alles wat je verder voor me gedaan hebt.
Prof. Dr. L.M.A. Akkermans, beste Louis, tijdens één van uw bezoekjes aan het 
datacentrum in Utrecht raakten we aan de praat over experimenteel onderzoek 
en de vervolgplannen na PROPATRIA.  of ik daar misschien in geïnteresseerd 
in zou zijn… Dat hoefde ik me geen twee keer te laten zeggen. Mijn aanstelling 
ging niet geheel zonder slag of stoot en ik moest uiteindelijk mijn studie 
Geneeskunde tijdelijk onderbreken. U hielp me met de administratie en de 
examencommissie te overtuigen om mij tussentijds mijn doctoraal toe te 
kennen, waarna ik full-time aan de slag kon bij de Pancreatitis Werkgroep 
Nederland. Daarna was u met name betrokken bij de experimentele studies. 
Naast uw enorme kennis op wetenschappelijk gebied was u ook een meester 
in het vertellen van mooie verhalen, grotendeels allemaal zelf meegemaakt. Zo 
herinner ik me nog het verhaal over het naar u vernoemde plantje…fantastisch! 
Ik vond het een eer dat u mij wilde toespreken tijdens mijn buluitreiking en ik 
hoop dat we in de toekomst nog veel contact zullen hebben. Dank voor alles!
Leden van de manuscriptcommissie, prof. dr J.P.H. Drenth, prof. dr. M. Ritskes-
Hoitinga en prof. dr. I.H.M. Borel Rinkes, dank voor het plaatsnemen in de 
manuscriptcommissie en voor het beoordelen van mijn proefschrift.
Leden van de promotiecommissie, prof. dr. J.L.L. Kimpen, dank voor het 
plaatsnemen in de corona. Prof. dr. H.M. van Goor, beste Harry, dank voor de 
altijd oprechte interesse in mij en mijn onderzoek. Het hoogleraarschap is je 
van harte gegund. Ik vond het een genoegen om met je samen te werken en 
wie weet  gaan we in de toekomst nog eens samen iets publiceren. Prof. dr. 
J.J.G.M. van den Oord, beste Ome Joost, wat een eer dat ik mijn proefschrift 
tegenover u mag verdedigen. Dr. V.B. Nieuwenhuijs, beste Vincent, onze 
eerste ontmoeting was in Australië waar ik een tijdje wetenschappelijk 
onderzoek onder jouw begeleiding. Terug in Nederland hebben we altijd 
contact gehouden en hoe mooi is het dat ik nu mijn proefschrift tegenover jou 
mag verdedigen. Dank voor alles wat je voor me gedaan hebt!
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Onderzoekers van de Pancreatitis Werkgroep Nederland, ik heb maar 
anderhalf jaar op het datacentrum doorgebracht, maar wat een mooie tijd. Een 
hechte groep en altijd bezig om jezelf te verbeteren. Regelmatig tot in de late 
uurtjes of in de weekenden, het datacentrum had bijna letterlijk een personele 
bezetting van 24/7. Hjalmar van Santvoort en Olaf Bakker, beiden betrokken 
bij een aantal artikelen uit mijn proefschrift, ik heb veel van jullie geleerd. 
Jullie kritische blik leidde vaak tot een verbetering van een onderzoeksvoorstel 
of artikel, maar ook wel eens tot felle discussies. Niet alles ging zonder slag of 
stoot, maar uiteindelijk kwam er altijd een oplossing en kwam het de kwaliteit 
alleen maar ten goede. Dank voor jullie medewerking aan de inhoud van 
dit proefschrift! Thomas Bollen, als student heb ik nog lange tijd voor jou 
gewerkt om alle CT-scans van patiënten met acute pancreatitis te verzamelen. 
Inmiddels alle ziekenhuizen in Nederland gezien en in de loop van de tijd een 
mooie dataset verzameld. Dank ook voor jouw hulp aan dit proefschrift. Stefan 
Bouwense, we begonnen ongeveer gelijktijdig in Nijmegen op het datacentrum. 
Daarna in het CWZ nog een half jaar collega’s geweest. Ons promotietraject 
had ongeveer eenzelfde verloop, dat wil zeggen, even een soort van korte 
break gehad toen we in opleiding kwamen. Uiteindelijk weer vol aan de bak 
gegaan en jij bent nu ook binnenkort aan de beurt om het alles verlossende 
“Hora est” te horen. Het ga je goed en ik hoop dat we ook in de toekomst 
contact blijven houden. Wie weet ooit nog een keer een hotelkamer van 4m2 
delen samen met Yama Issa in Stockholm? Usama Achmed Ali, de chronische 
pancreatitis-man. Bezeten van onderzoek en statistiek en een leuke collega. 
Al snel vertrok je naar Amerika om je met een nieuw project bezig te houden. 
Inmiddels weer terug en klaar om je eigen proefschrift af te ronden. 2015 
moet jouw jaar worden, met opleiding en promotie. Alle succes toegewenst, 
het is je gegund! Yama Issa, opvolger van Usama, inmiddels volledig je eigen 
weg gevonden in onderzoeksland. Wat hebben we vaak over onderzoek en 
andere zaken gesproken toen je nog in Nijmegen op het datacentrum zat. 
Helaas werd uiteindelijk het AMC jouw uitvalsbasis, maar gelukkig hebben we 
altijd contact gehouden. Het ga je goed en ook voor jou ligt er een mooie 
promotie en opleidingsplek voor de chirurgie in het verschiet! Rian Niimeijer, 
inmiddels in opleiding tot MDL-arts en gepromoveerd. Samen verzorgden we 
het experimentele onderzoek van de werkgroep. Totaal verschillend van het 
klinisch onderzoek, maar zeker niet minder leuk. Ellenlang doorbrengen in het 
lab, zelf je proefopzet maken, je experimenten uitvoeren en vervolgens zelf je 
bepalingen doen, dat heeft ook wel iets. Dank voor de goede gesprekken over 
van alles en nog wat. Goed om te zien dat je je eigen weg hebt gekozen en het 
prima naar je zin hebt bij de MDL. Nicolien Scheeper, mega energiek, altijd 
enthousiast. APEC opgezet en momenteel langstdienende op het datacentrum. 
Het jagershuisje in Loenen was echt fantastisch! Mountainbiken, BBQ, wild 
spotten in de nacht, wat een mooi weekend was dat. Hopelijk komt er nog 
een keer zo een weekend! Heel veel succes met APEC en alle andere lopende 
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studies. Het kan niet anders dan dat ook jij een mooi proefschrift en een 
mooie carrière als MDL-arts tegemoet gaat. David da Costa, Bob Holleman en 
Janneke van Grinsven, de jongste onderzoekers op het datacentrum. Ik was al 
weg uit Nijmegen toen jullie begonnen. Ik hoop dat jullie net zo een mooie tijd 
bij de Pancreatitis Werkgroep Nederland hebben als dat ik heb gehad. Succes 
met al jullie projecten en dat het mag uitmonden in een mooi proefschrift.
Sandra van Brunschot, collega-onderzoeker, collega op de werkvloer, 
maar bovenal een hele goede vriendin. Wij zijn bijna tegelijkertijd in het 
datacentrum begonnen en van begin af aan hadden we een goede klik. Vele 
mooie momenten hebben we meegemaakt als onderzoeker, zoals bijvoorbeeld 
de EPC in Praag. Wat een week was dat en wat hebben we een lol gehad! 
Vooralsnog geen gezamenlijke publicatie, maar dat kan nooit lang meer duren. 
Dat we weer directe collega’s zijn, spreekt toch wat makkelijker af. Rowena 
en ik kijken altijd uit naar de etentjes met jou en Ben en we hopen dat we 
nog veel van die avonden mogen meemaken. Ben van den Elshout, voor jou 
ook nog een paar woorden. Ik leerde je kennen als partner van Sandra, maar 
je bent uitgegroeid tot een echte vriend. Ongelofelijk gezellig en veel humor, 
kortom, een echte Brabander. Ik heb nog de foto van ons tweeën voor ogen 
na een supersnelle afdeling met mountainbiken: Ben en Mark op hun best! 
Echte vrienden helpen je waar nodig, en die hulp  kregen we van jullie bij onze 
verhuizing! Jullie hulp de hele dag en natuurlijk de legandarische uitspraak: 
“het zou leuk als je nu weeën zou krijgen” zullen  we nooit vergeten. Sandra en 
Ben, ik hoop dat we vrienden voor het leven blijven en dat we nog vele mooie 
momenten mogen meemaken!
Uiteraard wil ik ook graag de researchverpleegkundigen van het datacentrum 
bedanken voor hun hulp en gezelligheid tijdens mijn periode in Utrecht en 
Nijmegen. Altijd stond er een kop koffie klaar en was er tijd voor een gezellig 
praatje. Vera Zeguers, Annie Bakker, Anneke Roeterdink, Hetty van der Eng 
en Helen van Wezel, dank voor de welkome afleiding in de wereld van de 
wetenschap!
Mijn kamergenoten in Nijmegen, ook jullie bedankt voor de gezelligheid en 
wanneer nodig een luisterend oor. Tjarda Tromp, hard werkend, maar ook erg 
gezellig. Als we samen aan het werk waren, dan was het altijd eerst een paar 
uur knallen, maar daarna standaard tijd voor een kop koffie en een babbel. 
Dank voor de gezellige momenten! Marjan de Vries, je begon met een volledig 
nieuw project en hebt alles van de grond af aan opgebouwd. Ik vind het 
bewonderenswaardig hoe jij je als niet-medicus zo goed staande kon houden 
tussen al die eigenwijze medici. Je bent een harde werker, maar gezelligheid 
en praatjes waren zeker zo belangrijk voor je. Met jouw instelling ligt er 
een mooie carrière  voor je in het verschiet, waar je ook later terecht komt! 
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Richard ten Broek, jouw promotie is nu bijna een feit en je bent inmiddels ook 
in opleiding tot chirurg. Dank voor dat je mijn vraagbaak wilde zijn wat betreft 
statistiek en tekenprogramma’s. 
Een groot deel van mijn onderzoeksperiode heb ik in het dierenlab 
doorgebracht. Graag wil ik iedereen bedanken die mij heeft geholpen bij mijn 
experimenten. Ilona van den Brink en Francien van de Pol, jullie hebben mij 
wegwijs gemaakt in het dierenlab en samen hebben we het pancreatitismodel 
nieuw leven ingeblazen. Het was een lange aanloop, met iedere keer weer een 
tegenslag, maar uiteindelijk hadden we een goed lopend model. Jullie waren 
altijd enthousiast en vrolijk, en schoten te hulp waar nodig. Zonder jullie 
was het nooit gelukt om mijn experimenten tot een goed einde te brengen. 
Ondanks dat jullie vaak op de achtergrond acteren, zijn jullie onmisbaar voor 
elke onderzoeker. Heel veel dank voor een mooie tijd in het dierenlab en voor 
al jullie hulp en inzet. 
Daphne Reijnen, ook jij hebt veel geholpen met mijn experimenten, met name 
ook in de weekenden. Daarnaast hielp jij me, samen met Ilona en Francien, 
goed op weg in de wereld van de dierexperimenten. Heel erg veel dank 
voor jouw hulp en gezelligheid in het dierenlab. Ook zonder jou had ik mijn 
experimenten niet tot een goede einde kunnen brengen!
Ik wil ook graag de proefdierdeskundigen Roel Snepers en Philip Mulkens 
bedanken voor hun steun, aanwijzingen en tips tijdens mijn experimenten. 
André Verheem, jij kwam uit Utrecht om ons een 3-daagse cursus te geven 
om zo het pancreatitsmodel onder de knie te krijgen. Heel veel dank voor de 
tijd en moeite die je in ons gestoken hebt om ons het model eigen te maken. 
Zonder jouw hulp geen experiment.
Michiel van Rens, als student kwam jij me helpen op het dierenlab. Je hebt 
het experiment van begin af aan meegemaakt en mij ongelooflijk veel werk uit 
handen genomen. Je deed alles geheel vrijblijvend en allemaal in je vrije tijd. 
En goed ook! Ik had met een gerust hart een week weg kunnen gaan, je kon 
het experiment met Ilona, Francien en Daphne makkelijk draaiende houden. 
Die auteursplek bij het artikel is dan ook meer dan verdiend. Met jouw humor 
en instelling ga je alles bereiken wat je maar wilt in de toekomst, daarvan 
ben ik overtuigd. Inmiddels afgestudeerd en ANIOS chirurgie, misschien in de 
toekomst ook directe collega’s?
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Graag wil ik ook de mensen bedanken die me hebben geholpen bij de analyses 
van de proefdierexperimenten. Wilbert Peters, Hennie Roelofs en Christopher 
Geven, veel dank voor jullie hulp bij de amylasebepalingen.
De experimenten bij TNO met het TIM-1 model heb ik alleen maar kunnen 
uitvoeren door de goede begeleiding van Koen Venema, Marjorie Koenen en 
Mark Jelier. Ik wil jullie allen bedanken voor jullie hulp aan mijn experimenten.
Prof. dr. I.D. Nagtegaal, beste Iris, dank dat je me wilde helpen met de 
histologische beoordeling van mijn prepareten. Mede door jou is mijn interesse 
in de pathologie gewekt en heb ik er ook voor gekozen om een keuzecoschap 
pathologie te doen. Achteraf gezien ook een goede keuze, aangezien ik veel 
geleerd heb en het zes weken erg naar mijn zin heb gehad.
Dr. J.J. Hermans,  beste John, we hadden een mooi idee om met een nieuw 
soort CT-scan het pancreas van de rat af te beelden tijdens een aanval van 
acute pancreatitis. Helaas waren onze ideeën iets te vooruitstrevend en is het 
uiteindelijk gebleven bij een pilot-studie. Ik vond het in ieder geval leuk en 
leerzaam om met je samen te werken en wie weet gaat het in de toekomst wel 
lukken om onze ideeën ten uitvoer te brengen.
Dr. P. Kohout, dear Pavel, thank you for your support to chapter 4. You asked 
me to come to Prague to collect and analyze data of patients with acute 
pancreatitis and treated with probiotics. I remember your recommendation 
for a place to stay during my period in Prague: “You should make a reservation 
in hotel The Swan, it is close to the hospital and, more importantly, they serve 
good food and beer!”. I had a great time in Prague and I hope we will meet 
again soon. I wish you all the best!
Willem Renooij, voorheen voorzitter van de Mucosale-barrière werkgroep, de 
onderzoeksgroep in Utrecht. Helaas is het niet gelukt om het Caco-2 celkweek 
project in Nijmegen op poten te zetten. Toch wil ik je heel erg bedanken voor 
de tijd en moeite die je in me hebt gestoken om mij de basis van de basale 
wetenschap bij te brengen. Je pensioen is je van harte gegund en ik wens je 
nog vele mooie jaren toe in je buitenhuisje in Frankrijk.
 
Ik wil de medewerkers van Winclove Probiotics BV bedanken voor hun hulp 
en steun aan verschillende experimenten uit dit proefschrift. Dank voor het 
leveren van de probiotica, maar met name veel dank voor het meedenken 
en hulp bij het interpreteren van de resultaten van de TIM-1 studie. Peter 
Pekelharing, Frans Rombouts, Sarah Meeuws, Luuk van Duijn en Isolde van 
der Vaart, hartelijk dank!
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Chirurgen en assistenten van het Tweesteden Ziekenhuis en St. Elisabeth 
Ziekenhuis, ook jullie staan in mijn dankwoord. Dank voor jullie interesse in 
mijn onderzoek, maar vooral ook in het leven naast het onderzoek!
Mijn hockeyteam, Den Bosch Heren 6, voor jullie ben ik inmiddels Van Baal, 
de rattenman. Ik hoop dat ik na het afronden van dit proefschrift wat meer 
tijd heb om samen met jullie een “Ouwe Jan” te gaan drinken in BLD. Dank 
voor jullie begrip dat ik er niet altijd bij kan zijn, maar hopelijk gaat dit snel 
veranderen!
Ronald en Karin Gijsberts, dank voor de welkome afleiding die jullie regelmatig 
boden op de zaterdagavond! Inmiddels wonen we wat verder van elkaar af, 
maar dat doet niets af aan onze vriendschap. Dat we nog samen nog vele 
avonden met een wijntje en biertje mogen meemaken!
Erik Manning, heel veel dank voor jouw creatieve input en de schildering van 
mijn cover! Je hebt er een waar kunstwerk van gemaakt!
Mijn schoonfamilie, Michael, Ria, Inge, Désirée, Vincent, Josefien, Kim en 
Cynthia, dank voor de afleiding die jullie regelmatig boden!
En dan, last but not least, mijn familie. Ghislaine van Baal, Ghiesje, mijn kleine 
zusje. Inmiddels al een volwassen dame, maar je blijft voor altijd mijn kleine 
zusje. Na je tenniscarrière heb je je eigen leventje opgebouwd in Nijmegen 
en dat doet me goed. Het eerste jaar logopedie was niet helemaal naar wens 
verlopen, maar ik weet zeker dat het je dit jaar allemaal mee zal zitten. Je 
werkt er immers hard genoeg voor. Hopelijk heb je dan nog wel wat tijd om 
af en toe nog het kaartspel te spelen. Dat is er afgelopen paar jaar door mij 
een beetje bij ingeschoten, maar ik beloof dat ik mijn leven zal beteren. Ik zal 
ook wat vaker langskomen in Nijmegen om gezellig een hapje te komen eten! 
Juliette van Baal, Juultje, in Amsterdam bezig aan je eigen proefschrift. Je zal 
merken dat het je meer bezighoudt en opslokt dan je vooraf zou verwachten. 
Met name de laatste loodjes zijn erg pittig. We zien en bellen elkaar eigenlijk 
veel te weinig, maar met onze drukke agenda’s is het gewoon lastig afspreken. 
Je bent inmiddels weer helemaal into de gynaecologie en volgens mij past dat 
ook het beste bij je. Eindelijk heb je die promotieplek gevonden, iets waar je 
al lang naar op zoek was. Je kunt het, dat heb je in Engeland al laten zien. Heel 
veel succes met je eigen proefschrift en ik hoop dat je een mooie toekomst 
in de gynaecologie tegemoet gaat. Het is je gegund! Lieve zusjes, ik wil jullie 
allebei bedanken voor alles, gewoon, omdat jullie mijn lieve zusjes zijn!
Mijn paranimfen, Geert en Jaap van Baal, mijn twee broertjes. Hoe mooi is 
het dat jullie zometeen naast mij staan! De afgelopen twee jaar hebben jullie 
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elke keer weer gevraagd wanneer we bij elkaar konden komen om de promotie 
door te spreken, maar bovenal, wanneer we die fles korenwijn konden gaan 
leegdrinken. Nu is het eindelijk zo ver! De dag is inmiddels doorgesproken 
en die fles korenwijn heeft goed gesmaakt. Lieve broertjes, we spreken en 
zien elkaar te weinig, maar ik hoop dat dat gaat veranderen na 11 december. 
Geert, ik heb supermooie herinneringen aan jouw huwelijksdag, maar vooral 
ook hele mooie herinneringen aan de nacht tevoren en de ochtend zelf. Zaten 
we daar, met z’n drieën, het laatste ontbijtje met ons vrijgezelle broertje. 
Gewoon, broertjes onder elkaar, wat was dat een mooi moment! Voor mij in 
ieder geval heel speciaal en iets wat me altijd zal bijblijven. Lieve broertjes, 
heel veel dank dat jullie mijn paranimfen willen zijn, maar voor jullie geldt ook, 
heel veel dank, gewoon omdat jullie mijn broertjes zijn!
Lieve pap en mam, eindelijk is het zover. Het heeft even geduurd, maar 
het boekje is nu een feit. Van begin af aan hebben jullie mij gesteund, 
bij alles wat ik deed. Af en toe met wat scepsis, maar uiteindelijk is het 
allemaal goedgekomen. Jullie motto was altijd: “als je iets doet, doe het 
dan goed. Nooit half werk leveren en altijd je talenten benutten.” Een 
mooi motto, wat ik bij alles wat ik doe in gedachten probeer te houden. 
Ik ben jullie ongelooflijk dankbaar voor de kansen en mogelijkheden die 
jullie ons geboden hebben, zodat wij ons hebben kunnen ontwikkelen tot 
de personen die jullie kinderen nu zijn. De sporten die we vroeger hebben 
mogen doen, de muziekinstrumenten, maar later ook jullie steun zodat 
ik acht maanden in Australië onderzoek kon gaan doen. Pap, die twee 
weken die je toen langs kwam zal ik nooit vergeten. Wat vond ik het mooi 
om een rat te opereren terwijl je toekeek. We hebben daar mooie 
momenten meegemaakt met veel hoogtepunten, maar die ene dag in 
het dierenlab staat bij mij bovenaan het lijstje! Mam, altijd zorgen om 
je kinderen, en je altijd volledig weggecijferen voor ons. Samen hebben 
we een aantal jaar het Lulof Open georganiseerd. Stressvolle weken, 
maar o zo mooi om dat samen met jou te doen. Ik kijk met heel veel 
plezier terug op deze periode en ik vind het oprecht jammer dat dat 
nu voorbij is. We waren een goed team, waarschijnlijk ook omdat we 
volgens pap hetzelfde karakter hebben. Inmiddels ben je aan je tweede 
leven begonnen en ik geniet er van je zo te zien opbloeien. Lieve pap 
en mam, mijn dank is eigenlijk niet in woorden te beschrijven. Ik ben 
trots op jullie als ouders en heb, zeker nu ik vader ben, heel veel respect voor 
hoe jullie het voor elkaar hebben gekregen om vijf kinderen op te voeden. 
Oneindig veel dank en dat we met de hele familie nog heel veel mooie 
momenten mogen meemaken!
Mijn kinderen, lieve Tijn en kleine uk, jullie zijn het mooiste geschenk in 
mijn leven, mooier dan ik ooit had kunnen bedenken. Tijn, met één lach 
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maak je mijn hele dag goed en smelt ik ter plekke. Helaas kun je niet bij de 
promotie aanwezig zijn, maar ik zal zeker een boekje voor je bewaren. Deze 
dag komt net even te vroeg, alhoewel je al wel met drie weken levenservaring 
je eerste wetenschappelijke congres hebt bijgewoond met bijbehorend 
aanwezigheidscertificaat. Lieve Tijn, je weet het zelf nog niet, maar je maakt 
mama en mij elke dag weer zielsgelukkig! Kleine uk, jij mag wel bij de promotie 
aanwezig zijn, veilig in de buik van mama, dat wel. Jij gaat ons leven helemaal 
compleet maken. We kijken heel erg uit naar je komst en kunnen bijna niet 
wachten tot het zover is. Lieve uk, nog even goed groeien en over een paar 
maanden mag je papa en mama de gelukkigste ouders ter wereld maken!
Lieve Rowena, wijffie, de laatste woorden van dit proefschrift zijn voor jou. 
Wat moet ik zeggen? Woorden schieten tekort. Ik heb je leren kennen, net 
voordat ik met mijn promotie-onderzoek begon. Je hebt alles van begin af aan 
meegemaakt en je hebt me altijd en overal gesteund waar mogelijk. Meer dan 
ik ooit had durven dromen! Zelfs tijdens het klussen vlak voor onze verhuizing 
naar Nijmegen moest ik nog regelmatig even checken hoe het met mijn ratjes 
ging, en nooit heb je geklaagd! De laatste anderhalf jaar zijn ongelofelijk 
hectisch geweest, maar gelukkig weten we ons elke keer weer overal doorheen 
te slaan. Dat bewijst maar weer wat voor een sterke vrouw je bent. Wijffie, 
lieve schat, ik ben supertrots op je en hou zielsveel van je. Ik wil je bedanken 
voor wie je bent en wat je allemaal hebt gedaan voor mij. We gaan samen een 
hele mooie toekomst tegemoet en ik hoop dat we nog heel erg lang van elkaar 
mogen genieten!
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